1. What Arrowhead reported this morning

On September 15, Arrowhead released interim topline results from the Phase 1/2a study of ARO-DIMER-PA. The numbers below are from that release and nothing else has been presented. Fuller detail goes to a medical congress later.

ARO-DIMER-PA is one molecule carrying two payloads. One switches off PCSK9, which governs how much LDL cholesterol the blood clears. The other switches off APOC3, which governs triglycerides. Both targets are reachable through hepatic delivery, and both have been silenced before, separately, by separate drugs.

Putting two independent triggers on one conjugate, and showing that both stay active in a person, is the novel part.

The obvious reading of this morning’s release is a convenience story. Two mechanisms, one injection, a large and undertreated market. That reading is correct and it is the smaller half of what happened.

2. The number to look at is the gap

Arrowhead reported mean maximal single-dose reductions of 72 percent for PCSK9 and 88 percent for APOC3.

A sixteen point spread sounds lopsided. The right question is not whether the two numbers match each other. It is whether each one is close to what a drug built for that job alone would have delivered.

Figure 1. Reductions as reported. Comparisons to other drugs are across different trials and populations and should be held loosely.

On that test both halves did their work. APOC3 fell 88 percent, which sits in the range a dedicated APOC3 drug produces. PCSK9 fell 72 percent. Downstream, LDL cholesterol fell 54 percent from a single dose, in the range of the roughly 50 percent LDL-C lowering reported with inclisiran on its established regimen. Nothing in those numbers suggests either trigger became pharmacologically irrelevant because it traveled with the other.

Whatever competition may exist between them, neither trigger was functionally crowded out. That was the thing worth finding out, and it is the thing the release does not spell out.

Had one looked strong while the other barely moved, Arrowhead would still have had a lipid drug. What it would not have had is clean evidence that two payloads can share the architecture without one becoming materially compromised. Future dimers will still be engineering projects. They no longer begin with the unanswered question of whether two functional triggers can coexist on the architecture at all.

3. What the lipid numbers say

Downstream of the gene silencing, the numbers a cardiologist cares about came out well.

LDL cholesterol down 54 percent. Triglycerides down 73 percent. Non-HDL cholesterol down 61 percent. ApoB down 50 percent.

James Hamilton pointed at the last one and he was right to. Because each atherogenic lipoprotein particle carries one ApoB molecule, ApoB estimates the total burden of those particles rather than the cholesterol sitting inside one class of them. In a patient whose problem is both high cholesterol and high triglycerides, treating one number can leave much of that burden intact. Fifty percent off ApoB from a single injection is the number that shows most clearly how broadly the treatment reduced that burden.

The comment from Steven Nissen in the release is worth reading for what it highlights. Even with intensive statins and a PCSK9 inhibitor, substantial risk remains in these patients, and the triglyceride-rich remnants may be part of what is left. That is a cardiologist saying the current standard of care does not finish the job.

4. Why one to two is the expensive jump

Here is why this matters beyond a lipid drug, and it comes down to where the difficulty sits.

Going from zero triggers to one was solved years ago and every approved siRNA drug does it. Going from one to two asks something genuinely new. Does a single conjugate carry two different payloads to the same cells. Do both get loaded into the silencing machinery. Does one crowd out the other. Does the molecule survive being twice as complicated.

Going from two to three still raises engineering questions. A third trigger could bring new competition for the silencing machinery, new potency or chemistry constraints, new manufacturing problems. It is a different kind of question now, though. Before this morning, the open issue was whether two triggers could share one architecture and both stay functional.

That first multiplexing boundary looks crossed. The next one has not been tested.

5. What this does to a pipeline

Many of the diseases medicine struggles with are not single-target problems. They are networks, with several genes or pathways contributing at once. Building one small molecule that precisely modulates several chosen targets is extraordinarily hard. Giving a patient a separate biologic for each is technically possible and quickly becomes an exercise in dosing, toxicity, manufacturing and cost.

Worth being precise about what that does and does not mean. This is not polygenic risk in the genetic sense, where hundreds of common variants each make small contributions and there is no practical way to address the whole distributed signal with a drug. It is the narrower case where a handful of known targets in the same tissue, reachable through the same delivery chemistry, each matter, and treating one leaves the others running.

RNAi offers a different possibility. Target recognition is encoded largely in sequence, and if multiple sequences can share one delivery architecture without losing activity, multiplexing starts to look less like combination therapy and more like molecular programming. Until this morning that proposition rested on chemistry and preclinical work. Now there is a human dataset behind it.

Which makes the interesting question not what ARO-DIMER-PA does for mixed hyperlipidemia. It is which combinations Arrowhead nominates next, and whether the patent estate already tells you.

It does, partly. US-20260176631-A1 is directed to hepatic delivery platforms carrying multiple RNAi agents on one conjugate. US-20250376688-A1 is directed to PCSK9. US-12365899-B2 covers APOC3. A further filing covers dual inhibition of both targets together, which the company lists in its annual report as its APOC3 and PCSK9 dimer group. Arrowhead did not discover this morning that dimers might work and then go looking for protection. The architecture was mapped first.

6. What got de-risked, and what did not

The biological question, whether both targets can be knocked down at the same time, looks answered. The architectural question, whether two triggers can share one conjugate and both stay active, now has human evidence behind it. The major product questions remain open: dose, durability, repeat dosing, safety at the intended regimen, and eventually whether any of it prevents a heart attack.

The biggest de-risking this morning was architectural, not commercial.

Four things, and they matter more than the ones being quoted.

No time points. Mean maximal reduction is the deepest number reached, not the number three months later. For a drug meant to be given quarterly, the trough matters more than the nadir and it is not in this release.

No dose attribution. Escalation completed through 400 mg. Whether 72 and 88 came from the same dose, or whether the best PCSK9 number and the best APOC3 number came from different cohorts, changes how you read the symmetry.

No numbers per cohort. The study enrolls up to 78 subjects across single and multiple dose portions. Early cohorts are small and these are means.

The multiple dose portion is still running. Which is where a quarterly regimen actually gets defined. A single-dose result tells you the architecture works. It does not tell you what the product looks like.

One thing the release does report and this note has otherwise passed over. The most common adverse events were injection site reactions and headaches, with no drug-related serious adverse events, and escalation completed through 400 mg. That is reassuring for this stage. A small single-dose dataset cannot establish the safety profile of the repeat-dose regimen the drug would actually be given on.

Additional detail goes to a medical congress, which is where these questions get answered.

7. What I would watch from here

Whether a second dimer gets nominated in the months ahead, and what it pairs. That will be the first test of whether Arrowhead treats this morning as a one-off product or a reusable capability.

Whether the durability supports quarterly dosing when the multiple-dose data arrives.

Then whether anybody else attempts it. Arrowhead now has a human result and a patent estate around the architecture. The interesting signal over the next year is how many other companies start talking about multi-target RNAi, because that tells you whether the field thinks this generalizes.

A drug that lowers two lipids is a product. A molecular architecture that can silence two independent targets at once is a capability.

Arrowhead reported the product this morning. The capability may end up worth more.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All ARO-DIMER-PA figures are from the company release of September 15, 2026, which reports interim single-dose topline results. Comparisons to inclisiran and to APOC3-targeting drugs are across separate trials with different populations and designs. Patent filings referenced are as published. The framing of the architectural problem is the author's own.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The trade nobody remembers

In July 2008 Roche bought a small Madison company called Mirus Bio for $125 million. Mirus had spun out of University of Wisconsin research in 1995 and had spent more than a decade on nucleic acid delivery, work that predates therapeutic RNAi entirely. That expertise turned out to be unusually valuable once RNAi arrived and the field ran into its defining problem, which was getting the molecule into the right cell.

The year before, Roche had paid Alnylam $331 million for access to the field. Add the milestones and the development spending and Roche had committed something close to half a billion dollars to becoming a leader in RNAi.

In 2010 they changed their minds and exited the field entirely.

Figure 1. Transaction figures as reported at the time. The 2026 market capitalization is approximate.

In October 2011 Arrowhead acquired Roche’s Madison operation. Not the technology alone, but an operating research site, its equipment, the intellectual property, the licenses from Tekmira and Alnylam, and a team of more than forty scientists.

Those figures are not comparable purchase prices and I do not want to present them as such. What they show is the scale of what Roche spent assembling a capability Arrowhead ended up inheriting.

Arrowhead paid no cash at closing. Roche took a promissory note of fifty thousand dollars and an equity stake of just under ten percent. Arrowhead subsequently recorded total purchase consideration for the transaction at roughly $5.27 million, comprising about $5.13 million in shares, the note, and a small amount assigned to contingent consideration.

That is not the same as paying nothing, and it is worth being precise. Roche also kept rights to negotiate for certain future products, milestone payments that trigger only after regulatory approval, and low single-digit royalties on some sales. The consideration was real. Much of what Roche stood to receive was contingent on success that had not happened yet, which meant Arrowhead committed very little cash at a moment when it had very little cash to commit.

Arrowhead’s own document explaining the deal said it more plainly than I could. “Fortunate to stand on these broad shoulders.”

2. The part that actually mattered

Everyone focuses on the price, which was remarkable. The more interesting question is why the team was still there to acquire.

Picture the same thing happening in Cambridge. Roche announces it is shutting its RNAi site. Forty scientists with deep delivery expertise hit the market on a Tuesday. By Friday they have offers from Alnylam, from Dicerna, from half a dozen startups, from whatever startup raised a Series A that month. The building gets subleased. The knowledge scatters across the ecosystem and stops being a platform.

Now picture it in Madison in 2011. Roche announces the same thing. Where does a delivery chemist go?

This is not a place without scientists. It is a place without competing employers, and those are entirely different problems.

There was almost nowhere local for an RNAi delivery team to go, and that may be the most important part of the story. Isolation did not make the team cheap. It made the team intact.

When Arrowhead arrived with stock and a plan, they were not recruiting forty individuals. They were acquiring a group that had worked together for years and would have been difficult to reassemble anywhere.

The handoff shows up in the personnel records. Within a month of closing, Arrowhead named David Lewis and David Rozema to run biology and chemistry in Madison. Both had held those functions under Roche, Lewis as site head and director of research, Rozema as director of delivery chemistry. The company also granted inducement options to thirty-seven selected new employees at the Madison facility. The intellectual property changed owners and a good deal of the operating organization crossed the bridge with it.

The conventional model treats talent density as the asset. Arrowhead’s history suggests the inverse can also hold. When the product is a platform rather than a molecule, talent stickiness is worth something too.

There is a way of framing that which I think generalizes beyond this company. A patent makes knowledge harder for a competitor to appropriate. Geography can make a team harder for a competitor to take apart.

The moat was never that the scientists could not leave. It was that leaving usually meant changing cities rather than changing badges, and friction is what lets an advantage last long enough to compound.

Geography did not create the capability. It gave the capability time to compound.

3. Why continuity is what compounds

A delivery platform is not a molecule and it is not a patent. It is accumulated knowledge about what works, what fails, and why, most of which never gets written down properly.

Which linker survives the bloodstream. What happens when you change the sugar. Why the third version worked and the second did not. That kind of understanding lives in the people who generated it, and it only compounds if those people keep working on the same problem together.

Boston is optimized for talent liquidity. You can staff a program in a month. You can also lose it in a month. That trade works perfectly well when the value sits in an asset. It works much less well when the value sits in accumulated organizational knowledge.

The Madison lineage was doing the reverse. Decades on the same underlying problem, across three different owners. Under Arrowhead alone, fifteen years of iteration carried that work from liver to lung, muscle, fat and brain, each step informed by the chemistry and delivery work that came before it.

For that kind of company, the ability to hire quickly matters far less than the difficulty of being raided.

4. The same distance, opposite value

Roche’s RNAi effort was spread across Madison, Kulmbach and Nutley inside a global company headquartered in Basel. Madison was not an afterthought, and it is worth correcting the easy version of this story. Roche itself described Madison and Kulmbach as centers of excellence for RNA therapeutics.

What distance did do was put the decision somewhere else. When Roche made a portfolio-level judgment to leave the field, the fate of the Madison organization was settled by people who were not in Wisconsin, and the sites in Germany and New Jersey went the same way.

Under Arrowhead the same geography produced the opposite effect. Madison went from being one node inside a global pharmaceutical company to being a core scientific operation inside a much smaller one, while the thin local labor market likely helped hold the group together long enough for that to happen.

One property, opposite effects, depending entirely on who controls the capital allocation.

5. Building outside the cluster

In December 2021 Arrowhead bought thirteen acres in the Verona Technology Park for just under three million dollars. On that land it built a GMP manufacturing plant and a lab and office building, together running to roughly three hundred thousand square feet. The investment was estimated at two hundred to two hundred fifty million at announcement. By the end of 2025, with the build-out substantially complete, Arrowhead reported costs incurred of approximately $298.5 million.

Figure 2. Figures from company announcements and the Wisconsin Economic Development Corporation.

Look at the land number again. Thirteen acres for under three million dollars. There is effectively no comparable transaction available in Cambridge or South San Francisco at anything resembling those economics.

The other half of the ledger is the direction the money flows. Verona authorized up to sixteen million in tax increment financing toward site improvements, repayable out of future tax increment. The state offered up to two and a half million in refundable credits contingent on job creation and capital spending. Neither is a check handed over at closing. Both are public money pointed at a campus Arrowhead owns.

In a place where everybody wants to be, you pay a premium to get in. In a place that wants you, they pay you to stay.

Arrowhead also owns the plant rather than renting capacity from a contract manufacturer. For a company whose platform advantage depends heavily on chemistry and delivery, having the people who make the molecule in the same organization as the people who design it is not a cost saving. It is a feedback loop.

6. The university nobody mentions

The weakest objection to Madison is that there is no talent there, and it is worth taking apart because it is simply wrong.

The University of Wisconsin has been doing serious nucleic acid science for most of a century. Har Gobind Khorana did the work there that helped crack how the genetic code turns RNA into protein, and won a Nobel for it. Howard Temin discovered reverse transcriptase there, which rewrote what everyone thought they knew about how genetic information moves, and won a Nobel for that. James Thomson derived the first human embryonic stem cell lines there.

None of that is a direct lineage into siRNA delivery and I would not pretend otherwise. What it establishes is narrower and sufficient. Madison is not a scientific wilderness, and it has not been one for a very long time.

The university also runs one of the oldest and most successful technology transfer operations in the country, the Wisconsin Alumni Research Foundation (WARF), founded in 1925. The blood thinner warfarin is named after it. Mirus Bio itself spun out of university research in 1995, which is how the delivery expertise that later became central to RNAi took root in Madison.

The state development agency put Arrowhead’s Madison research headcount at roughly two hundred ten in 2022, in a hundred and eleven thousand square foot facility, with intern and trainee pipelines into local institutions. Arrowhead has also disclosed research use of a primate colony housed at the Wisconsin National Primate Research Center, a university affiliate. That is not a company scraping for staff in a scientific vacuum. It is a company sitting inside an ecosystem.

Chris Anzalone talks about the place in the language of a relationship rather than a location decision. “A dedicated member of the biotech community in the greater Madison area” for more than a decade. “Strong local relationships.” A “productive and mutually beneficial relationship” with the local business community for many years.

That is the vocabulary of somebody who has been somewhere long enough for it to matter, which is the asset this whole paper is about.

7. The costs, which are real

None of which makes this free.

Arrowhead is a split company. The executive office is in Pasadena, the delivery chemistry and manufacturing in Wisconsin, more research in San Diego. That is a genuine organizational cost and anyone who has worked across time zones knows it.

Senior recruiting is harder. An accomplished executive who has built a life in the Bay Area will not casually move to Dane County, and Arrowhead has to pay up or wait longer to fill those roles.

The informal information flow is thinner too. In Cambridge you learn what a competitor is doing because somebody’s spouse works there. Arrowhead does not get that, which cuts both ways since nobody learns what Arrowhead is doing either.

8. What a buyer would actually be getting

This is where the argument starts mattering to anybody modeling a bid for this company.

Platform acquisitions carry a peculiar risk. The buyer can acquire every asset and still slowly lose the platform. A large company buys a small one for its capability, integrates it, moves reporting lines, folds the labs into an existing structure, and over a couple of years the people who actually held the capability in their heads take their payout and go. What is left is buildings, patents and an org chart.

Every acquirer of a platform company is really buying a bet that the people stay. The question is not what Arrowhead owns. It is what walks out the door on the Monday after closing.

In Cambridge that bet is a retention package, and retention packages have a known expiry. In Madison the bet is a fact about the map.

There is also an unusually clean natural experiment here, of a kind few platform companies can point to. The Madison organization has already been through one of the harsher versions of what an acquisition can do. Roche bought Mirus in 2008, ran the Madison organization for a little over two years, then reversed strategy and walked away from the field.

The transfer to Arrowhead did not happen until late 2011, and that gap may be the most telling part. The owner had already abandoned the field, and enough of the organization stayed coherent that somebody could still acquire it as an operating group. That is a change of ownership followed by abandonment, which is the failure mode buyers worry about, and the group came out the other side intact enough that Arrowhead retained dozens of them and put two of Roche’s own site leaders back in charge.

Most teams have never been tested. This one has been acquired, abandoned, transferred, and is still working on the same underlying problem in the same city nearly two decades on.

The corporate structure helps too, in a way that looks accidental and is worth noticing. Arrowhead keeps its executive office in Pasadena, its manufacturing and delivery chemistry in Wisconsin, and further research in San Diego. In almost any acquisition the synergies come from eliminating duplicate corporate functions, and those sit in California. A core part of what a buyer would want to preserve sits two thousand miles from the corporate functions it might want to cut.

You can take out a headquarters without anybody in a lab noticing. That is not true of a company where finance and chemistry share a cafeteria.

Which means the geography that looks inefficient in a standalone company becomes unusually efficient in an acquisition. A buyer would not need to relocate the Madison delivery organization or work out where manufacturing should live. Those questions have already been answered by the map, and the answer is Wisconsin.

Then there is the plant. Dedicated GMP capacity for this class of medicine is not easy to come by, and companies without their own remain dependent on outside manufacturers and their schedules. A buyer acquiring Arrowhead gets roughly a hundred and sixty thousand square feet of owned manufacturing built for exactly this chemistry, plus the process development group that knows how to run it. For anybody planning to launch more than one product, that is not a real estate line. It is control over a critical part of the launch schedule.

Roche had already written the playbook, which makes the Madison story stranger rather than simpler. When it acquired the rest of Genentech in 2009 it deliberately kept research and early development as an independent center in South San Francisco, explicitly to preserve the culture that had produced the pipeline. Roche understood the value of organizational continuity. A year later it simply concluded that RNAi itself no longer justified the investment, and Madison went with the decision.

The cheapest way to avoid breaking the factory is to buy one that is already standing somewhere you were never going to move it to.

9. The outpost

Chess has a square worth understanding here.

An outpost is a square deep in the opponent’s half where you can plant a knight and no enemy pawn can ever attack it. Put a knight there and it sits for the rest of the game, controlling squares, impossible to dislodge, growing more valuable with every piece that gets traded off.

The square itself is nothing special. It is a square. What makes it an outpost is that nothing can drive the piece away.

Madison is not a better place to do science than Cambridge. It is a place where a team that is already good is hard to dislodge, and over fifteen years of Arrowhead ownership that may have turned out to be the more valuable property.

The scientific lineage running through Madison can be traced through Arrowhead’s expansion out of the liver and into everything after it. The chemistry that reaches liver cells. The ligand that reaches the airway. A molecule given as a shot under the skin, now being tested in people for whether it can reach the central nervous system and silence tau.

Roche bought the team, funded it, and gave up on the field. Arrowhead took the square and never moved the piece.

Boston and South San Francisco are where you go to hire quickly. Nobody planned Madison as an alternative to either. It simply turned out that a company trying to accumulate one capability for the better part of two decades needed somewhere that would hold still.

Talent density is worth a great deal if you are building a drug. It is worth much less than continuity if you are building a factory that makes them.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. Transaction details are from contemporaneous reporting and from Arrowhead’s own disclosures and filings at the time of the 2011 acquisition. The consideration comprised a promissory note, restricted common stock, negotiation rights, post-approval milestones and royalties rather than cash at closing, recorded by the company at approximately $5.27 million. Verona campus figures reflect the single project announced in 2021, with costs incurred through December 2025 as reported by the company; incentive amounts are authorized maximums contingent on performance rather than payments received. Arrowhead also operates research facilities in San Diego and its corporate office in Pasadena. The characterization of why the Madison team remained available is the author’s interpretation and not a claim about any individual’s decisions.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. Three notes, one week

Morgan Stanley, Stifel and Bank of America all published fresh commentary on Arrowhead within days of the ESC presentations. All three are positive. All three carried price objectives set earlier in the summer, at $120, $104, and $100, and none of them moved.

I read all three looking for what they disagreed about. What struck me instead was what they had in common, and it is not a disagreement at all. It is a shared limit in the tool.

2. What each of them does

Morgan Stanley runs a single discounted cash flow. That means projecting the company’s future cash and discounting it back to today, in their case at 10 percent a year with 1 percent growth after that. There is no breakdown by drug and no disclosure of what odds are being assigned to any of them. The $120 is one number produced by one model, and a reader cannot see which assumption is carrying it.

Stifel says the quiet part out loud and then does it anyway. Condulis writes that the market gives the brain program, the dual-target molecule and the two obesity assets essentially no credit. He is right. He then builds a valuation that gives those same programs what he describes as highly risk-adjusted credit, which is a polite way of saying not much. He identifies the mispricing and then only partly corrects for it.

Bank of America shows its work, which is why its note is the most useful of the three. Gerberry breaks the valuation into pieces. The APOC3 franchise, meaning the approved drug plus the wider patient population it is applying to sell into, carries about half the entire company. The partnered liver program carries 9 percent. The two obesity programs carry 6 percent.

Everything else sits in one bucket worth about a quarter of the company, marked down on the assumption that each program has less than a 30 percent chance of working.

Figure 1. Composition as described in the published note. Percentages are approximate.

Look at what is inside that quarter. The brain platform, a systemically delivered route into the central nervous system with extensive primate data and its first human clinical readout arriving this month, with a patent listing thirty-four targets behind it. The dual-target molecule reading out this month. Two inhaled antiviral programs. Whatever else has not been announced.

More than twenty clinical programs spanning liver, lung, muscle, adipose and now the central nervous system, on a delivery platform with an unusually broad tissue footprint. Half the value sits in one drug and the brain program shares a quarter-slice with everything the company has not announced yet.

3. Why this happens, and it is not carelessness

These three notes do not all use the same method, and that is part of the point. What they share is a modeling convention: value what can be modeled, discount it for risk and for time, and leave out what cannot be modeled.

The most common implementation is called risk-adjusted net present value, where you value each drug separately. Morgan Stanley instead runs one company-wide cash flow. Different arithmetic, same convention underneath.

The idea is simple and it is sound.

You take each drug, estimate the cash it would generate if it works, multiply by the odds it works, and discount the result back to today. Add up all the drugs and you have a company. A cancer drug in Phase 1 might get 10 percent odds. An approved drug gets close to 100. It is disciplined, it makes you say out loud what you are assuming, and for most biotech companies it is exactly the right tool.

The trouble starts when a company’s biggest asset is not a drug at all.

Every discount in that calculation gets applied to something that already exists. A molecule with a name, a trial running, a date on a calendar. Conventional practice has no line for the thing that produced those molecules and will produce the next twenty. An analyst could create one. Nothing in the arithmetic forbids a line for the platform, for how productively it generates candidates, or for what people call optionality, meaning the value of being able to do something you have not committed to yet. It is simply that doing so requires assumptions that are hard to defend in print. The line therefore does not get created, and the ability to invent the next drug carries no explicit value at all.

As conventionally built, risk-adjusted valuation prices the inventory and not the factory. For most biotech companies that distinction does not matter, because there is no factory.

4. Undrilled acreage

There is an industry that built a language for exactly this problem decades ago, and I think the comparison is worth walking through.

Nobody values an oil company by adding up the cash from wells that are pumping today. That would be absurd. It would price a company sitting on an enormous untapped field exactly the same as one that has already pumped its last barrel.

The industry built categories instead:

1. Wells that are producing.

2. Reserves that have been found but not yet developed, where you know the oil is there and have not built the infrastructure.

3. Prospects, which are locations the seismic work has identified as worth drilling but where nobody has drilled.

4. Then undrilled acreage, which is land you hold and have not yet surveyed.

Each of those categories can carry value, and acreage itself regularly changes hands at a price per acre. Companies pay real money for the right to drill holes that may find nothing, because the option to find something is worth something before you know.

Now put Arrowhead into those buckets.

Figure 2. Categories adapted from oil and gas reserve reporting. The mapping is illustrative.

Plozasiran is producing. Approved in five geographies and generating commercial revenue. A valuation counts it, and it should.

The clinical pipeline is discovered but not yet developed. ARO-MAPT, the dual-target molecule, the two obesity programs, zodasiran. Real trials, real timelines, with delivery demonstrated clinically for the lipid and obesity programs and preclinically for the brain one. A valuation counts these too, heavily discounted, which is reasonable.

Then it stops counting.

Here is the part I think gets missed. Arrowhead holds a patent listing thirty-four specific targets its brain delivery system is designed to carry. Not a vague ambition to work in neurology. Thirty-four named genes, written into a filing, covering Huntington’s disease, three genetic forms of ALS, four inherited ataxias, prion disease, Parkinson’s, chronic pain and more.

That number, however, is easy to run away with. A list of targets in a patent tells you what a company thinks its technology could be pointed at. It does not tell you there are thirty-four drugs sitting in a drawer somewhere. Nobody has shown that each of those genes can actually be drugged, that a molecule against it works, or that the resulting medicine would sell.

What it does establish is that somebody has done the survey work. In oil terms these are mapped prospects: locations identified as worth drilling, written down with coordinates, sitting behind a delivery route whose first human data arrive this month. That is not raw land.

They should not be valued as thirty-four drugs. Treating thirty-four identified applications of a heavily validated preclinical delivery system as carrying no explicit value today is also an assumption, and it is the one conventional modeling effectively makes.

The patent estate is the map. The brain patent is the one I have read closely. It is not the only one of its kind, and once you look at the whole estate the structure is unmistakable. It maps onto the oil categories almost exactly.

Arrowhead reports roughly 643 issued patents and 833 pending applications worldwide, across more than a hundred patent families. For the purposes of this analogy, two recurring kinds of filing matter most.

One kind claims a route into a tissue. GalNAc sugar clusters for liver. αvβ6 integrin ligands for inhaled delivery to the lung. Antibodies against the transferrin receptor, TfR1, for the central nervous system, which is the door ARO-MAPT walks through. Then skeletal muscle delivery platforms and lipid conjugates for adipose tissue, where the published titles name the tissue rather than the chemistry.

Five tissues, five dedicated delivery families, each with its own filings. That is the acreage side of the portfolio. Arrowhead is staking out the routes it intends to protect.

The second kind is target-specific. Filings aimed at a particular gene, or a defined combination of them, appearing as individual programs emerge. APOC3, ANGPTL3, alpha-1 antitrypsin, PNPLA3, HSD17B13, Lp(a), complement C3, complement factor B, XDH, factor XII, MARC1, PCSK9, INHBE and more in the liver. Alpha-ENaC, beta-ENaC, MUC5AC, RAGE, MMP7 and TSLP in the lung. DUX4 in muscle. ALK7 in adipose. MAPT in the brain. Influenza A and coronavirus for the inhaled antivirals.

Better than thirty named genes with their own filings, across five tissues plus the antiviral work.

Somebody should push back here, because listing targets in a patent is what patent attorneys do. The marginal cost of adding another contemplated target to a broad disclosure is tiny next to the cost of actually developing it. Broad biotech target lists can reflect lawyering as much as development intent, and treating one as a pipeline would be foolish.

What makes this one different is the conversion record. Arrowhead has done the same thing in tissue after tissue. Liver now has more than a dozen targets with dedicated patent filings. Lung has six. Adipose has ALK7, where the company has already shown direct knockdown in human fat tissue, and there is no obvious reason a working route stops at one gene. Arrowhead does not stake out a route and then work a single target in it. It works the ground.

That is the difference between a list and a record. A list tells you what somebody thought to write down. A demonstrated history of turning names into programs makes it reasonable to expect that at least some of the remaining names will become programs too.

Those are the wells. The brain estate is where you can actually watch one get drilled.

Several of the thirty-four have already made that trip. SOD1 sits on the brain delivery target list and has its own dedicated filings. Worth stating that ARO-SOD1 was discontinued before the planned Phase 1 study enrolled, so this is not a success story. It still progressed from a name on the platform map to dedicated IP and a clinical-stage program, which is the conversion I am pointing at. Huntingtin has made the same trip, the gene behind Huntington’s disease. MAPT has as well, which is the one reading out this month. Prospects on a map became locations somebody decided were worth drilling, and the paperwork followed them across.

That is the machine, visible in the filings. Delivery patents stake out ground. Target patents get filed as the company works through it. Better than thirty genes now have filings of their own, and the brain list still holds most of its thirty-four.

The dual-target molecule reading out this month is visible in the estate too, though the filings did not arrive in a tidy conceptual order. APOC3 had its own target filings years ago. PCSK9 came later. A separate family covers hepatic delivery platforms carrying multiple RNAi agents on one conjugate. Then a dedicated filing for dual inhibition of both targets at once, which the company lists in its annual report as its APOC3 and PCSK9 dimer group. Which patent came first is not the point. The point is that the estate holds all three layers: the individual targets, the architecture for carrying more than one at a time, and eventually the specific combined drug.

A conventional valuation counts the wells. It does not count the ground, and it does not count the fact that the company keeps walking across it.

Nearly nineteen years of assembling all of it, and little of that capability appears explicitly in a conventional valuation, because there is no individual drug to attach a probability to.

5. The best argument against me

There is a serious case on the other side.

Platform value is exactly the sort of claim that gets abused. Every biotech with two molecules calls itself a platform company. Most of them are not. The graveyard is full of delivery technologies that worked once and never again, and an analyst who declined to pay for optionality was right far more often than wrong.

Analysts cannot model what does not exist. Refusing to assign value to an unnamed future drug is not a failure of imagination. It is discipline, and the alternative is a valuation that can be justified at any number you like.

Optionality is also unfalsifiable. If I say the platform is worth several billion dollars and you disagree, neither of us can settle it. If every unnamed future target can be invoked to justify today’s price, platform analysis stops being valuation and becomes storytelling. That is a genuinely bad property for a valuation input, and I understand entirely why a professional putting their name on a published number would rather leave it out.

6. What survives that

Three things.

The blind spot comes from the convention, not from a judgment that the platform is worthless. Three firms took different routes and arrived in the same neighborhood. That is not three analysts independently concluding the pipeline is worth little. It is a shared convention that tends to arrive there by construction, because standard practice gives the arithmetic nowhere to put platform optionality unless an analyst deliberately builds a separate category for it.

The analysts themselves know it. Stifel wrote that the market gives these programs no credit. That is not a stray observation. His own model then gives them some heavily risk-adjusted value, but only partly repairs the gap he had just identified. When somebody identifies a pricing failure and then only partly corrects for it in the same document, the constraint is more likely in the framework than in the analyst.

There is a third thing, and I hold it more loosely. Acquirers run these calculations too, so the difference is not that they use a different arithmetic. It is that a strategic buyer can pay for things a published asset-by-asset model has no room for, including competitive position, what the target denies a rival, and what the organization might produce next. When Roche bought the rest of Genentech it paid roughly $46.8 billion for the 44 percent it did not own, implying a total above $100 billion.

Genentech had enormous approved products by then, so I would not claim Roche was paying purely for the engine. What is more suggestive is what Roche chose to preserve after buying the rest. Genentech research and early development continued as an independent center inside Roche, explicitly to protect the culture and the research approach that had generated the pipeline. Roche bought the products. It also took unusual steps not to break the factory.

Everything described so far is public. A pharmaceutical company can pull the same patents, study the same conversion record and reach its own view about what the remaining ground is worth. The asymmetry does not require privileged information.

What differs is the burden of explanation. A buyer can debate a platform premium internally. An analyst who lets the same assumption materially move a published price target has to explain it to clients and live with it in the model months later.

The buyer still faces diligence, return hurdles, integration risk and internal approval, and a serious bidder may later see things public investors never do. None of that is needed to notice the optionality in the first place.

That is the strange part. The value does not have to be concealed to be hard to express. It can simply sit in a category that published research handles awkwardly and a private strategic judgment handles more comfortably.

7. What better would look like

Not a bigger number. A visible one.

If a note showed each asset separately with its own probability of success attached, a reader could argue with the pieces. If it carried a line, even a small one, for programs the company has demonstrated it can generate but has not yet named, a reader could argue with that too. The number might come out lower than $100. That would be fine.

Somebody is going to ask what a platform line would even be built out of, and that is a fair question. It does not require pretending thirty-four drugs already exist. It could start with things that are actually observable: how often this company has produced a clinical candidate, how long each one took, how reliably its delivery chemistry has carried from one target to the next inside a tissue, and what a program has historically been worth once it reaches the clinic.

Then discount all of it heavily, because the targets are unnamed and most of them will fail.

The point is not the number that comes out. The point is that zero is a number too, and for programs that have not yet been named and modeled, it is the one conventional practice uses by default.

The problem is not that the resulting values are too low. It is that when half the value sits in one drug and the entire brain franchise is inside a bucket labelled everything else, there is nothing specific to disagree with.

That standard should apply to my own work as much as anybody’s. When I put a number on Arrowhead in an acquisition context, I showed three possible buyers, what each could afford, what holds each of them back, and how a contested sale would end up setting the price. Anyone who thinks I am wrong can say which of those is wrong. That is the bar, and I would rather be visibly wrong than opaquely right.

8. Why this matters right now

Two readouts land this month. One asks whether a single molecule can switch off two genes at once. The other asks whether a shot under the skin can switch off a gene inside a living human brain.

Both of those sit inside the 25 percent bucket.

If they work, the thing that changed is not that two drugs got better odds. DIMER working tells you something about DIMER and something about whether Arrowhead can build molecules that hit two targets at once as a general matter. MAPT working tells you something about MAPT and something about whether a shot under the skin can produce meaningful target knockdown in the human central nervous system at all.

A drug readout updates the probability of one drug. A platform readout updates the probability distribution of drugs that do not exist yet. Conventional models naturally register the first and usually leave the second implicit.

The market finds out this month whether the land has oil under it. The question is whether the models treat that as information about two wells, or as information about the field.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. Patent counts reflect the author's review of Arrowhead patent families, with each target family counted once regardless of jurisdiction or continuation. Valuation methodologies and composition figures are as described in published research notes from Morgan Stanley, Stifel and Bank of America following the ESC Congress, and percentages are approximate. Nothing here should be read as a criticism of any individual analyst's competence or integrity. The Genentech transaction value is as reported at the time.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. What happened

Novartis announced this afternoon that its big Lp(a) trial failed. Across 8,323 patients with established cardiovascular disease and high Lp(a), pelacarsen failed to reduce the combined risk of cardiovascular death, heart attack, stroke and urgent coronary procedures versus placebo.

Read the next sentence of their release carefully, because it is the whole story. Lower Lp(a) levels were achieved with pelacarsen.

The drug did exactly what it was designed to do. It lowered the thing. Lowering the thing did not improve outcomes in the overall study population.

2. Why this is a hypothesis failure and not a modality failure

The distinction matters and it is going to get blurred in the coverage over the next few days.

Pelacarsen is an antisense drug, which is a different chemistry from Arrowhead’s RNAi but aimed at the same job of silencing a gene’s message. Ionis discovered it and licensed it to Novartis. Nothing here says either chemistry is broken. The molecule got to the liver, reduced production of apolipoprotein(a) and kept Lp(a) low in thousands of people for years.

What failed is narrower than the target itself. HORIZON refuted the proposition that the depth and duration of Lp(a) lowering pelacarsen achieved, in this treated secondary prevention population, produces a detectable cardiovascular benefit. That is a specific claim and it is now dead. Whether Lp(a) is a viable target at all is a wider question this trial does not fully settle.

Twenty years of genetic evidence said Lp(a) causes cardiovascular disease. That evidence appears to have been right about causation and wrong about reversibility, at least in this population and at this level of lowering.

Genetics measures what happens to somebody who carries elevated Lp(a) from birth. HORIZON asked something different. It asked whether lowering it late, after atherosclerosis is already built and while statins and blood pressure drugs are doing their work, undoes enough of that accumulated history to change what happens next.

Those are not the same experiment, and causation does not guarantee reversibility. The industry has spent a long time treating them as though it did.

3. What it costs Arrowhead directly

Olpasiran is Arrowhead’s own Lp(a) drug. Arrowhead built it and licensed it to Amgen back in 2016, and Amgen is now running OCEAN(a)-Outcomes, which tests the same idea with Arrowhead’s chemistry instead of Ionis’s.

The economics are less exposed than they look, because of a decision made four years ago.

Figure 1. Amounts as disclosed in company filings and the November 2022 agreement.

In November 2022 Arrowhead sold its entire olpasiran royalty interest to Royalty Pharma for $250 million in cash, plus up to $160 million in milestones payable back to Arrowhead. The first of those, $50 million on completion of OCEAN Phase 3 enrollment, was collected in 2024.

That means $300 million has been received. The filings state plainly that Arrowhead is not obligated to repay it.

What is now in doubt is the remaining $110 million from Royalty Pharma, since both remaining triggers require an approved and selling drug, and much of the roughly $375 million in Amgen milestones still outstanding, particularly the regulatory and sales portions, which Arrowhead retained when it sold the royalty.

Arrowhead sold a royalty stream in 2022 for $250 million it never has to give back, four years before anybody knew whether the drug worked. Royalty Pharma bought the risk. This afternoon that looks like one of the better capital allocation decisions this management team has made.

I would not oversell it as foresight. Monetizing a partnered royalty to fund your own pipeline is a reasonable thing to do regardless of how the trial turns out. The trade was available to be made badly, though, and it was not made badly.

4. What happens to OCEAN(a)

Amgen almost certainly finishes. Enrollment closed in 2024, the trial runs to roughly seven thousand patients, it is event-driven, and the money is spent. Companies do not stop trials at this stage because a competitor missed.

The probability of success dropped hard this afternoon, though, and anyone telling you otherwise is selling something.

OCEAN(a) is not a carbon copy, and the differences deserve a fair hearing. It enrolled 7,297 patients at a higher Lp(a) threshold. Olpasiran produces substantially deeper suppression, above 95 percent at the higher doses in Phase 2 against roughly 80 percent for pelacarsen. Its primary composite is not identical to HORIZON. Novartis also wrote that the findings did not demonstrate reduced risk in the overall study population, which leaves the prespecified 90 mg/dL subgroup unaddressed.

Those differences are enough to keep the experiment worth running. They are not enough to pretend the prior probability has not moved. The surviving argument is that the effect needs sicker patients or deeper suppression than pelacarsen delivered, which is not absurd and is also what every program in this position says. I would want the subgroup data from the congress before giving it much weight.

5. The part that matters more than the money

Set the milestones aside. They are small against a twelve billion dollar company.

What happened this afternoon is the most expensive demonstration available that moving a biomarker is not the same as helping a patient.

Eight thousand three hundred and twenty-three people. Years of follow-up. A drug that unambiguously lowered the marker it was built to lower, in a target with two decades of human genetic evidence behind it, in a population where the marker is present in roughly one person in five. Then no demonstrated benefit.

Chess has a word for this. A refutation is a concrete demonstration that a line which looked perfectly sound actually loses. It does not mean the opening is bad or the pieces are wrong. It means that particular sequence has been worked out to the end and does not hold. Theory gets rewritten and everybody stops playing it.

This version of Lp(a) lowering was theory. Eight thousand patients was the refutation. The pieces are fine. That line is not.

6. What this should do to how you read September

Arrowhead reports first human data on ARO-MAPT at the end of this quarter or early next. The number everybody will trade on is tau reduction in cerebrospinal fluid.

That number tells you the drug got where it was going and reduced production of the protein it was built to target. That would demonstrate something RNAi has not previously established clinically, which is systemic delivery to the human central nervous system from a simple shot under the skin.

It is also exactly the kind of number pelacarsen produced.

I wrote earlier this week that a drug readout updates the probability of one drug while a platform readout updates the probability of drugs that do not exist yet. Both of those are still true. What this afternoon adds is the other half of the same idea. A biomarker readout establishes target engagement, not patient benefit, until somebody connects the two.

That connection is exactly what CELIA has begun to suggest for tau without yet establishing it. Diranersen lowered cerebrospinal tau by 50 to 65 percent and produced a clinical signal, and it missed its primary dose-response endpoint because higher doses did not produce greater benefit. For neurofilament in ALS, the FDA accepted a reduction as reasonably likely to predict clinical benefit, which is a regulatory judgment rather than a proven link. For Lp(a), Novartis has just spent eight thousand patients failing to establish that connection in the overall population.

If September delivers deep tau knockdown, that is a delivery result and it is worth a great deal to the platform. It is not, by itself, evidence that ARO-MAPT helps anybody with Alzheimer’s disease. Today is a reminder of how expensive it is to learn the difference.

7. Where that leaves things

For Arrowhead, a modest financial hit against milestones that were never in the base case, and a partnered program whose odds just got materially worse.

For Ionis, a harder afternoon. They lose the pelacarsen economics on top of already competing against plozasiran in severe hypertriglyceridemia.

For Novartis, worth watching. They face the largest patent expiry in their history and just lost a cardiovascular asset that was meant to help fill it. That does not reduce their need to buy something. It sharpens it.

For anybody holding this stock into a first-in-human CNS readout, a well-timed reminder that the number in the headline and the question that matters are not always the same number.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. Lp(a)HORIZON details are from the Novartis release of September 4, 2026. Olpasiran deal terms are from the November 2022 Royalty Pharma agreement and Arrowhead's subsequent quarterly filings. Full Lp(a)HORIZON results have not been presented and the analysis here is based on topline disclosure only.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The question I get more than any other about ARO-MAPT is not how much tau it will lower. It is how quickly this could reach patients, and whether it could qualify for accelerated approval.

This note is an attempt to answer it properly.

The conventional answer is grim. Alzheimer’s trials measure how fast a patient declines, and demonstrating a convincing difference generally takes many months to years, with eighteen to twenty-four months typical for pivotal programs. A program built that way puts approval somewhere in the middle of the next decade. Fast Track designation does not change that. It buys more meetings with the FDA and can make a program eligible for rolling review, meaning the application is submitted in pieces rather than all at once. It does not, by itself, turn a conventional efficacy trial into a shorter one.

There is a faster route, and it is not hypothetical. The FDA can approve a drug based on a biomarker that is reasonably likely to predict clinical benefit, with the trial proving it actually helps patients finished afterward. Two Alzheimer’s drugs have come through that door. A neurology drug almost nobody outside the field has heard of came through the same door.

The difference between how those cases went is the whole subject of this note, and it points at a number that is not currently being discussed.

1. A word on who actually decides

One thing has to be explained first, because both stories below turn on it.

When the FDA reviews a drug, it can convene an advisory committee. That is a panel of outside experts, clinicians, statisticians and often a patient representative, who read the application, hear the company and the agency present, and then vote in public on specific questions.

The vote is advice. The FDA is not bound by it and has gone against it before.

There is a second detail that matters more than it sounds. The agency writes the questions. It decides what the committee is asked to vote on and what stays off the agenda. Hold onto that.

2. How it goes wrong

On June 7, 2021, the FDA approved aducanumab for Alzheimer’s on the basis of reduced amyloid plaque.

Its own advisory committee had been unenthusiastic to the point of hostility. On the central question, whether it was reasonable to treat the one positive trial as primary evidence of effectiveness, the vote was 0 yes, 10 no, 1 uncertain. Its own statistical reviewers had rejected the application. Within days of the approval, three members of that committee resigned, one describing it as probably the worst drug approval decision in recent United States history.

The detail that matters most is procedural rather than scientific. None of the four questions put to the committee asked whether reducing amyloid plaque met the standard for accelerated approval. According to committee members writing afterward, the lead FDA scientist told them during the meeting that the agency was not using amyloid as a surrogate for efficacy. Seven months later the agency approved the drug under the accelerated approval pathway on the basis of amyloid reduction.

What followed was worse for the company than the controversy. The Centers for Medicare and Medicaid Services restricted coverage to patients enrolled in clinical trials. Major hospital systems declined to administer it. The drug was eventually withdrawn.

An approval that leaves the vast majority of eligible patients without coverage is not much of a commercial approval. The lesson of aducanumab is not that the surrogate was wrong. It is that a surrogate never argued in the open does not survive contact with the people who decide what gets reimbursed.

3. How it goes right

On April 25, 2023, the FDA approved tofersen for a genetic form of ALS under accelerated approval, based on a drop in a blood marker called neurofilament light chain, or NfL.

The Phase 3 trial had missed its primary endpoint, and not narrowly. The measure was a functional rating scale covering things like speech, swallowing, walking and breathing. Drug and placebo separated by 1.2 points on it, with a p-value of 0.97.

That last number deserves a translation. A p-value estimates how often a result this size would show up by chance if the drug did nothing. Below 0.05 is the conventional threshold for calling a result real. At 0.97, the trial was not close to the line. It was about as far from it as a result can get.

The advisory committee, meeting a month earlier, was asked two questions rather than one. On whether the drop in NfL was reasonably likely to predict clinical benefit, the vote was 9-0 in favor. On whether the clinical results were convincing evidence that the drug worked, the vote was 5-3 against, with one abstention.

Read that again. The committee rejected the clinical evidence and endorsed the biomarker, in two separate recorded votes, and the FDA approved on the biomarker. Nobody resigned. The review team’s own document notes that it identified no issues precluding accelerated approval.

The confirmatory trial, running in people who carry the mutation but have not yet developed symptoms, has a primary completion date in 2027 and runs into 2028.

4. The difference

Aducanumab and tofersen offer two sharply contrasting accelerated approval precedents, less than two years apart. One collapsed commercially. The other remains intact while its confirmatory trial runs. The distinction runs along two lines, and both matter for tau.

The first is what the biomarker measures. Amyloid plaque reduction tells you the pathology the drug was aimed at has changed, and the FDA does treat plaque reduction as reasonably likely to predict clinical benefit. It sits close to the therapy, in the same compartment the drug was designed to act on. NfL sits further out. Nerve cells release it when their fibers are damaged, so a falling NfL suggests the rate of neuroaxonal injury is coming down. It is not a measure of whether the drug hit its target. It is a measure of what is happening downstream of it.

Tofersen had a target engagement measure available. Its developers tracked the SOD1 protein in spinal fluid, which tells you directly whether the drug hit its target. That is not what the approval rested on.

The FDA did not approve tofersen because the randomized trial established clinical benefit. It did not. It approved tofersen because the evidence taken together supported NfL as reasonably likely to predict that it would.

There is a third case that belongs here, because it complicates the neat version of this story.

Lecanemab received accelerated approval in January 2023 on the same amyloid surrogate that had gone so badly for aducanumab. Six months later it converted to traditional approval, because its confirmatory Phase 3 demonstrated clinical benefit. Same biomarker, same pathway, opposite outcome.

Which means the lesson is not that pathology biomarkers fail and injury biomarkers succeed. The lesson is that a surrogate has to sit inside an evidentiary package that makes the clinical inference credible. Aducanumab had a contested surrogate, conflicting trials and a regulatory process that drew extraordinary criticism. Lecanemab had the same surrogate and a clean confirmatory result. Tofersen had a downstream marker, a coherent mechanistic story and a public committee endorsement.

The second difference is procedural. Tofersen’s surrogate was written into the questions, argued in public, and won a unanimous vote on the record. Aducanumab’s surrogate was never put to the committee as a question, and then became the basis for approval. One approval had a public record of expert endorsement behind it. The other did not. That does not mean a committee endorsement would have changed the reimbursement decision, and CMS grounded its restriction in insufficient evidence of improved health outcomes rather than in anything procedural. It does mean the approval entered the reimbursement debate without a public expert record validating the surrogate the FDA had ultimately relied on.

5. What CELIA just did to the tau surrogate

Which brings this to July, and to a result that has been read almost entirely as good news for tau. It is good news for the mechanism. It is bad news for the simplest version of the surrogate argument, and almost nobody has said so.

Diranersen, a drug that lowers tau, reported eighteen-month Phase 2 results in 416 patients with early Alzheimer’s. Total tau in spinal fluid fell 50 to 65 percent across all three dosing schedules. Tau imaging showed reductions across all doses while placebo rose. On the cognitive measures, the lowest dose arm slowed decline by 26 percent on one clinical scale, 42 percent on another, and 50 percent on a third. Worth noting immediately that this arm had 60 patients in it. Impressive percentages from small groups deserve to be read with the group size attached.

Caveats aside, that is the strongest randomized evidence yet that lowering tau might change the course of Alzheimer’s disease. The trial did not prove it, and it missed the endpoint it was built around. It is still the most encouraging thing this mechanism has produced, and it de-risks the biology for everyone working in it, including Arrowhead.

Now the problem. Higher doses produced greater tau reduction without producing greater clinical benefit. The cognitive measures favored the drug across all doses, but more tau lowering did not buy more slowing. The trial’s primary endpoint was an assessment of dose response, and on that measure it failed.

Sit with what that means to a regulator. A drug lowered tau robustly, in a dose-dependent way, confirmed by imaging. The strongest clinical signal came from the lowest-dose group, even though the higher doses produced greater tau reduction. Whether that reflects an optimal dosing window, a non-linear exposure relationship, a difference between the tau being measured and the tau doing damage, or simply noise in a 416-patient study, nobody yet knows.

If somebody asked the FDA today to accept the size of a spinal fluid tau reduction, by itself, as evidence that a drug will help patients, CELIA is the obvious counterexample, and there is currently no good answer to it.

Tau reduction, on this data, behaves like target engagement. It tells you the drug reached the brain and did its job. It does not, on its own, tell you the patient will be better off. That is one reason the tofersen precedent is particularly interesting for a tau-lowering program.

6. What Arrowhead would need

All of which produces a specific checklist rather than a general hope. Six things, roughly in order of how hard they are.

Deep tau reduction that lasts. The obvious one, and the one everybody is watching. It is necessary and nowhere near sufficient.

Two things make it harder than it sounds. A 50 percent reduction in healthy volunteers does not guarantee the same magnitude in somebody with established tau pathology, so the healthy volunteer number cannot simply be assumed to carry over. A reduction that fades between doses is also worth much less than one that holds, because a patient spends the back half of every dosing cycle drifting back toward where they started.

Figure 1: Where the evidence for each link currently comes from. Only the first is what September tests.

The NfL trajectory bending, and considerably more than that. This is the item nobody is discussing, it is the center of the whole case, and the tofersen file shows the bar is far higher than simply getting the number to move.

A surrogate is a measurement that stands in for the thing you actually care about. What anyone actually cares about in Alzheimer’s is whether the patient can still recognize their family in three years. You cannot wait years for that outcome every time you test a drug, so you look for something that moves earlier and reliably predicts it.

Tau reduction is not quite that, on the current evidence. It tells you the drug got in and did its job.

Chess has a word for the position tau is now in. A piece is pinned when it cannot usefully move, because moving it would expose something more valuable sitting behind it. The piece is still valuable. It simply cannot do the work by itself, and the reason has nothing to do with the piece.

That is where the tau number stands after CELIA. It is the figure management benchmarked, the figure September reports, and the figure the market will trade on. Sitting behind it is the ultimate question that matters, which is whether patients end up better off. Tau does not answer that question on its own, and diranersen just demonstrated it by lowering tau further without producing greater clinical benefit.

The consequence matters more than the metaphor. A bigger tau number does not fix this. Pushing harder on a pinned piece accomplishes nothing, because the problem was never how hard you pushed. What breaks a pin is bringing another piece to bear, and the pinned piece then becomes useful again.

NfL is the different piece. It is a marker of axonal injury and neurodegeneration, released when nerve fibers are damaged. When NfL falls, it suggests the rate of neuronal injury is falling. It is not a measure of whether the drug hit its target. It is a measure of what is happening downstream, in the disease itself. Tofersen’s accelerated approval centered on a blood-based biomarker, NfL, which is why the file matters so much here.

One caveat belongs up front. In SOD1-ALS, axons die quickly and in large numbers, so the NfL signal is loud and moves within months. Alzheimer’s is slower and the elevation is milder. The FDA accepting NfL in one disease does not commit it to accepting NfL in the other, and the agency will say so. Other markers have done it, amyloid in Alzheimer’s and dystrophin in muscular dystrophy among them. NfL is unusual because it measures downstream neuroaxonal injury rather than target engagement.

Now the complication, and it is a real one. The only reported human trial of a tau-lowering drug that I am aware of measuring NfL did not find what this argument needs.

In the Phase 1b study of diranersen, published in 2023, CSF NfL was tracked as an exploratory measure. Eight weeks after the last dose it showed no dose-responsive effect. NfL fell in the placebo group and in the lowest dose group, and rose slightly in the higher dose groups. The authors said plainly that the changes were not dose responsive and not concordant, and that assay variability and small sample size limited what could be read into them.

Anyone building a case on NfL has to deal with that, so here is the case.

The study enrolled 46 people across five arms. Individual dose groups had six to thirteen participants. It looked eight weeks past the last dose. That is a small, short experiment, and its own investigators said so.

More importantly, it may have been asking the wrong question. In somebody who already has Alzheimer’s, substantial neuronal and axonal injury has already occurred, and NfL is elevated because of it. A drug working upstream, at the level of tau production, would not be expected to reverse damage that has already happened. The relevant signal may therefore be a reduction in the rate of new injury rather than an immediate fall below baseline.

The right question is therefore probably not whether NfL falls. It is whether the climb slows.

Picture two lines over eighteen months, in illustrative indexed units rather than real values. On placebo, NfL runs 100, then 112, then 124, then 136. On drug, it runs 100, then 104, then 107, then 110. NfL never drops below where it started. That would still be one of the most important results this field has produced, because it would suggest that the rate of ongoing neuroaxonal injury had slowed.

One further caveat belongs here. NfL is not specific to Alzheimer’s disease. It rises with many kinds of neurological injury, climbs with age, and is affected by kidney function among other things. That raises the bar for using it as a surrogate, though a randomized design with repeated within-patient measurements helps mitigate those problems far better than a single absolute reading does.

Stated precisely, the question is whether the longitudinal slope differs from placebo, not whether the treated group’s absolute NfL value falls. Answering it requires a long trial with repeated measurements, which is exactly what the Phase 1b was not. The longitudinal experiment this hypothesis needs has not actually been reported.

One practical note follows from all of it. NfL can be measured in blood as well as spinal fluid. Plasma carries the practical advantage, because it can be drawn at ordinary study visits and repeated as often as the schedule allows, which lets investigators estimate an individual patient’s trajectory rather than relying on a handful of lumbar punctures. A program serious about this question collects plasma NfL longitudinally and treats CSF as complementary.

What the tofersen file actually required. Biogen’s advisory committee materials are public, and they are the clearest statement available of what the FDA wanted before accepting a novel surrogate. The agency’s own guidance, quoted in those materials, says a reasonably likely surrogate depends on two things: the biological plausibility of the relationship between the disease, the endpoint and the desired effect, and the empirical evidence supporting that relationship.

Biogen met the second requirement with roughly a hundred published citations spanning 1996 to 2023. That literature established, independently of any drug, that NfL is elevated in ALS above nearly every other neurodegenerative disease, that it distinguishes ALS from conditions that mimic it, that it correlates with the rate of decline across multiple separate cohorts, and that it predicts survival. Decades of work by people with no stake in the outcome.

They then did something more demanding than showing the marker moved. They built a model estimating how much clinical benefit each unit of NfL reduction bought. For every 10 pg/mL fall in plasma NfL at Week 16, the model predicted 0.77 points of preserved function on the ALS rating scale at Week 28, with a p-value of 0.0038, alongside parallel estimates for quality of life and for the risk of death.

The bar was not that the biomarker moved. It was a quantified relationship between how far it moved and how much the patient benefited, sitting on top of thirty years of independent literature.

There is a mirror-image piece of evidence in the same materials, and it is the kind of thing that makes a regulator believe a marker. A different antisense drug, aimed at a different ALS gene, raised CSF NfL by 37 percent. The patients receiving it did worse. A biomarker that moves the wrong way and drags outcomes with it is powerful confirmation that it tracks something real.

One process detail completes the picture. Biogen held a formal meeting with the FDA in April 2022 specifically to discuss the utility of NfL for accelerated approval, three months before filing. The surrogate was negotiated with the agency in advance and then ratified in public by the committee. It was not sprung on anybody.

Several markers agreeing, not one. The strongest version of this argument is not a single impressive number.

CELIA’s real problem was disagreement. Tau went down, imaging confirmed it, but the strongest clinical signal came from the lowest-dose group. When the biology and the clinical results point different directions, a regulator has no way to know which one to believe.

The fix is not a better single measurement. It is having tau, NfL, imaging and the cognitive scores all move the same way at the same time. Any one of them can be a fluke. Four of them agreeing is a story.

A dose-response that behaves. Regulators look for an exposure-response relationship that makes biological sense. It does not have to be a straight line, and more drug does not have to produce endlessly greater benefit, since real drugs plateau and therapeutic windows exist. What it does have to be is interpretable.

CELIA is hard to interpret on exactly that basis. Across the doses studied, increasing tau reduction did not translate into increasing clinical benefit. That single fact is the hardest thing in its dataset to explain and it is why the trial formally failed. A program that shows benefit rising with exposure has an argument available to it that diranersen currently does not.

The surrogate argued in public. The lesson from aducanumab, where the committee never voted on the surrogate the approval ultimately rested on, is not optional. It is also cheaper to follow than to skip.

For the strongest possible regulatory and reimbursement case, a tau surrogate should be written into the questions put to an advisory committee, debated openly, and endorsed on the record. The FDA is not obliged to convene a committee at all. The argument here is not that it cannot approve without one, but that after aducanumab, nobody should want a contested surrogate approval without transparent outside validation behind it. Approving first and explaining later is what happened in 2021, and the people watching most closely were not at the FDA at all.

They were at the Centers for Medicare and Medicaid Services, which decides whether Medicare pays. CMS is a separate agency with a separate process, and after aducanumab it restricted coverage to patients enrolled in clinical trials. An approved drug that Medicare will reimburse only under highly restrictive conditions, in a disease of the elderly, is not much of a commercial product. Winning the FDA argument and losing the CMS one is the worst outcome available.

The confirmatory trial already running. Accelerated approval is conditional. The company gets to sell the drug while it runs the study that proves the biomarker was telling the truth, and if that study fails, the approval can be withdrawn.

For years, companies collected the approval and let the confirmatory work drift. Congress has since given the FDA explicit authority to require that the confirmatory study be underway before accelerated approval is granted, and current agency policy strongly favors starting that work early rather than waiting until after approval. That pulls a great deal of expensive work forward, which is exactly the point.

The opportunity is not to replace tau with NfL. It is to connect them. Tau shows that ARO-MAPT is doing what it was designed to do. NfL could show that what it is doing matters to the disease.

7. What the current trial is not designed to do

Worth being clear about where things actually stand.

Public trial registries require a company to state, in advance, what a study is designed to measure. For the ongoing ARO-MAPT study, the single primary measure is side effects, tracked through day 270. The secondary measures are twelve readings of how the drug moves through the body, meaning how much gets absorbed, how long it lasts, how it clears, plus three routine safety checks on spinal fluid: total protein, glucose, and cell count.

Neither tau nor NfL appears in that list. That is a statement about what the study is formally designed to prove. It is not a statement that either biomarker is going unmeasured.

That is not a criticism. This is a first-in-human safety and pharmacokinetics study, and it is registered as one. Management has said the update will include tau knockdown in healthy volunteers, so tau is presumably being tracked as an exploratory measure. That is entirely normal, and exploratory biomarker measurements do not necessarily appear among a registry’s primary and secondary outcome measures.

The point is what it tells you about the number the market will trade on. It will arrive as an exploratory result, meaning a measurement taken out of interest rather than one the study was built to prove, from a trial designed to answer a different question, quite possibly in a small number of participants. It is the beginning of the regulatory argument, not evidence that can settle it.

Which also means the question worth asking is forward-looking. Once adequate target engagement is established, whether NfL is being collected now, and whether Arrowhead plans to carry it into the patient cohorts and the Phase 2 design, tells you more about the timeline to approval than the precise magnitude reported in September.

8. The faster door is not Alzheimer’s

There is a route to an accelerated approval that runs around the Alzheimer’s problem entirely, and Arrowhead’s own language already gestures at it. The program is described as being for Alzheimer’s disease and other tauopathies.

The other tauopathies may come first.

Progressive supranuclear palsy is a primary 4R tauopathy. Amyloid is not a defining pathology, unlike in Alzheimer’s disease. It moves fast and you can measure it. It is rare enough that trials run in the low hundreds instead of the thousands. There is no approved disease-modifying treatment. The protein the drug silences is the defining pathological protein in the disease, which makes it an unusually clean test of the mechanism.

Tofersen is the useful analogy here, though the analogy is regulatory rather than biological. A rare, fast-moving, well-defined neurodegenerative disease with major unmet need, approved on a biomarker after a Phase 3 that missed, is a far more applicable precedent for progressive supranuclear palsy than anything in the amyloid history. The disease biology, the biomarker kinetics and the trial endpoints are not interchangeable between the two, and the regulatory argument would still have to be built from scratch.

A tau drug that changes the course of a rare tauopathy could give the FDA a much stronger human precedent for accepting tau biology as part of the regulatory case in the common one. The rare disease is not the consolation prize. It is the argument.

9. The odds, and what would change them

Making a case for something is not the same as predicting it, so here are the odds as I actually see them.

Accelerated approval for ARO-MAPT in Alzheimer’s disease is unlikely. My estimate before CELIA was somewhere around ten to fifteen percent, and CELIA moves it in both directions at once, strengthening the mechanism while weakening the simplest version of the surrogate argument. I would leave it roughly where it was.

That number is not arbitrary, and it is worth showing the parts. Getting there requires deep and durable tau knockdown in patients, which I would put at better than even. It requires a measurable separation in the NfL trajectory, which I would put below even, given the limited human evidence to date rather than because the biology argues against it. It requires the FDA to accept NfL as a surrogate in Alzheimer’s specifically, having only ever accepted it in ALS, which I would put well below even. It requires the biomarkers and the cognitive data to point the same direction. It requires the confirmatory program to be underway early enough to satisfy the FDA’s accelerated approval expectations.

One distinction is worth drawing inside that list. The scientific probability and the regulatory probability are not the same thing, and the second is lower. Even a convincing NfL result would still leave Arrowhead having to establish that NfL is a valid surrogate in Alzheimer’s disease specifically, which is a separate argument from having produced good data.

The chain is long enough that even reasonably plausible probabilities at each step would produce a low-teens result overall. That is a conceptual probability tree rather than a calculated model, and it is offered as one. Any one of those links failing could close this particular route, which is why the number stays small even though several of the individual steps are more likely than not. It would not necessarily close every route, since a different biomarker package, unexpectedly strong clinical data, or a different indication could each open another.

A convincing NfL dataset in patients would move that number more than anything else, plausibly doubling it. That is a real if, given that the one reported tau-lowering trial I am aware of that measured NfL did not deliver it, and it is the single most important thing to watch over the next three years. Convergence across several markers and a clean dose-response would matter nearly as much.

An accelerated approval in progressive supranuclear palsy may be a materially better opportunity than the Alzheimer’s version, and could arrive years earlier if pursued in parallel from the start.

The reimbursement question sits behind all of it. The FDA approving a drug is not the same as patients getting it, and aducanumab is the reason that sentence has to appear in any honest note on this subject.

10. Where this leaves the September readout

The September number is a first step and will be treated as a verdict.

What it can establish is human central nervous system target engagement after subcutaneous dosing, meaning that systemic dosing produced a measurable pharmacodynamic effect within the central nervous system. If that had not worked, nothing else would have mattered. That is worth a great deal, and it is worth more to the platform than to this particular drug.

What it cannot establish is whether lowering tau helps a patient, because CELIA has just demonstrated that the two questions come apart.

The most credible path I can see to patients getting this drug early runs through a biomarker that was not in the headline, in a disease that is not Alzheimer’s, argued in front of a committee that has not yet been convened.

The case for early approval is real. It simply does not run through the number everyone will be looking at in September.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The presentation nobody went to

Nine in the morning on Monday, in a session called Beyond statins, a physician from Peking Union Medical College Hospital in Beijing presented the first Phase 3 results anywhere in the world for zodasiran.

It appeared in the program under Visirna’s development code, VSA003, rather than zodasiran or ARO-ANG3, the name most Arrowhead investors know it by. Arrowhead mentioned it in one sentence on its investor call an hour later. As far as I can tell, almost nobody wrote about it.

The disease is homozygous familial hypercholesterolemia (HoFH). About as rare as diseases get, somewhere between one in 170,000 and one in 300,000 people.

Here is what these patients are dealing with. Your liver clears cholesterol out of your blood using a receptor on the surface of its cells. These patients inherit defects that leave that receptor pathway severely impaired, in some cases close to nonfunctional. Statins work largely by making the liver produce more of those receptors, so in this disease there is much less receptor function to work with. Untreated, patients develop heart disease as children.

The trial enrolled 46 people in China, 30 on drug and 16 on placebo. Average starting LDL cholesterol was around 390 milligrams per deciliter. A normal number is under 100.

2. The number, and who to measure it against

LDL cholesterol dropped 44.8 percent from where patients started, and 43.9 percentage points more than placebo, at six months. ANGPTL3, the protein the drug is designed to suppress, fell 89.4 percent from baseline, which is 86.2 points more than placebo.

Two comparisons make that number mean something, and neither is obvious from the press coverage.

The first is Arrowhead’s own earlier study. A Phase 2 called GATEWAY, run in a similar population, produced a 35.7 percent LDL reduction at this same dose. The China Phase 3 beat it by about nine points.

That should get your attention. It would have been reasonable to expect some fade in a larger, properly blinded Phase 3, particularly coming off an open-label Phase 2 where everybody knew who was getting the drug. GATEWAY was open-label. This one was blinded. The effect got bigger anyway.

The second is the drug this would compete with. Evinacumab is an approved antibody for this disease, it hits the same target, and in its pivotal trial it lowered LDL by 47.1 percent from baseline. It is given by intravenous infusion, once every four weeks.

Zodasiran came in at 44.8 percent on the same measure. Roughly two points apart. It is a shot under the skin, once every three months.

Figure 1. Both figures are reduction from baseline. They come from separate trials in different populations and are not directly comparable.

3. Why those two points are worth giving up

Thirteen infusions a year against four injections. That sounds like a convenience argument until you think about who is receiving them.

This disease gets diagnosed in childhood. Treatment never stops. Plenty of these patients are also on apheresis, which is a procedure that filters cholesterol out of the blood mechanically, and it means hours hooked to a machine every week or two on top of everything else. The average patient in this trial was in their thirties. Four of them were teenagers.

An evinacumab infusion needs a clinic, an appointment, a nurse, an IV line and most of a morning, every four weeks. A quarterly injection is a fundamentally smaller procedure. Even if every zodasiran dose were given in a clinic rather than at home, that is four brief visits a year instead of thirteen infusions. Spread across forty or fifty years of treatment, that stops being about convenience.

Chess has a name for this kind of trade. Giving up the exchange means handing your opponent a rook, the more valuable piece, in return for a bishop or a knight and a better position. On the scoresheet you have lost material. Tigran Petrosian built a world championship partly on these, and for years both computers and commentators undervalued them, because material is easy to count and position is not.

Zodasiran gives up roughly two points of cholesterol lowering. It gets back nine infusion visits a year, every year, for the rest of somebody’s life. Anyone scoring this on the efficacy number alone is counting material and ignoring the position.

Worth adding: two thirds of the patients in this trial were already on a PCSK9 inhibitor, and the drug worked on top of it.

4. What the slides left out

Two things are missing from the presentation, and I think both are informative rather than sinister.

The responder rate stops at 30 percent. The trial design slide says they planned to report the share of patients who cut LDL by at least 30 percent and by at least 50 percent. The results give you the 30 percent number, which was 83.3 percent of treated patients. The 50 percent number never appears. In a deck built to show a drug at its best, the omission suggests that number was not the headline.

Goal attainment is missing too. The presentation does not report how many patients reached a specific LDL target, and a group average cannot answer that question, because patients did not all start in the same place or respond by the same amount. What the average does tell you is how brutal this disease is. The treated group started around 383 milligrams per deciliter, and even a 45 percent cut leaves the average patient well above what guidelines want for an adult with this condition. Some individuals may well have reached goal. The slides do not say how many.

This should eventually get a real answer. The global Phase 3, called YOSEMITE, lists the proportion of patients getting below 100 milligrams per deciliter as a secondary objective. It is fully enrolled at 70 patients with completion expected around the middle of 2027.

5. The liver signal

Start with the context. Overall side-effect rates were essentially identical, 76.7 percent on drug against 75.0 percent on placebo, and there were no drug-related serious adverse events at all. Against that backdrop, one thing stands out.

Three patients on drug had liver-related adverse events flagged. None on placebo did.

Two were mild elevations in a liver enzyme called AST, three to five times the normal ceiling. One was moderate, above five times, and the investigator judged it probably unrelated to the drug. All three cleared up within six weeks. Total bilirubin stayed below twice the normal ceiling in every case, and that matters: a substantial bilirubin rise alongside those enzyme elevations would raise considerably more concern for clinically significant drug-induced liver injury.

The slide separately notes two moderate drug-related events in patients whose liver enzymes were already abnormal before they started. Both were still unresolved when the database closed.

Three events in thirty patients is a small number and a real one. I would watch it rather than worry about it, and I would want the imaging. An earlier zodasiran study measured liver fat directly by MRI and found it moved in the favorable direction. This trial did no imaging at all, and that is a gap I would want closed somewhere in the broader zodasiran safety package.

One detail says somebody was paying attention. Worsening blood sugar in diabetic patients was written into the protocol in advance as something to watch for specifically. Zero events, both arms.

There was one death, sudden cardiac death in a 61-year-old woman with several risk factors, judged unrelated to treatment. In a population carrying extreme lifetime cardiovascular risk, a sudden cardiac death is unfortunately not unexpected. Somebody will still quote it without the context.

6. The number worth watching

Lipoprotein(a) came in 28.9 percentage points lower than placebo, with a p-value of 0.0016. Lp(a) is set by your genes, barely responds to anything, and independently drives cardiovascular risk. A reduction that size from a drug not designed to touch it would be genuinely interesting.

I would hold it loosely. The placebo group started with much higher Lp(a) than the treatment group, 148.8 against 116.5, which is a real imbalance in a 46-person trial. The spread around the estimate is wide. The pivotal antibody data against this same target did not show anything close to this magnitude of Lp(a) lowering.

Worth watching in the global study. Not worth building anything on yet.

7. The pattern, which is the actual story

This is the second time in two days that Arrowhead presented a Phase 3 result resting on the same foundation.

Sunday: plozasiran matched or beat an approved competitor on triglyceride lowering and offered four injections a year against that competitor’s twelve.

Monday: zodasiran came within roughly two points of an approved competitor on LDL lowering and offered four injections a year against that competitor’s thirteen intravenous infusions.

Different disease, different target, different competitor, different continent. One sentence describes both. Comparable efficacy, radically better delivery.

That is what a platform looks like when it is working. Raw potency is not the common denominator here. Efficient delivery and durability are. Arrowhead is getting a molecule where it needs to go and producing gene silencing durable enough to dose on a schedule a patient can actually live with, which is the thing that has always been hardest in this field.

8. What it is actually worth

Very little directly. Quite a lot indirectly.

The direct commercial opportunity is not the point. China has roughly 5,000 patients with this condition, and only about four percent of them are on any cholesterol-lowering therapy at all. Greater China rights are licensed to Visirna, which is Arrowhead’s majority-owned regional vehicle rather than an unrelated partner, so the economics are not entirely someone else’s. Even so, nobody should be modeling meaningful revenue off a few thousand Chinese patients.

What it buys is a positive, blinded Phase 3, run separately by Visirna in China, on the same molecule in the same indication as the global YOSEMITE program. Zodasiran has had a complicated history, and in this disease specifically, until Monday it was an asset with encouraging open-label Phase 2 data and an open question about the liver. It is now an asset with a blinded Phase 3 that beat its own Phase 2.

That does not make zodasiran approved in Arrowhead’s major commercial markets. It changes what it is reasonable to assume about the trial that would.

9. The chair

Strip out the endpoints and it comes down to something simple.

Somebody with this disease will spend their life in treatment. The question Monday answered was not whether a new drug lowers cholesterol, because the approved antibody already does that, and slightly better. The question was how much of that life has to be spent sitting in a clinic.

Arrowhead did not present a better cholesterol drug on Monday. It presented one that is nearly as good and asks for a fraction of the patient’s life. That has been the argument all week.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Trial figures come from the presentation delivered at the ESC Congress on August 31, 2026. Comparisons to GATEWAY and to evinacumab are across separate trials in different populations and are directional only. Zodasiran is investigational and has not been approved by any regulatory authority for this indication. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. What was actually new

The headline numbers came out on July 22. Triglycerides down 79 and 81 percent in the two studies, pancreatitis events down 78 percent, both trials hitting every goal they had set. The market has had six weeks to think about that.

Sunday added what a press release cannot fit. Who the patients were. What happened to them month by month. Which side effects showed up and how often. The details behind the averages.

Buried in there is one chart that changes how you should read the whole program, and I have not seen anyone write about it yet.

2. The chart that matters

Patients got four injections, spaced three months apart, at Months 0, 3, 6 and 9. The trial then measured its main result at Month 12.

Sit with that timing for a moment. Month 12 is three months after the last shot. That is the point in the cycle when the drug has had the longest time to wear off, in the fourth cycle of the year, when any accumulating problem would have shown up.

It is, in other words, the point in the dosing cycle where you would expect the drug to look its weakest.

Every drug looks good right after you take it. The question that decides whether a once-every-three-months schedule actually works is what the patient looks like just before the next injection is due.

Here is the answer. At Month 10, triglycerides were down 84 percent in both studies. At Month 12, they were down 79 and 81 percent.

Roughly four points given back from Month 10 to Month 12, as patients reached the end of the three-month dosing interval in the fourth cycle of treatment. That is not meaningful wear-off. That is a remarkably flat curve through the end of the quarter.

That number does real work, because olezarsen is injected monthly. Twelve shots a year against four.

Before Sunday, the advantage of quarterly dosing was mostly a convenience argument, and a slightly hand-wavy one, since nobody had shown what happens at the end of the quarter. After Sunday, the durability needed to support that schedule is demonstrated. The drug holds at the exact point in the interval where meaningful waning should have been easiest to see.

3. Head to head with olezarsen

One fact has to sit underneath this entire comparison. Olezarsen was approved by the FDA for severe hypertriglyceridemia on June 24, six days ahead of its June 30 decision date. It is on the market for this condition right now, and any read of the SHASTA data that skips that is incomplete.

A caution goes with it. These two drugs have never been tested against each other. Everything below compares separate trials, run in somewhat different populations, and olezarsen measured its main result at six months where plozasiran measured at twelve. The gaps are large enough to be informative. They are not head-to-head evidence.

How do the two drugs actually stack up?

Triglyceride lowering: plozasiran, and it is the consistency that stands out. Olezarsen ran two pivotal trials as well. In the first, its two doses lowered triglycerides 63 and 72 percent more than placebo. In the second, the same two doses managed 49 and 55 percent. Plozasiran produced 79 and 81 percent across its two trials.

Look at what happened to olezarsen’s higher dose between studies: 72 percent, then 55 percent. That is a seventeen-point swing in the same drug at the same dose. Plozasiran moved two points. Whatever explains the difference, and trial populations and placebo performance can account for a good deal of it, the contrast is striking. Plozasiran’s replication across its two studies is unusually clean.

Getting patients to a safe number: plozasiran. Percentage reduction tells only part of the story. What a doctor actually wants to know is how many patients ended up below the danger line. At Month 12, 91 and 93 percent of plozasiran patients were under 500 mg/dL, the threshold that defines severe hypertriglyceridemia. Olezarsen reported 86 percent.

More striking is the normal range. Over half of plozasiran patients got below 150 mg/dL, which is a normal triglyceride level. In one of the two placebo groups, 2 patients out of 98 managed that. Two.

Pancreatitis: olezarsen looks slightly better on paper, and I would not make much of it. Both drugs cut pancreatitis attacks sharply. Olezarsen reduced them about 85 percent, plozasiran about 78 percent. The ranges around those two estimates overlap heavily, and olezarsen enrolled roughly 1,100 patients against Arrowhead’s 757, which buys you a tighter estimate regardless of how good the drug is. The honest read is that both drugs prevent pancreatitis and neither trial can tell you which does it better.

What plozasiran did produce is a striking number in the sickest patients. Among those who had already suffered a pancreatitis attack, close to 4 in 10 on placebo had another one within the year. On plozasiran it was roughly 1 in 25. That subgroup was small, 35 placebo patients against 60 treated, so the precise figure is soft. The direction is not.

There is one matched comparison worth having, in the sickest patients of all, those above 880 mg/dL with a prior attack. Ionis reported that four such patients would need treating for a year to prevent one attack. Arrowhead reported no events at all in that group. The caveat travels with it: the subgroup was small enough that the company did not publish the underlying numbers, so the direction is more informative than the figure.

Dosing: plozasiran, and Sunday is what turned it into an argument. Olezarsen is monthly. Plozasiran is quarterly, and the Month 10 to Month 12 data show the interval genuinely holds rather than merely being claimed. Four injections a year instead of twelve is a meaningful difference in a group of patients who are already managing a lot. Between 54 and 63 percent of the people in these trials were already diabetic, and roughly two thirds were taking two or more other cholesterol drugs before they enrolled. Every additional appointment is another chance to fall off treatment.

Liver enzymes: plozasiran. Olezarsen’s label lists liver enzyme elevations among its most common side effects. SHASTA showed no meaningful liver enzyme changes compared with placebo.

Figure 1. Every figure is as reported by each sponsor. The two programs were never compared directly.

4. Two places the data are thinner than they look

Two findings deserve more scrutiny than the coverage has given them. Both happen to sit exactly where Arrowhead would most want strength.

Liver fat. The press release says a planned MRI substudy found no meaningful increase in liver fat, with a p-value of 0.70. That reads as a clean result, and it has been repeated everywhere.

The substudy had 36 patients in it. Thirteen on placebo, 23 on plozasiran, at whichever trial sites happened to have the right scanner. Liver fat went up 1.0 percent on the drug and down 0.5 percent on placebo.

The p-value was 0.70, meaning the substudy did not detect a statistically significant difference between the groups. What that number cannot tell you is whether the study was large enough to confidently rule one out.

A p-value of 0.70 in 36 patients does not establish that there is no effect. It says the study did not find one, and with a sample that small, considerable uncertainty remains around the estimate.

This matters more than it might appear. Liver fat was supposed to be the clean differentiator against olezarsen, which showed increases of roughly 2 to 4 percent that grew with dose. Arrowhead’s own chief medical officer said in June that if plozasiran turned out to show something similar, both drugs would be in the same boat.

Sunday did not settle that question. It left it open, with a number that sounds like it settled it.

Blood sugar. Side effects related to worsening blood sugar control were reported in 14.3 percent of plozasiran patients against 8.7 percent on placebo. That is the first real imbalance this program has produced.

The defense is reasonable and it is in the data. Between 54 and 63 percent of enrolled patients were already diabetic, with average HbA1c, the standard measure of blood sugar control over the preceding months, between 6.4 and 6.6 percent. This is a population already at substantial risk of worsening blood sugar, which helps put the 8.7 percent placebo rate in context. When you look at the actual measured HbA1c rather than the reported side effects, it barely moved over twelve months in either group.

A side effect somebody wrote down and a lab value that actually changed are different things, and the lab values are reassuring. Even so, a 5.6-point imbalance in a population with this much baseline diabetes is conspicuous enough that regulators and clinicians are likely to ask about it.

One more figure belongs here, since this section exists to look at the uncomfortable parts. Three deaths occurred among plozasiran-treated patients, two cardiovascular and one from chronic myelomonocytic leukemia. Investigators attributed all three to pre-existing disease and judged them unrelated to treatment. Serious side effects overall were actually lower on drug than on placebo, 8.3 percent against 10 percent, and investigators found no treatment relationship for any of the three deaths. There is no evident mortality signal here, but the events are worth stating anyway.

5. What the call added

Management restated Sunday for most of the hour. The genuinely new material came from the independent discussant, and it did not point the way Arrowhead would have chosen.

Borge Nordestgaard presented unpublished registry data from Denmark covering 3.4 million people between 2008 and 2021, none of whom had cardiovascular disease at baseline. Within them he identified roughly 29,000 with severe hypertriglyceridemia. That group produced 400 cases of acute pancreatitis and 2,000 cardiovascular events. On an incidence basis, 2 per 1,000 patient-years against 18.

Five times as many cardiovascular events as pancreatitis attacks, and nine times the rate once you account for how long people were followed, in patients who had no cardiovascular disease when the clock started. His conclusion was not that the pancreatitis work is misdirected. It was that he would like to see studies going after both diseases, and that the long-term need in this population is cardiovascular.

Arrowhead put an independent expert on its own investor call, and he used the time to point out that these patients are roughly nine times more likely to suffer a cardiovascular event than the event the label is being built around.

That cuts in both directions. On the bearish side, if payers price plozasiran purely on pancreatitis prevention, the addressable market is narrower than headline patient counts suggest. Arrowhead’s own slide identifies roughly one million high-risk patients within the roughly three million Americans with the condition, and the initial commercial focus is that high-risk segment. Management nonetheless put a three to four billion dollar annual US opportunity on the same call.

On the bullish side, plozasiran reduced remnant cholesterol by 72 to 76 percent in these trials. If the drug ever runs a cardiovascular outcomes study and that reduction translates, the opportunity is a different order of magnitude than a pancreatitis label. That remains entirely hypothetical. SHASTA was not designed to demonstrate cardiovascular benefit and does not. Nordestgaard did not say otherwise. He simply pointed at where the events actually are.

What the glycemic number actually counted. An analyst asked what the imbalance actually consisted of, and Watts answered it. The 14.3 percent was not a single measurement. It pooled several loosely related endpoints, among them impaired glucose tolerance and the need to increase antidiabetic medication. On that basis he said it is difficult to make much of a five-point difference. He described the HbA1c change as very minor, not clinically significant, and something that resolves once treatment is intensified, adding that patients typically finish these studies with better control than they started with. Nordestgaard called the safety profile excellent against the risk these patients carry.

How the strongest numbers are constructed. The high-risk numbers arrive in three tiers, and the tiers matter. Across patients with triglycerides at or above 880, or above 500 with a prior attack, the number needed to treat is nine. Among those with a prior attack regardless of triglyceride level, it is three. In the narrowest group, above 880 with a prior attack, no events occurred at all. Watts called that last analysis exploratory and said plainly that the numbers are small. The direction is more reliable than any single figure until the publication lands.

The question management would not answer. The most useful exchange on the call came from Jefferies. Maury Raycroft said his back-calculation showed an imbalance among patients without a prior pancreatitis history, with three to four events in the plozasiran arm against none on placebo, and asked whether there was anything distinctive about those patients.

Management declined, citing the pending publication, and redirected to the point that the pooled endpoint was prespecified and hit statistical significance across the whole population. Both things are true. It is also true that a reader who wants to understand where the benefit concentrates, and where it does not, will have to wait for the manuscript.

A class effect, in his words. One more thing worth recording. Nordestgaard told the call that all five drugs in this class, across every study run so far, have produced roughly an 80 percent reduction in acute pancreatitis. His word was extremely consistent. That is the strongest available argument that neither company should be claiming an advantage on this endpoint, and it came from the independent discussant rather than from either sponsor.

The question nobody asked. Watts described the result as very reassuring, Arrowhead’s commercial lead described it as no liver fat elevation relative to placebo, and the size of the study went unmentioned by anyone on the call or in the questions that followed.

The switching question, answered by the wrong people. Bank of America asked the two physicians whether they saw any barrier to switching a patient from olezarsen to plozasiran. The answers were not the ones the switching argument wants.

Watts said switching happens in practice and that the quarterly interval is a patient preference matter, allowing that it leans in plozasiran’s favor. He also predicted the more likely response to inadequate control on olezarsen is a dose increase rather than a switch, while noting that the higher olezarsen dose carries its own problems.

Nordestgaard was blunter and less helpful to the thesis. Patients who get used to a drug and are having no trouble with it, he said, tend to stay on it, absent clearly more side effects or a real price difference. He then said what he had said twice already, which is that he would rather both companies spent their effort finding the enormous number of untreated patients than fighting over the ones already on therapy.

Management took the same line, framing severe hypertriglyceridemia as an untapped market with room for both drugs rather than a share contest. That is the diplomatic answer and it may also be the correct one. It is not, however, the answer that supports a thesis built on converting a competitor’s patients.

6. The longer route

Here is where this leaves things.

Arrowhead has the better drug on triglyceride lowering, on repeating that result across two trials, on getting patients into the safe range, on dosing schedule, and on liver enzymes. It has a comparable drug on preventing pancreatitis, which is the outcome that actually matters to a patient. It gives four injections a year where the competitor gives twelve.

What it does not have is permission to sell. Olezarsen has been approved for this condition since June. Arrowhead plans to file a supplemental application by the end of 2026, expanding the label on a drug the FDA has already approved rather than seeking a first approval. It will use a priority review voucher bought on August 4, which changes the FDA’s review goal from roughly ten months to six. Filing in December on that timeline points to a decision around the middle of 2027.

Call it a year of a competitor selling into a market before you can enter it. In a specialty field with a few thousand prescribing physicians, a year is enough time for habits to form.

That concentration cuts both ways, though, and the second edge is the one people forget. A small prescriber base lets Ionis establish habits quickly. It also means Arrowhead has a finite and identifiable audience to reach when it arrives, whether by converting patients already on therapy or, as management would prefer, by bringing untreated ones into it. This is not primary care, where changing behavior means reaching tens of thousands of physicians who have never heard of the disease.

Chess has a word for what happens next. A transposition is when two games reach the same position by different move orders. One player gets there down one path, the opponent down another, and once they both arrive, the order stops mattering. What is left on the board is the position.

The analogy is imperfect in a way worth naming. In chess both players arrive at the same moment. Here, Ionis got there a year early and has been using the time.

Pharmaceutical history offers plenty of reminders that arriving first is not the same as staying ahead. Lipitor was the fifth statin to market. Keytruda entered behind Opdivo. Neither case is proof of anything about this one, since market leadership turns on far more than which molecule performs better. What travels across all of them is that physicians can switch when the product difference is real. Nordestgaard’s answer on the call is a useful warning against assuming that dosing frequency alone will move a patient who is doing perfectly well. For a patient who is inadequately controlled, unhappy with monthly injections, or starting therapy for the first time, four injections a year instead of twelve gives Arrowhead an unusually simple conversation to have with a physician.

What Sunday did was hand Arrowhead the material for that conversation. What it could not do was change the order of arrival.

Ionis got there first. Arrowhead got there better. The position on the board is what settles it, and Arrowhead simply took the longer road to reach it.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. SHASTA-3 and SHASTA-4 figures come from Arrowhead's August 30, 2026 release and the slides presented at the ESC Congress Hot Line session the same day. Olezarsen figures come from the CORE and CORE2 results published in the New England Journal of Medicine and from sponsor disclosures. Comparisons across separate trials are directional only; the two programs measured their main results at different timepoints in somewhat different populations. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

On August 24, Arrowhead confirmed that the twelve-month results from SHASTA-3 and SHASTA-4 will be presented in Munich on Sunday, August 30. The topline came out on July 22 and the stock has already digested it. A scheduling announcement is not usually worth writing about.

This one is, because two of the details in it were decided by the European Society of Cardiology rather than by the company, and both say something about how the field intends to receive this trial.

The market already has the headline. Sunday is about validation, and validation is awarded by people who do not work for Arrowhead.

Hot Line is not the same as late-breaking

The presentation is in a Hot Line session, in the Munich Auditorium, Hall B3, at 17:30 on Sunday. The session is numbered nine, which is a scheduling detail and nothing more. The two words that carry weight are Hot Line.

Congresses run a great deal of late-breaking science. Hot Line is the tier above it, and it runs alongside a separate and larger late-breaking science track. By the society’s own July announcement, this year’s Hot Line program spans twelve sessions and 59 trials. Arrowhead’s slot is in the Munich Auditorium, Hall B3, which is where the Hot Line sessions are held.

The society describes the selection in its own words. Professor Tomasz Guzik, who chairs the ESC Congress Program Committee, said this year brought a record number of late-breaking submissions, and that the committee, in his phrase, rigorously selected the studies with the greatest scientific quality and potential clinical impact.

That is an editorial judgment made by cardiologists reviewing submitted data. It is not a slot a sponsor can buy. The inference worth drawing is bounded but real: a committee that saw a record volume of submissions looked at what Arrowhead sent and put it on the main stage.

The discussant is the tell

Every Hot Line presentation is followed by an assigned discussant whose job is to place the trial in context for the field and say plainly whether it should change what physicians do.

The discussant here is Borge Nordestgaard of Copenhagen University Hospital.

That name deserves explanation for anyone who does not follow lipid research. For decades he has led the Copenhagen population studies. Much of the modern evidence that high triglycerides actually cause heart disease, rather than simply appearing alongside it, comes from that work. When guideline committees debate whether triglycerides are worth treating, his data are central to the discussion.

The society did not assign a drug-development specialist to discuss this trial. It assigned the researcher whose work established that lowering triglycerides should matter in the first place.

That is a choice about framing. It signals ESC is treating SHASTA as evidence bearing on the triglyceride hypothesis itself, not simply as a registration trial for a rare disease drug.

The presenter reinforces the same reading. Gerald Watts of the University of Western Australia has chaired international guideline work on inherited lipid disorders. Between the presenter and the discussant, the society has put two people with real influence over treatment guidelines on the same stage.

Worth noting separately: Arrowhead has both of them on its investor webcast the following morning at 8:00 Eastern, alongside management, taking questions. That does not mean the company knows what Nordestgaard will say. He is independent, and the point of a discussant is that his assessment is his own. What it does mean is that whatever he says, favorable or critical, investors will hear it directly rather than filtered through a press release.

What actually lands on Sunday

The July topline reported median triglyceride reductions of 79 and 81 percent in the two studies, a 78 percent reduction in acute pancreatitis events across the broad severe hypertriglyceridemia population, and a 100 percent reduction in the highest-risk subgroup. Both trials met their primary endpoint and all pre-specified secondary endpoints.

Sunday brings the full dataset behind those numbers, across approximately 750 randomized patients, and the specific thing worth watching is durability.

The primary endpoint is percent change in fasting triglycerides from baseline to Month 12. Patients received four doses, one every three months. Which means the twelve-month measurement is taken at the end of the fourth dosing cycle, when drug effect is at its weakest point before the next injection would be due.

Any drug can look good at peak effect. A quarterly regimen is only real if the effect is still where it needs to be at the end of the quarter, four cycles into a year of treatment. That is what this endpoint measures, and it is the number that determines whether quarterly dosing is a convenience claim or a clinical fact.

Two things not in the release

Liver fat. James Hamilton, Arrowhead’s chief medical officer, confirmed in June that liver fat data would accompany these results, and the competitive stakes are specific.

The rival drug is olezarsen, from Ionis. Both drugs switch off the same gene, APOC3, but they do it with different molecular machinery. Olezarsen is an antisense oligonucleotide. Plozasiran is an siRNA. Same target, different tools.

That distinction is the whole question. Olezarsen showed liver fat increases of roughly 2 to 4 percent that grew with dose. Plozasiran showed none at its commercial dose in mid-stage testing. If the effect comes from suppressing APOC3 itself, both drugs should eventually show it. If it is a property of the antisense chemistry, only olezarsen will. Hamilton has pointed out that another antisense drug against a different lipid target showed the same pattern, which argues for chemistry, and he has also said openly that it may be a combination of both, and that if plozasiran shows a similar increase the two drugs are in the same boat.

Sunday, across 750 patients, is where that question gets a real answer.

Pancreatitis events, case by case. Triglyceride reduction is the primary endpoint. Pancreatitis is the outcome that matters to a patient, and it was pre-specified and pooled across both studies rather than found afterward. It is also the strongest clinical claim in the program, and it rests on a process most investors never see.

A patient in one of these trials turns up at a hospital with abdominal pain. Is that an attack of pancreatitis, or something else? The answer decides whether the event counts toward a pre-specified clinical outcome, and the sponsor cannot be the one deciding. An independent committee of physicians therefore reviews each suspected case and rules on it, separately from the sponsor. The process is called adjudication, and the committee that performs it exists precisely because the company has an interest in the answer.

The full presentation should show that process, the individual events, and the statistical range around a reduction reported as 100 percent in the highest-risk group, where the total number of events is necessarily small. A 100 percent reduction on four events is a different fact from a 100 percent reduction on forty.

The presentation nobody is watching

Monday morning at 9:00 Munich time, in a session titled Beyond statins: the next wave of lipid-lowering therapies, a Phase 3 trial of zodasiran in Chinese adolescents and adults with homozygous familial hypercholesterolemia will be presented by Zhuang Tian of Peking Union Medical College Hospital.

It appears in the ESC program under the designation vsa003 rather than any name Arrowhead uses in its own materials, which is one reason it is easy to overlook.

Homozygous familial hypercholesterolemia is genuinely ultra-rare, with global prevalence estimated between one in 250,000 and one in 360,000. It is hard to treat for a specific reason. Statins and most cholesterol drugs work through a receptor on the surface of liver cells. That receptor pulls cholesterol out of the blood. These patients inherited two broken copies of that receptor, so the usual drugs have little to work with. Zodasiran switches off a different gene entirely, one that does not depend on that receptor functioning.

This is a second late-stage asset presenting late-stage data at the same congress, in a named session, and it has attracted almost no attention. Which is the smaller version of the same point this note began with. The information that moves a company is not always the information the market is looking at, and it is frequently sitting in a program listing that nobody reads.

What this week is

Nothing presented in Munich is new information in the sense that the market has not seen the headline. The topline was July 22.

What happens on Sunday is different from a data release. It is the moment a trial stops being a company announcement and becomes part of the medical literature, presented by a guideline author, assessed in public by the researcher whose own work created the question the drug was built to answer.

Approvals determine whether a drug can be sold. Congresses like this one determine whether physicians believe it should be.

Chess used to settle unfinished games the same way. When a game ran past its time limit it was adjourned, and in many competitions the result could be decided by adjudication, in which an appointed master examined the position and ruled on what it was worth. Both players had already made every move. Nothing on the board could change. What remained was a judge, appointed by the federation rather than chosen by either side, declaring in public what the position was worth.

Arrowhead has made its moves. The data are locked and the topline is five weeks old. One set of adjudicators has already done its work, quietly, ruling case by case on which hospital admissions counted. Munich supplies a different kind, who rules in public on what the whole thing means. Neither side picked either of them.

Regulators have already said plozasiran can be sold in familial chylomicronemia syndrome, the rarest form of this disease. Sunday is about the much larger population behind it, and whether cardiologists believe the drug belongs there. ESC has chosen who tells them.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Two Arrowhead readouts land in September. One of them will get all the attention, and it deserves attention. ARO-MAPT is Arrowhead’s first human test of subcutaneous delivery to the brain, and a companion paper of mine argues at length that it could reprice the company.

The other readout has been treated as a footnote. ARO-DIMER-PA is a single molecule built to silence two genes at once, and its first clinical data are expected in the same month. Far less has been written about it. This paper is about why that is a mistake, and about what the readout actually tests, which is not what a conventional preview would say it tests.

Chess has a name for a move like this. A zwischenzug is an in-between move, played in the middle of a sequence the opponent has already worked out. Its power is not that it is stronger than the expected continuation. Its power is that nobody was looking at it, so the evaluation of the position changes before the main line resumes.

One distinction organizes everything below. The brain program tests whether the engine can reach a new place. The dimer program tests whether the engine can build a new kind of thing. Those are different questions, they fail in different ways, and one of them does not appear in the sum-of-the-parts breakdown this paper examines at all.

1. What ARO-DIMER-PA is

Start with the molecule. Conventional RNAi drugs silence one gene. A patient who needs two genes silenced takes two drugs, which means two prescriptions, two co-pays, two prior authorizations, and two regulatory approvals. ARO-DIMER-PA is one molecule carrying two different silencing payloads, called triggers, aimed at APOC3 and PCSK9. Silencing APOC3 lowers triglycerides. Silencing PCSK9 lowers LDL cholesterol. One injection, two lipid abnormalities.

The target population is patients with mixed dyslipidemia, meaning elevated LDL and elevated triglycerides at the same time, which is a common combination and a poorly served one. The trial is a Phase 1/2a study running in patients with mixed hyperlipidemia rather than in healthy volunteers, which matters because it means lipid effects are measurable in the relevant population from the first study, not years later. The company describes the target indication as atherosclerotic cardiovascular disease arising from mixed hyperlipidemia.

Arrowhead’s own framing, from its June webinar, repays a close look, because the company chose the words carefully. The dimer is described as a single chemical entity to silence two gene targets, with regulatory advantages over two co-dosed drugs. That phrase, single chemical entity, is doing regulatory and commercial work as well as scientific work. Two separately approved drugs taken together remain two drugs, each with its own approval and its own label. Building them into one product would mean developing a fixed-dose combination, with its own program and its own approval. A single molecule is neither. It is one drug from the start.

2. Seven years in plain sight

The first thing to know about this program is that it is not new. Arrowhead has been building the capability behind it, and disclosing the progress, since 2019.

At an R&D Day in New York on October 18, 2019, the company told investors it was presenting data demonstrating that a new dimer structure, delivering multiple siRNA sequences together, could achieve high levels of knockdown of two different genes. Note the framing. The dimer was described as an addition to the delivery platform, not a drug program. It was announced as a capability, nearly seven years before its first human data.

The critical update came at the R&D Day of June 1, 2023, and it was significant enough to earn its own headline bullet. The improved hepatic dimer platform, Arrowhead reported, achieved equivalent or better knockdown of two target genes with longer duration than a monomer mixture, in non-human primates. A monomer mixture, in this context, means the two conventional single-target drugs administered together, which is the comparison that matters.

Set that against the problem described in the next section and its importance becomes clear. Equivalent or better answers the concern that one address label carrying two payloads ought to be less efficient than two labels carrying one each. Longer duration is the genuinely unexpected part, since nothing about combining two triggers obviously extends how long they keep working.

From there the sequence is public and dated. Preclinical data on the named candidate, ARO-DIMER-PA, was presented at the National Lipid Association 2025 Annual Scientific Sessions. A clinical trial application was filed on October 7, 2025. The first subjects were dosed on January 27, 2026. In June 2026 the program received flagship billing at the company’s cardiometabolic webinar, with its own section presented by the chief medical officer and a cardiology key opinion leader closing the event around it. Arrowhead expects to release early Phase 1 data in September.

Nearly seven years from platform disclosure to first human data, with the decisive preclinical result reported in 2023 and the candidate named in 2025. This is not a program that appeared opportunistically. It is a capability that was built deliberately, in public, while almost nobody was watching.

The June webinar is the last beat in that sequence and the most recent tell. Management gave a Phase 1 asset flagship billing three months before its first human data, which is a statement about internal conviction, disclosed through behavior instead of a forecast. Behavior is the more reliable of the two.

3. The real question the readout answers

A conventional preview might frame the September data as a test of whether APOC3 and PCSK9 silencing works. That framing is wrong, and getting it right is the whole point of reading this paper before the data lands.

Both targets are already validated in humans, extensively. PCSK9 silencing by RNAi is an approved medicine: inclisiran achieves roughly 50 percent sustained LDL-C reduction, with maintenance dosing every six months. APOC3 silencing by RNAi is an approved medicine: Arrowhead’s own plozasiran reduced APOC3 by up to 85 percent in early studies, and delivered triglyceride reductions in the range of 56 to 62 percentage points at 24 weeks in the mixed hyperlipidemia population studied in MUIR. Nobody needs September to learn whether these two targets are druggable.

The unvalidated element is the molecule. Specifically, whether one construct can deliver two triggers into the same cell and have both load into the silencing machinery efficiently enough to match what the two separate drugs achieve.

There is a concrete reason to think this is hard. Getting a drug like this into a liver cell depends on a targeting ligand, which works like an address label: it binds a receptor on the cell surface and gets the whole molecule carried inside. A conventional construct of this type carries targeting functionality for one payload. A dual construct asks the same targeting architecture to deliver two. The effective ligand-to-cargo ratio therefore falls.

This is not theoretical. Published work on dual-targeting antisense oligonucleotides, a related class carrying the same kind of address label, found that the dual versions worked but were less potent, and attributed the shortfall to precisely this change in the label-to-cargo ratio. The evidence comes from a neighboring chemistry, not from siRNA directly, so treat it as a caution and not a prediction. It is still the tax the architecture has to overcome.

The second constraint comes from how the two triggers are arranged. In Arrowhead’s construct, and in the competing construct now in clinical development, the triggers sit in sequence rather than side by side: the ligand attaches to the first, and the second attaches behind it. Section 7 takes up that geometry in full. It creates a different failure mode from the one just described. A broad shared-ligand penalty would be expected to weaken both triggers. A positional penalty in the chain could preferentially weaken one.

Arrowhead has two pieces of evidence that these can be overcome, and they arrived three years apart. The first is the 2023 platform result described in the previous section. The second is specific to this candidate: in cynomolgus primates, a single 6 mg per kg subcutaneous dose produced roughly 50 percent reductions across non-HDL cholesterol, LDL cholesterol, and triglycerides, with potency matched to the two single-target drugs given together.

Matched to the monomers is the phrase that matters. It means the animal data showed no meaningful penalty from combining the triggers, and the earlier platform work suggested there might even be an advantage. September asks whether either finding survives the move into humans.

4. A scorecard, written before the data

What follows is a grading rubric, published in advance so it cannot be adjusted afterward to fit whatever arrives. Readers can hold it against the press release.

It has two levels, and keeping them apart is the point. The first asks whether the architecture worked. The second asks whether the resulting drug competes. Those are different questions with different evidence, and commentary can easily collapse them into a single lipid number.

Level one, the architecture test. The cleanest measure of whether two triggers both loaded and functioned is the suppression of the two proteins themselves, PCSK9 and APOC3, not the lipid changes downstream of them. Arrowhead describes its own preclinical work in exactly that order, reporting that the construct lowered serum PCSK9 and APOC3 before discussing what happened to cholesterol and triglycerides. Watch four things at this level: the depth of suppression on each target, whether the two are symmetric or one lags, the dose-response relationship, and how long suppression persists.

Level two, the product test. Then the downstream lipid profile, which is what determines whether this becomes a competitive medicine: LDL cholesterol, triglycerides, non-HDL cholesterol, and the dosing interval those effects would support.

Management has named its own bar. At an investor conference in June, the chief medical officer said a total ApoB reduction of roughly 40 percent would feel competitive against existing PCSK9 inhibitors, that the construct should produce inclisiran-like effects on PCSK9, and that combining the two mechanisms should add to the ApoB reduction. That is the number to grade against, because it is the one the company chose. For reference, inclisiran achieves roughly 50 percent sustained LDL-C reduction with maintenance dosing every six months, and plozasiran produced triglyceride reductions in the range of 56 to 62 percentage points at 24 weeks in the mixed hyperlipidemia population studied in MUIR. Arrowhead’s own primate benchmark was roughly 50 percent across non-HDL cholesterol, LDL cholesterol, and triglycerides from a single dose, with potency matched to the two single-target drugs given together.

Full success. Both proteins suppressed deeply and symmetrically, with a lipid profile that lands near the single-agent benchmarks and a tolerability picture resembling the parent compounds. That result would say the architecture works and the ligand-to-cargo constraint has been engineered around.

Partial success. One target suppressed to a depth consistent with its single-target reference while the other materially lags. This is the most informative outcome and the one least discussed, because it narrows where the problem is likely to sit. Asymmetric knockdown would be more consistent with a positional or trigger-specific problem than with a general failure of the shared targeting element, since a broad ligand-to-cargo penalty would be expected to affect both triggers. That would be potentially more tractable than a general potency shortfall, because it would implicate one trigger’s position or design rather than the viability of unimolecular delivery.

Miss. Both targets materially below their relevant single-target references, or a tolerability signal that points to the combined construct instead of either target. That would suggest the ligand-to-cargo constraint is real in humans in a way it was not in primates, which is a platform-level finding rather than merely a drug-level finding.

Duration, the item most likely to be overlooked. The 2023 platform data reported longer duration than a monomer mixture, which would be a commercial advantage independent of potency. Any signal about how long suppression persists deserves as much attention as the depth of it, because dosing interval is where this molecule would compete.

The pairing does real work. The construct carries two separate engineering risks, and the two level-one measurements help distinguish them. Depth primarily informs the shared targeting constraint. Symmetry informs whether a positional effect is emerging. Read together, the two measurements can say not only whether the construct worked but where the problem may lie, which is a more useful thing to know in September than a single verdict.

One caution on all of the above. This is an early dose-ranging study, so the relevant comparison is what the dimer achieves at its selected dose against what the monomers achieve at theirs, not a raw number-to-number contest. Read the dose alongside the effect. Note too that a Phase 1 disclosure may report lipid changes without the underlying protein data, in which case level one will have to be inferred from level two, and inference is weaker than measurement.

5. The asymmetry nobody is positioned for

The September pair diverges most sharply here, and not in the way most readers would guess.

The brain program carries a placeholder. In the sum-of-the-parts breakdown JPMorgan published with its $95 target, the line covering the brain platform was carried at $1 a share. Small, but present.

The dimer program has no line at all. It does not appear in the breakdown. That absence need not be an oversight or a verdict that the program is worthless. The cited model was built without an explicit line for this asset, and management has since provided the outline of a strategy without the inputs a conventional forecast requires: no detailed Phase 2 design, no outcomes-trial size or timing, no registrational assumptions, no commercial forecast. Direction is not the same as a model. There is still no row to reprice.

The consequence runs against intuition. If there is no line for the dimer, a clean result adds nothing to the sum of the parts, since there is no line to increase. An analyst who wanted to credit the result would first have to create one, and doing that credibly requires development and commercial assumptions that have not yet been disclosed. A disappointing result subtracts nothing either, for the same reason. Against the model, this readout is symmetric at zero.

The model is symmetric at zero. The narrative is not. Everything therefore runs through sentiment and through the platform narrative, and sentiment is not symmetric. A clean result confirms the direction already suggested by the public primate data and by the validation of both targets, so the immediate surprise may be limited. Confirmations generally carry less surprise than failures. A miss does something larger. It would end a near-unbroken translation record that the platform argument leans on, and it would raise the possibility that the ligand-to-cargo constraint described in Section 3 was deferred rather than engineered around.

Note the precision required here, since this paper has argued that the two September readouts test different things. A construct that fails is a failure of architecture, not of tissue delivery, and the two are genuinely separable on the science. Whether investors separate them in September is a different question, and many will not.

There is no line for the dimer, so a good result has nothing to raise in the existing model. The readout cannot help the model, and it can still hurt the narrative. That is the reverse of how a validated-target program is normally held, and the reverse of the brain program reporting the same month, where a placeholder at least exists and the surprise runs the other way.

There is a second-order consequence that nobody appears to be pricing, and it is the reason to hold the two September readouts together. The two events share a dependency. Arrowhead’s translation record, the claim that virtually everything it has taken into the clinic has translated from animal models to humans, is load-bearing for both programs and for the platform argument generally. A dimer miss would blemish that claim in the same month the brain program reports, which would ask the market to evaluate the hardest delivery frontier the company has attempted while the translation record had just taken a visible hit. That the two failures would be of different kinds is a distinction the science supports and the tape may not honor.

The reverse holds as well. A clean dimer result strengthens the translation claim going into the brain data, and strengthens it on a molecule of entirely new construction, which is a more demanding version of the claim than another liver target would have supplied. Treating the two readouts as independent events understates both the risk and the value. They are correlated through a shared premise, and the smaller one reports on the premise the larger one depends on.

6. One readout, a multiplied design space

This is where the readout starts to matter more than the drug it is testing.

A pipeline grows by addition. Each new program adds one asset, and the arithmetic is linear. A capability grows differently. If a dual-trigger construct shows the architecture can work as a reusable method rather than as a one-off success with two particularly cooperative targets, then what has been unlocked is not one drug but a design space.

The change runs deeper than the number of possible combinations. It changes the unit of design. The starting point no longer has to be one gene that yields one drug. It can be a disease mechanism requiring two coordinated interventions, engineered as a single molecule from the beginning.

In concrete terms: Arrowhead has built a substantial roster of liver programs over more than a decade, many of them carried into or through the clinic. Proving the dual architecture does not add one program to that set. It establishes the first human-validated member of a potentially combinatorial design space, in which clinically sensible pairings among those targets become candidate molecules. The arithmetic stops being additive and starts being combinatorial.

Two limits belong on that claim. Most pairings are not clinically rational, since two targets have to make sense in the same patient at the same time to justify a combined molecule. Every real combination also needs its own development program, its own trial, and its own approval. The design space expands; the work does not disappear.

A second multiplication sits behind the first, and it is the one that connects this readout to everything else Arrowhead has built. Tissue reach and construct type are independent capabilities. The first answers where a molecule can go. The second answers what kind of molecule can be built.

One clarification belongs on that. The delivery technology is an architecture rather than a single ligand, and the targeting chemistry differs by tissue. Management has said so directly, noting that the brain program uses a transferrin-targeted Fab while the adipose work uses a small-molecule lipid, and that a result in one does not de-risk the other. Generalization is a claim about the architecture, not about one ligand working everywhere. A company that has taken that architecture into five tissues clinically, and that can also assemble multi-target constructs, holds something closer to the product of the two than to their sum, since a dual-trigger design is in principle applicable in any tissue the platform already reaches.

The qualification in that sentence is load-bearing. A successful hepatic dimer would establish the architecture in one tissue, with one delivery chemistry and one pair of triggers. It would not establish that the same construct works equivalently in lung, muscle, adipose, or brain delivery, each of which uses a different targeting approach. What it would establish is that the architecture is real somewhere, which is the precondition for asking where else it travels.

That is where the competitive statement belongs, and it needs to be made carefully, because the obvious version of it is wrong. Silencing two genes with one product is not new and is not unique to Arrowhead. Sirnaomics has been running a dual-target siRNA in human trials since roughly 2017, and has taken it through Phase 2 in skin cancer and into early trials in adipose tissue, using a nanoparticle platform aimed at skin, fat, and muscle alongside a separate liver-directed one. Anyone claiming that dual-target silencing in extrahepatic tissue is unprecedented has not looked.

The distinction that matters is structural, and it is the same one Section 3 turns on. Sirnaomics’ product consists of two separate siRNA molecules packaged together in one nanoparticle, a co-formulation, not a single chemical entity. The academic literature treats those as a different category from unimolecular constructs for good reason. A nanoparticle carrying two payloads does not face the same ligand-to-cargo constraint, because it is not relying on one targeting ligand to haul twice the cargo through a single receptor. That constraint appears only when the two triggers share a single conjugate, which is exactly Arrowhead’s design and exactly what makes the September readout a question rather than a formality.

Stated at the level the evidence supports: dual-target products have been in the clinic for years, unimolecular dual-trigger conjugates are only now entering the clinic, and Arrowhead is attempting one while also holding clinical delivery across five tissues. Whether anyone else is doing both is a harder question than it looks, since several Chinese developers advertise multi-target platforms alongside extrahepatic delivery without disclosing which of their constructs are single molecules and which are mixtures.

The temptation here is to convert that into a claim about the quality of the people, and it is worth resisting, because it would be the weakest version of the argument. Every company in this industry describes its scientists as excellent, the claim cannot be checked, and a shareholder making it sounds like a shareholder. The timeline in Section 2 is the better evidence, because it describes a property of the organization rather than of any individual in it, and that is the property a buyer would actually be purchasing.

Even with those limits, the point stands. One Phase 1 readout in September either opens a combinatorial design space or calls into question whether Arrowhead has unlocked it, and conventional asset models have no obvious row for either implication. The market may initially process the event as news about one cardiometabolic drug, because a drug is the only unit of analysis a conventional model has.

7. The architecture question

Arrowhead is not alone in attempting this, and the two programs are closer in construction than a first look suggests.

Rona Therapeutics, with operations in Shanghai and California, filed in December 2025 to begin a Phase 1 study of RN5681, a GalNAc-conjugated dual-targeting siRNA designed to silence PCSK9 and Lp(a) simultaneously, with dosing slated for early 2026. No clinical data from that study appear to have been published. The company described it as the first bi-valent siRNA from its platform and framed multi-valency as a strategic direction. Arrowhead, for its part, has titled its own announcements around the first dual functional RNAi therapeutic. Two companies are claiming the same ground, which is usually a sign that a category is being defined in real time.

The structural detail has gone unremarked in coverage of either program, and it is not a difference. Both constructs arrange their two triggers in sequence, not side by side. The targeting ligand attaches to the first trigger, and the second trigger attaches behind it, forming a chain. Two companies arrived at the same structural answer to the same problem, and both inherit the same question along with it.

Both molecules are chains. That is not merely a detail of assembly. It creates a specific failure mode worth watching, and it is the reason one line on the scorecard deserves particular attention.

A chain raises a positional question. One trigger sits close to the ligand and the other sits behind it, which creates a plausible route to asymmetric release, or to asymmetric loading into the silencing machinery, meaning one target silenced well and the other less so. The concern is not invented for this paper. It is a plausible consequence of the geometry, and it is why the scorecard treats symmetry between the two targets as a first-order measurement and not a footnote.

Read Arrowhead’s primate result against that concern and it becomes more informative than it first appears. Potency matched to both co-dosed monomers, rather than to one of them, is precisely the outcome a chain architecture does not guarantee. Something in the design, the linker chemistry, the trigger order, or the spacing, appears to have kept the distal trigger from paying a penalty. September asks whether that holds at clinical doses in people.

The competitive picture changes with it. If both companies have chosen the same gross geometry, architecture at that level is not where the differentiation lies. What separates them sits elsewhere: Arrowhead has clinical delivery across five tissues and a construct already dosed in humans, while Rona’s platform, on its own materials, is liver-directed. Geometry is common ground. Reach and timing are not.

One caveat belongs here. Published academic work on unimolecular dual-targeting scaffolds compared linear and branched configurations in the central nervous system and found the linear form performed equivalently, evidence that linear geometry is not necessarily penalized, at least in that experimental setting. That is encouraging for both programs. It is also a reason to treat symmetry as a question September should answer rather than a problem already known to exist.

8. The population, and why it is still unserved

Any commercial case starts with how many patients there are, and this one has an unusually well-documented starting point. It also has a warning attached to it that enthusiasm about the market tends to ignore.

The raw count first. National survey data covering 2007 through 2014 found that 25.9 percent of United States adults, roughly 56.9 million people, had fasting triglycerides at or above 150 mg per deciliter. Among adults already taking a statin, the figure was 31.6 percent, or about 12.3 million people. Those numbers are more than a decade old and obesity and diabetes have both risen since, so they are more likely to understate the present population than to overstate it.

The subset that matters here is narrower than either figure, and Arrowhead has defined it in its own trial protocols. The company describes mixed dyslipidemia as a patient on stable optimal statin therapy who still has cholesterol above target, meaning LDL at or above 70 or non-HDL at or above 100, and who also has fasting triglycerides between 150 and 499. That is a patient failing on both axes despite treatment. Working from the statin-treated figure above, that population plausibly numbers several million in the United States alone, though the precise intersection is an estimate, not a directly measured survey result.

What makes this a real market rather than a theoretical one is that the unmet need has been quantified in events, not just in prevalence. Analyses of the same survey data project more than three million cardiovascular events over ten years among adults with triglycerides at or above 150, including roughly one million among people already taking statins. Mean ten-year cardiovascular risk in statin users rises from about 11 percent to about 19 percent as triglycerides climb. These are patients under treatment who continue to experience cardiovascular events, which is the cleanest definition of residual risk there is.

A population of that size, in a disease this well studied, does not remain unserved by accident. It remains unserved because it has defeated nearly everything aimed at it.

That is the warning, and it belongs in any serious version of this argument. Residual triglyceride risk is one of cardiology’s most thoroughly failed targets. Fibrates lowered triglycerides and did not reduce events when added to statins. Niacin raised HDL, lowered triglycerides, and failed twice in large outcomes trials. Cholesteryl ester transfer protein inhibitors failed repeatedly, one of them with evidence of harm. The most recent and most damaging result came from a modern fibrate that lowered triglycerides by roughly a quarter in a large outcomes trial and produced no reduction in cardiovascular events at all.

The lesson from those failures is narrower than the headline version, and the difference matters here. In that fibrate trial, triglycerides fell while ApoB, the measure of atherogenic particle burden, did not. What failed was not the idea that triglyceride-rich lipoproteins contribute to risk. What failed was lowering a measured triglyceride number without reducing the particle burden that carries the risk. Triglyceride concentration, remnant-particle biology, and atherogenic particle count are related quantities and not interchangeable ones. Note where that leaves September. Management has named ApoB as the measure it expects to move, which means the readout speaks directly to the variable that the modern fibrate trial failed to move.

That history changes what the market size means. The mixed dyslipidemia population is not a large untouched opportunity waiting for someone to notice it. It is a large population that has absorbed several billion dollars of failed development, which is why regulators are unlikely to accept triglyceride lowering alone as evidence of benefit, and why payers are unlikely to reimburse a branded injectable on a biomarker claim in a population where biomarker improvement has repeatedly failed to translate.

The counterargument, and the reason this molecule is not simply the next entry in that list, rests on the mechanisms, not on the market. Half of the dimer is a PCSK9 inhibitor, and lowering cholesterol through that pathway is validated by completed outcomes trials, not by inference. The other half targets APOC3, where the supporting evidence is human genetics: people carrying loss-of-function variants have lower triglycerides and lower cardiovascular risk across their lifetimes. Genetic validation is not the same as an outcomes trial, and it should not be sold as one. It is nonetheless a different and stronger evidentiary basis than the fibrates and niacin ever had, both of which lowered a number without any comparable genetic support for the pathway.

One further point on arithmetic, because large populations invite lazy multiplication. The commercial case does not require the whole population, or anything close to it. At pricing consistent with an established cholesterol-lowering injectable, a few hundred thousand patients is a substantial business, and a million is a very large one. That is low single-digit penetration of the statin-treated residual-risk population described above. The relevant question is therefore never the size of the market. It is what fraction converts, at what price, under what label, and all three depend on evidence that does not exist yet.

9. The comparator Arrowhead chose

Assume the readout comes in clean. The company has already told the market how it intends to position this molecule, and the framing is more specific than the coverage has generally registered.

Arrowhead’s June materials describe the dimer as a single chemical entity to silence two gene targets, and claim regulatory advantages over two co-dosed drugs. The deck goes further, laying out the logic against a combination of an approved cholesterol-lowering RNAi drug and Arrowhead’s own triglyceride-lowering one. The sentence names the comparator. Arrowhead is not positioning this molecule against any single existing product. It is positioning it against a two-drug regimen.

Much of the analysis around this program compares the dimer to one drug. Arrowhead is comparing it to two. That single choice changes the pricing math, the regulatory argument, and the definition of the addressable patient, and it is stated plainly in the company’s own materials.

Follow the consequence. A patient with both elevated cholesterol and elevated triglycerides, treated to guideline on each, takes two medicines. That means two prescriptions, two prior authorizations, two co-pays, two reimbursement decisions, and two injection schedules that may not align. The dimer’s claim is to collapse that regimen into one injection, and its regulatory claim is that one molecule is one drug rather than a fixed-dose combination of two, which could offer a simpler regulatory path than developing two agents for co-administration.

The pricing implication follows directly, and it is where the common analysis goes wrong. Measured against a single cholesterol drug priced near $6,500 a year, a dimer priced anywhere close to Arrowhead’s approved cardiometabolic product would look indefensible. Measured against a two-drug regimen, the umbrella is higher and the argument shifts from the price of a medicine to the total cost of treating a patient. Whether payers accept that argument is a separate and open question. It is nonetheless the argument the company has set up, and it deserves evaluation on its own terms rather than against a comparison Arrowhead never made.

A second signal sits in who Arrowhead chose to make the case. The June webinar closed with Dr. Steven Nissen of the Cleveland Clinic building the argument for mixed hyperlipidemia and atherosclerotic cardiovascular disease. Nissen is among the most prominent cardiovascular outcomes trialists in the field, a different kind of expert from a lipid specialist, and he is simultaneously directing several competing outcomes programs in the lipid space. Bringing an outcomes trialist to introduce a lipid-lowering molecule is consistent with a company thinking about a cardiovascular endpoint instead of a biomarker label.

That reading is an inference, not a disclosure, and it should be held loosely. The choice of speaker is not random, though, and the ambition it implies is considerably larger and more expensive than a lipid-lowering approval.

What remains genuinely hard, because the paper would be dishonest to skip it. The comparator argument only works for patients who would actually receive both treatments, and today many patients with mixed dyslipidemia are managed with a statin plus inexpensive generics, not two branded injectables. An outcomes trial, if pursued as management has described, would be a multi-year and expensive undertaking. The commercial organization Arrowhead has built serves a specialist population with acute risk, which is not the same organization that sells into broad cardiovascular practice.

On cannibalization of the approved triglyceride franchise, the concern is smaller than it appears. Patients with severe hypertriglyceridemia frequently have low or normal cholesterol, and standard cholesterol calculation is unreliable at very high triglyceride levels, so the dual mechanism offers that population little. The overlap sits in the moderate-triglyceride expansion territory, which is years away and where a dual molecule would simply be the better product. Obsoleting your own drug with a superior one is the version of cannibalization worth having.

Management has already sketched the path, which changes what September tests. In June the chief medical officer described adding a Phase 2 segment to the existing study, dosing patients for about a year, and then an outcomes study in mixed hyperlipidemia, with the stated intention of reaching it as fast as possible. The chief financial officer said separately that no out-licensing was planned. Management’s stated plan is therefore to keep the asset wholly owned and advance it toward a cardiovascular outcomes endpoint rather than stop at a biomarker program.

That makes the September disclosure a test of the plan rather than a reveal of it. An outcomes trial in mixed hyperlipidemia is the expensive, slow, and historically unforgiving route described earlier, and the data will determine whether the company still wants it.

10. What would make me wrong

Five ways the argument in this paper breaks.

The construct underperforms in humans. Primate data is encouraging and it is not human data. The ligand-to-cargo constraint described in Section 3 has been documented in related oligonucleotide chemistry, and it may show up at clinical doses in a way it did not at 6 mg per kg in cynomolgus monkeys. That would be a platform-level finding, not merely a failed program.

The disclosure is thin. No conference venue has been identified for this readout, which suggests a press release and possibly an interim dataset, not a full presentation. A sparse disclosure would leave the central question unanswered and the scorecard in this paper ungraded, which is a real possibility readers should hold.

The fixed ratio proves limiting. A dual construct commits to a trigger ratio at the design stage. If the clinically optimal balance between LDL lowering and triglyceride lowering turns out to differ across patients, a fixed-ratio molecule is less flexible than two drugs that can be titrated separately. That is an advantage of the combination approach the single-entity framing does not address.

The chemistry does not scale elegantly. A construct that works clinically still has to be manufactured reproducibly and economically. A single molecule carrying multiple triggers may be more demanding to synthesize, purify, characterize, and control for impurities than either monomer, and those challenges could increase further as additional triggers are added. A platform whose design space expands faster than its manufacturability would be worth less than the combinatorial argument implies.

The capability is less scarce than it looks. Rona has advanced a dual construct into clinical development, and the academic literature already contains published dual-targeting scaffolds. If unimolecular dual targeting becomes a general technique available to everyone, then proving it works is valuable to medicine and much less valuable to any one company’s competitive position.

11. The test inside the test

One closing observation turns September into something more interesting than a data event. There is the engine’s side of it and the market’s side, and the two are worth keeping apart.

A framework I set out elsewhere proposes four observable tests for a genuine discovery engine, as against one good drug with a story attached. Does it translate, meaning does laboratory work reliably reach humans. Does it generalize across more than one setting. Does it run efficiently, producing more per research dollar than peers. Does it keep a beat, producing on a schedule instead of in bursts.

A clean result in September would speak directly to translation and broaden a second criterion, generalization. It would provide another successful translation by showing that a construct that performed in primates also performs in people. The beat is different, because the September timing already supports it. A capability disclosed in 2019, demonstrated in primates by 2023, and dosed in humans by 2026 arrived roughly when an engine running on schedule would deliver it, whatever the data show.

There is a stronger version of that cadence point, and it likewise does not depend on the September data. Two distinct programs, one solving where a molecule can go and the other solving how it can be built, are set to reach first-in-human readout in the same month. Whatever the results turn out to be, running two distinct delivery and construction problems to that stage simultaneously is a statement about throughput rather than about either molecule.

The revision to generalization is the more interesting of the two, since a revision teaches more than a confirmation. That framework treats generalization as a question about places, meaning whether a delivery technology can move from one tissue to the next. This readout tests generalization along an entirely different axis, asking not where a molecule can go but what kind of molecule can be built. If the answer is favorable, then the criterion has two dimensions rather than one, and an engine that generalizes across both is a wider thing than the framework describing it assumed.

Be precise about what that would and would not establish, because the distinction carries the argument. Evidence that an engine deserves a premium is not the same as the market having paid one. A clean dimer result would strengthen the first and would say nothing whatever about the second. Which brings the question back to the market’s side of it.

Then the market’s side. A separate paper of mine argues that conventional valuation can price the drugs a company has made but has no explicit way to price the engine that keeps making them. The absence described in Section 5 tests that claim unusually directly. With no explicit DIMER asset value in the cited model to reprice, a clean result asks whether investors will pay for what the architecture implies beyond this one molecule, which is to say for the capability and not the drug.

The experiment is unusually clean, though not perfectly so. Investors could begin assigning value to this asset directly, ahead of any analyst building a line for it, and a flat reaction could reflect anticipation of the brain readout, or uncertainty about the cost, timing, and execution of the development path, rather than an inability to price a capability at all.

Watch the reaction as carefully as the data. If the construct performs and the price barely moves, that would be evidence consistent with the blind spot operating in public, on a live example. If instead the reaction reflects what a proven dual architecture would mean across the whole liver portfolio, then the market can price a capability after all, and the thesis in that other paper is weaker than I think.

Either outcome teaches something. That is a rare property for a catalyst, and it is the reason to pay attention to the readout nobody is discussing.

The brain readout asks whether the engine can reach somewhere new. The dimer readout asks whether it can build something new. September runs both tests at once, and only one of them is on anybody’s calendar.

Everyone is calculating the main line. The move that changes the evaluation is the one nobody wrote down.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

I have written about Arrowhead’s engine before, in The Execution Engine, in Zero, in the platform pieces, and each time I tried to value it carefully and kept the numbers conservative. I now think I undervalued it every single time. Not because the analysis was wrong, but because the engine keeps proving itself faster, and in more places in the body, than any careful model would dare to assume in advance. Every quarter Arrowhead adds another target, another tissue, another program that made the jump from animals to humans, and every quarter it reminds me that the thing worth valuing was never the drugs on the board. It is the machine that keeps putting them there. This paper is my attempt to fix that mistake, to value the engine itself instead of its output, and to explain why the market has had the same blind spot I did.

This paper makes one argument, then tests it. The argument is simple: the market knows how to model a list of drugs, but it has no explicit way to model the machine that produces them. Any company whose real asset is a proven, repeatable discovery engine will therefore tend to be undervalued by output-based models, in a way that is not a mistake anyone makes on purpose but a blind spot built into the math. Arrowhead is the clearest living example. The first half of what follows builds the idea on neutral ground, using nothing about Arrowhead at all. The second half holds Arrowhead up against it.

1. A list of drugs is not an engine

Start with a distinction most investors skip past. A pipeline is a list of drugs. You can name each one, count them, guess each one’s odds and market size, and add it all up. Analysts are good at this, and it is exactly what a sum-of-the-parts model does, SOTP for short: put a value on every drug on the board, total it, and call that the company.

An engine is a different animal. It is not a drug. It is the thing that makes drugs. Its real output is a stream of future programs, most of which do not exist yet and have no name today. What makes an engine valuable is not any one medicine it has produced but its proven ability to keep producing them, in new tissues, against new targets, year after year. The value is in the repeatability, not in any single result.

The market has good tools for the first thing and much weaker ones for the second. Markets price intangible things all the time, through multiples, sentiment, and the premium paid for a good story. What they cannot do is model an engine explicitly. When a company’s main asset is the engine rather than the list, the standard model has nowhere to put it, and whatever credit the engine receives arrives indirectly, as a multiple nudged by mood rather than a number anyone has built. The result is not that the engine is valued at zero. The result is that it is valued by accident.

2. Why the math cannot see the engine

The reason is mechanical, not a knock on any analyst, and it is worth walking through slowly because it is the heart of the paper.

A sum-of-the-parts model values things it can name, with odds and markets it can defend. That is its strength. It is also its cage. An engine’s value lives in drugs that have not been invented yet. They have no name, no trial, no disease, no odds you could write in a footnote and defend to a skeptic. A careful analyst therefore cannot put a line in the model for a drug that does not exist, and the value of the ability to create that drug quietly rounds to zero. Not because anyone decided it was worthless. Because there is no row to write it on.

This is the key idea. The engine is not underpriced because the Street is lazy. It is underpriced because the ruler cannot measure it. A model that paid in advance for drugs it could not yet name would be a fantasy, not a model. The very discipline that makes SOTP trustworthy is the same discipline that blinds it to the engine.

The chain of reasoning is worth keeping in this order, because each link is much harder to argue with than a blanket claim about market blindness. An SOTP model cannot explicitly value assets that do not yet have names. Public markets lean heavily on that method for companies like this one, so they systematically underprice the engine rather than ignore it outright. A strategic buyer, whose whole purpose is to own the future output, can explicitly value the engine’s expected productivity. That is the argument. Companies whose worth is mostly the visible list of drugs can at least be modeled explicitly. Whether the market gets those models right is a separate question, and often it does not. Companies whose worth is mostly the engine get priced on a placeholder plus whatever sentiment supplies, and the more of the value that sits in the machine instead of the list, the wider the gap between the price and the truth.

3. The Jordan Premium

There is a version of this you already understand, from a completely different world, and it makes the whole thing click.

When a team drafts a generational talent, it is not paying for next season’s points. Next season’s points you can estimate, and a decent role player who scored the same total would cost a fraction as much. What the team is paying for is the near-certainty of greatness it cannot spell out yet, year after year, in forms nobody can predict. The extra money, the amount over and above the projected stat line, is the price of proven repeatability. It is rational precisely because the greatness has already been shown, not just hoped for.

Call that gap the Jordan Premium: the difference between what an engine is worth and what its current, visible output is worth. It is the value of the machine on top of the value of what the machine has made so far. For a generational athlete, the premium is huge and the market pays it without blinking, because sports learned long ago to price proven repeatability. The stock market, handed a company whose real asset is a repeatable discovery engine, has not learned the same lesson. It pays for the box score and hands you the player for free.

One rule keeps this honest, and the rest of the paper leans on it. The premium is only earned when the repeatability is proven, not just promised. Most prospects scouts call can’t-miss do miss. The reason a true generational talent earns the premium is a real track record, not the hype in the scouting report. For a company, it is the same. The premium is earned by evidence, and by nothing else. A story about a platform is not an engine. The next section is how you tell them apart.

4. How to spot a real engine

Most companies that call themselves platforms are, when you look closely, one good drug wearing a costume. The jump from animal studies to human results is hit-or-miss, every new program is a fresh gamble, and the platform talk is marketing draped over what is really a short list. The real job, then, is telling a genuine engine from a good story, and it can be made concrete. A real engine leaves four marks you can actually check.

It translates. Does what works in the lab reliably work in people? A real engine turns targets into human-stage drugs at a rate well above the industry average, and it does it again and again, not once. This is the hardest mark to fake, because it shows up in the clinic, where stories cannot follow.

It generalizes. Does the same core trick work in more than one place? One drug in one tissue is an asset. The same technology working in tissue after tissue is proof that the underlying ability is general, not a fluke. Each new tissue, moreover, is not just one more market. It is a multiplier, because every tissue holds dozens of new targets to aim at.

It is efficient. Does it make more per dollar than its rivals? A better engine turns the same research budget into more drugs than the competition. That is the number-based fingerprint of a superior machine, and you can check it against public spending.

It keeps a beat. Does the output arrive on a schedule, or in random bursts? An engine produces. A story goes quiet between press releases. A steady, rising count of new drugs entering trials, year after year, is the mark of a process rather than a lucky streak.

A company that scores high on all four has earned the Jordan Premium, and the next question is whether the market has paid it yet. A company that scores high on one or two has a good drug and a good story, which is common and much cheaper. These four marks have nothing to do with any particular company yet. They are just the measuring stick. Now it is fair to pick a company up and hold it against the stick.

5. How rarely anything passes this test

The four marks are common one at a time and rare together, and that gap is the entire reason a premium exists. If proven repeatability were ordinary, it would be priced the way ordinary things are priced. Plenty of companies translate well inside a single modality. Plenty run cheaply, usually because they are small rather than because they are productive. Some keep a decent cadence for a while. What almost none of them do is generalize, meaning take the same core capability into domain after domain, which is the mark that separates a machine from one good drug with a story attached.

Set the bar at all four marks together, held over years, and the historical list gets short fast. Genentech’s recombinant protein method generalized from insulin to growth hormone to a clot-dissolving drug, and for years the market bought the products rather than the method. Regeneron’s antibody-generation platform produced a cholesterol drug, then an immunology drug that grew into one of the largest in the industry, then an oncology franchise, and a string of others behind them. Through much of that stretch the stock was discussed primarily as a bet on the company’s eye franchise, even while the antibody engine was quietly producing assets behind it. Alnylam’s liver-targeting approach generalized across a series of approved medicines, and it too was talked about as a rare-disease company well after it had become a delivery platform. In each case the engine is obvious in hindsight and was priced late.

Moderna is the case worth studying most closely, because there the frontier fell all at once. The generality of the platform was the entire thesis, and the market paid something for that promise. A pandemic then supplied the demonstration, and the repricing arrived in months rather than years. The sequel is just as instructive. When the demonstrated use case faded, much of the premium went with it. A Jordan Premium can be awarded and then withdrawn, which is a useful corrective for anyone inclined to read this paper as a one-way argument.

Now the warning that belongs on that list, because leaving it off would be the same error this paper keeps trying to avoid. Every company named above is an engine that worked, which is precisely why anyone remembers it. For each of them there were companies with equally confident platform stories whose generalization never arrived, and they are missing from the list because they failed and were forgotten. The base rate of platform claims in biotech is enormous. The base rate of platform claims that turn out to be engines is small. That asymmetry is not a reason to discard the framework. It is the reason the framework needs a test at all, and it is why the four marks insist on demonstrated behavior rather than stated ambition.

The honest scale, then, is a few per generation rather than a few per year. Note also where Arrowhead sits relative to that list, which is not on it. The companies above had already demonstrated substantial generalization by the time their platform value became impossible for the market to ignore. Arrowhead is a candidate standing at the moment before its defining test, which is a less comfortable position than membership, and also the only position in which the premium has not already been priced.

6. Arrowhead against the stick

Run the four marks in order.

It translates. Arrowhead’s own line is that just about everything it has taken into the clinic has made the jump from animal models to humans. Treat that as a claim to be checked, not swallowed, and it is still a strong one, because a false claim like that gets exposed fast, failed translation shows up as failed trials for everyone to see. A translation rate near the top of the industry, held across many programs, is the first and hardest mark, and Arrowhead appears to carry it.

It generalizes. Here the record is plain. The same delivery technology has reached the liver, then the lung, then muscle, then fat, and the brain program is in the clinic now, with its first data expected shortly. That is not one trick used once. It is one trick that keeps working in a new place each time, and each new place widens the field of targets by a large multiple. Generalization is the mark that most cleanly separates a real engine from a single lucky drug.

Arrowhead has taken this one into the clinic across more tissues than any other RNAi company. Competitors are working on the same frontier, and Alnylam in particular has clinical programs aimed at the central nervous system and adipose tissue, so this is a lead rather than a monopoly. On that record, Arrowhead has a strong claim to being the leading extrahepatic siRNA developer, which is the more useful way to state it: every approved siRNA drug to date targets the liver, and Arrowhead has gone furthest in leaving it.

It is efficient. The numbers were the subject of an earlier paper and they are blunt. Arrowhead has advanced more clinical programs per research dollar than either Alnylam or Ionis, its two closest peers, spending roughly $607 million on research and development in fiscal 2025 against their $1 billion and $916 million.

That comparison is rough, and it is worth saying why rather than leaving a skeptic to say it. Both peers carry heavier late-stage and commercial spending, and a single Phase 3 program can consume more cash than several discovery programs combined, so part of the gap reflects where each company sits in its life cycle rather than how good its engine is. Fiscal periods do not line up perfectly either. The gap is wide enough that the direction survives those adjustments. That is the claim being made here: not that the ratio is precise, but that more output per dollar is the number-based signature of a better machine, measurable rather than asserted.

It keeps a beat. The count tells the story. The clinical portfolio has climbed steadily toward a guided twenty-three drugs, owned and partnered, entering trials on a schedule rather than in fits and starts. There is a concrete reason the beat holds, and it is worth knowing, because it is the least glamorous item in this paper and one of the most important. Arrowhead built its own manufacturing plant. RNAi timelines across the industry have often been gated by waiting for batch slots at contract manufacturers, which means a rival’s program can sit idle for reasons that have nothing to do with its science. Owning the plant takes that queue out of the schedule. That is production, not luck. Arrowhead scores high on all four marks at once, which, measured against the record in the previous section, is the unusual case rather than the normal one.

7. The tell that the engine is still accelerating

Here is the part that should stop an investor cold, because it turns the engine from a story about the past into a story about the future.

Arrowhead is not done adding tissues. Behind the brain, two more are already in the works at the preclinical stage: the eye and the heart. The eye program aims at glaucoma, delivered by a small injection into the eye itself. The heart program, aimed at the heart muscle cell, the cardiomyocyte, is the one to sit up for, and it was not even on the company’s public pipeline slides until recently.

Reaching heart muscle with a gene-silencing drug is close to a holy grail. Heart muscle has been one of the great locked rooms in medicine, enormous numbers of patients, and until now almost no way to switch off a disease-causing gene inside those cells. Cardiovascular disease is the largest cause of death in the world. A delivery engine that reaches the heart muscle would not open one more drug. It would open a whole new front in the biggest disease category there is, at the genetic root. Two words of restraint belong on that sentence: this program is preclinical, years from a human test, and it may not work. What it demonstrates today is not a heart drug. It is the engine picking its next locked room.

Count the tissues: liver, lung, muscle, fat, brain, eye, heart. Seven, and the last two were added while nobody was pricing the first five. That is not a company with a platform. That is a machine that reaches a new part of the body on a schedule.

Here is the real point, the one that matters most and gets priced least. The named tissues are not the prize. The prize is the increasingly credible expectation that the engine keeps reaching new ones. A machine that has gone from the liver to the lung to muscle to fat to the brain in a decade, and is now engineering toward the eye and the heart, gives no good reason to assume seven is the limit. The reasonable expectation for an engine with that record is that it reaches an eighth tissue, and a ninth, in places nobody has named yet. Those unnamed tissues, the ones not on any slide, not in any model, not in anyone’s price target, are where the largest and least-priced value of all is hiding. You cannot write them into a spreadsheet. That is precisely why they are free.

8. What the market pays for all of this today

The framework predicts that conventional asset-by-asset valuation will pay almost nothing explicitly for a discovery engine, however good, until evidence forces that engine into the model. Arrowhead gives you the cleanest proof of that prediction you could ask for, and the number is worth saying out loud.

In the sum-of-the-parts breakdown JPMorgan published with its $95 target, the line covering the brain platform, the central nervous system programs and the delivery technology behind them, was carried at $1 a share. Not a billion. One dollar. JPMorgan has since raised its target to $100, on a quarter driven by commercial and cardiometabolic progress rather than any human brain data, so there is no reason to think the extra value reflects a new credit for the platform. Most of what any sane person would call the engine, the proven, generalizing, efficient, steady machine described above, sits in that model at a placeholder next to zero.

The preclinical tissues, the eye and the heart, sit inside the same platform line, which is to say they are carried at very close to nothing at all.

The stock does not trade at exactly the sum of those parts, and sentiment supplies some credit the model omits. The point is narrower and sturdier: the one part of the company that most deserves an explicit valuation is the one part no analyst has a row for.

The $1 is not an insult to the engine. It is the math doing exactly what the math does. An SOTP model cannot explicitly value a discovery engine, so it parks it at a placeholder, and given the method, the placeholder is honest. Arrowhead is not the exception that breaks the framework. It is the framework’s clearest proof.

9. What the premium is worth

The fair question is how big the premium should be, and the honest answer is a range with its assumptions visible, not a single number pretending to a precision it cannot have.

The premium is the gap between the engine-inclusive value of Arrowhead and its SOTP value. Its lowest layer is visible, and its highest layer is not. The lowest layer is revealed strategic value: what buyers have already shown they will pay for the engine’s output. Novartis put up $200 million up front and committed to as much as $2 billion in milestones for one program and a few targets built on this platform, before a shred of human brain data existed. In just the most recent quarter, Madrigal paid $25 million up front and committed to up to $975 million for a single clinical-stage liver program. Read those numbers precisely. The upfronts are cash that changed hands. The milestone figures are contingent, payable only if the programs succeed, so they are not money in the bank, but they do establish that sophisticated counterparties were willing to contract around substantial future economics for slices of this engine. That is observable evidence in signed contracts, not hypothetical value invented by a model.

The ceiling is the value of all the drugs and tissues the engine has not reached yet, including the ones with no name. It cannot be itemized, which is the exact reason the market leaves it out, and it is also potentially the biggest part of the premium. It is the value of the machine’s future, the same thing a team pays for when it drafts a generational talent instead of a year of projected points. No honest analyst can type it into a model. That same analyst can nonetheless see that its absence from the model is the mispricing, not a verdict on its worth.

Between that lowest layer and that ceiling the premium separates further, and naming them is more useful than pretending the whole can be reduced to a single figure. The bottom layer is revealed strategic value: the cash paid and the milestone economics sophisticated counterparties have already committed to for slices of the engine. Above it sits demonstrated platform value, implied by the fact that several independent partners have each chosen to build on the same architecture rather than on anyone else’s. Above that is unmodeled option value (targets in tissues already proven), the future programs inside tissues the engine has already reached, which are real, foreseeable, and still nameless. Higher again is frontier option value (tissues not yet proven), covering the eye, the heart, and whatever comes after them. At the top sits strategic control value, which is what an acquirer gains by owning the machine outright rather than renting pieces of it.

Each layer is progressively harder to defend with a number, even as the potential value it captures expands, which is exactly why conventional valuation stops at the first one and sentiment does uneven work on the rest. The point of this paper is not to squash the layers into a single figure, which would be false precision painted over an honest range. The point is that the premium is real, that its lowest layer is already visible in signed deals, and that its largest layers sit outside what the standard method measures. That is why it has never been priced in full. That is why it is still there for the taking.

One caution belongs on all of this, and it is the objection a valuation specialist would raise first. Platform confidence does not only live in a line labeled platform. It can also sit quietly inside the rest of a model, in a probability of success set a little higher because the technology has worked before, in a terminal assumption made a little friendlier, in a multiple that drifts up because the company is respected. To the extent that credit is already there, some of what this paper calls the premium is being counted a second time. The honest equation is not the sum of the parts plus the whole premium. It is the sum of the parts plus whatever engine value is not already embedded elsewhere.

Two things suggest that overlap is small rather than large. The first is the $1 itself. A model that had quietly folded substantial engine value into its other assumptions would have little reason to carry the explicit platform line at a placeholder, and the placeholder is what the published breakdown shows. The second is that the credit which does arrive through sentiment and multiples is unstable by nature, since it moves with mood rather than with evidence, which is a different thing from value a model has actually assigned. Neither observation proves the overlap is zero. Both suggest that the great majority of what is described here is genuinely incremental, and the premium in this paper should be read as the incremental portion rather than the whole.

10. The one buyer who can see it

There is one kind of buyer for whom the premium is not invisible at all, and this is where the argument completes itself. A strategic acquirer does not value a company with a public-market spreadsheet and a $1 placeholder. Its deal team values exactly the thing the spreadsheet excludes, the future programs, the tissues still to come, the repeatability itself, because the future output is precisely what an acquirer is buying. The blind spot this paper describes is a public-market artifact, not a universal one. The one participant structurally equipped to price the engine is the one that intends to own it.

Look again at the partner deals through that lens and they change meaning. Novartis contracting around as much as $2 billion for one program and a few targets, Madrigal around up to $975 million for a single liver asset, those are not just evidence that the engine has value. They are the premium being paid, in fragments, by the actors structurally equipped to price it. Each license is a strategic buyer pricing a slice of the machine that the public market has no explicit way to price. The fragments are already trading. Only the whole is not.

Follow that one step further and you reach the scenario where the premium gets priced most completely: a competitive buyout. In a contested acquisition, rival bidders do not converge on the sum of the visible parts, which any of them could assemble more cheaply elsewhere. They bid up the one thing that cannot be assembled elsewhere, the proven machine, which means a bidding war for Arrowhead would be, almost by definition, an auction for the Jordan Premium itself. Earlier papers of mine walk through who those bidders would be and why each may be cornered into competing. This paper deliberately does not re-argue or price that scenario, for the same reason the Keystone kept the control premium outside its numbers: the case here does not need a deal to work. The engine is underpriced today, on the evidence already in hand. A buyout is simply the venue where the premium would be priced most completely, and in public. The market prices the box score. An acquirer prices the player.

11. What would make me wrong

A paper that only accumulates reasons to agree with itself is advocacy, not analysis. Here are the four ways this thesis breaks, stated as plainly as I can manage, because a reader deserves to know where the load-bearing walls are.

The translation record could break. Everything above rests on a track record, and a track record is a statement about the past. The first mark, that the engine translates, is exactly the kind of claim that a single high-profile failure in a new tissue would damage badly, and the newer the tissue, the thinner the evidence behind it. Liver delivery is proven many times over. Brain delivery has not yet been proven once in a human. A miss in September would not merely disappoint on one drug. It would put the generalization claim itself back in question, which is the mark the whole premium leans on.

The engine costs money, and shareholders have paid for it. This is the counterweight I would want raised against me, so I will raise it myself. More tissues mean more programs, more programs mean more spending, and Arrowhead’s share count has roughly doubled over the past decade. The engine described in this paper was not free. It was funded, in significant part, by diluting the very shareholders who own it. An engine that requires continuous financing can produce wonderful science and still deliver ordinary returns, because the value created gets divided across a growing number of shares. Anyone paying a premium for repeatability should be honest that repeatability has a running cost, and that the cost has historically been paid in equity.

The premium may be structurally unpayable. Here is the deepest objection to this paper, and it deserves to be stated at full strength rather than waved at. If the public market genuinely cannot price a discovery engine, as Section 2 argues, then perhaps it never will, in which case the mispricing is not an opportunity but a permanent condition. A gap that never closes is not value waiting to be captured. It is simply how the asset trades. The honest answer is that this objection is largely correct about the public market and is the reason the strategic buyer matters more to this thesis than a framework paper would like to admit. The historical record cuts both ways here. In the cases from Section 5 the gap did eventually close, which is encouraging, and in every one of them it closed late and only when something forced it, which is not. Recognition tends to arrive when something forces it, proof across a doubted frontier, or a buyer willing to pay for what the spreadsheet omits. Absent one of those, an investor can be right about the engine and wait a very long time to be paid for it.

Someone else could solve delivery. The premium assumes scarcity. If a competitor demonstrates its own route into the brain or the heart, the engine stops being the only one of its kind and the pricing power that comes with being alone at the frontier erodes quickly. Nothing in the record guarantees Arrowhead stays ahead. It guarantees only that it has been ahead so far.

None of these dissolve the argument, and I do not think any of them is more likely than not. Taken together, though, they mark the boundary of the claim. The engine is real and it is underpriced. That is not the same as saying the gap closes on a convenient schedule, or that the shareholder captures all of it when it does.

12. When the market will finally see it

A framework is only useful if it tells you when the gap closes. This one does.

The pattern is this: an engine’s premium expands when it proves itself somewhere the market believed it might not reach. Not every engine has a single hardest job, and it would be convenient rather than true to invent a universal law that happens to point at this September. What is true is narrower. Doubt attaches to specific frontiers, and when a frontier falls, the doubt attached to it is released, along with some of the doubt attached to every frontier still ahead.

For Arrowhead, the brain is the frontier that carries the most doubt today, because it is a room the field has historically entered with a needle in the spine. That makes the September readout the highest-information event this engine has faced. It also means the same logic applies again later. If the brain falls, the heart becomes the next frontier the market doubts, and clearing that one would expand the premium a second time, on the same principle rather than on a new one.

This is where this paper shakes hands with the last one. The case that Arrowhead’s brain readout reprices the company, argued in full in The Keystone, is just this general idea in one specific instance. That paper is about the trigger. This one is about the machine the trigger reveals. A good readout does not merely add a brain drug to the model. It forces the market to face the Jordan Premium it has never been able to price. Proving the engine across a frontier the market doubted it could reach is the moment the engine stops being a story a skeptic can wave off. It becomes a fact a model can no longer park at a dollar.

The timing, finally, is close. Arrowhead announced initiation of the Phase 1/2a study of its lead brain program in December 2025, and management has guided to topline data from the healthy-volunteer portion in September. Note what that readout is and is not: management has described it as primarily safety and total tau knockdown in healthy volunteers, not evidence of benefit in patients. The argument here does not hinge on it, the engine is underpriced today on the evidence already in hand, but September is the moment the market is most likely to be forced to look.

Notice there are two doors the recognition can walk through, and September could open either. The first is the data itself, which forces the public market to reprice what it can now no longer dismiss. The second is a bid, because a proven engine invites the one buyer who can price it, and nothing teaches a market the value of something faster than watching someone else pay for it.

13. The bigger lesson

Step back from the ticker, because the durable idea is larger than any one stock.

Any company whose real worth is a proven discovery engine will be underpriced by output-based valuation, in biotech and well beyond it. The pattern is old enough to have a history, as Section 5 shows, and it has repeated across four decades and several modalities. The very thing that makes SOTP trustworthy, that it prices only what can be named and defended, is the thing that makes the engine invisible. This is not a bug you fix with a better spreadsheet. It is baked into the act of pricing the nameable, and it hands a standing opportunity to anyone willing to tell an engine from a list and put a value on the difference.

The rule that keeps this from being wishful thinking is the stick from Section 4. An engine is not a company that calls itself a platform. It is a company that translates, generalizes, runs efficiently, and keeps a beat, all at once and over years. Hold every hopeful up to that stick, and the premium is earned by evidence instead of handed out on enthusiasm. Arrowhead is today’s clearest case, scoring on all four marks while the market carries its engine at a placeholder and its next two tissues inside it. The rule, though, is the thing to keep. It will outlast this one example.

You do not draft a generational talent for the games you can already put on the schedule. You draft him for the ones you cannot imagine yet. That is what Arrowhead’s engine is, and it is the one thing a spreadsheet built to price the nameable can never fully capture.

Here is the whole paper in a sentence. The market is happy to pay for the drugs Arrowhead has already made, and it will hand you, for free, the machine that keeps making them and the tissues that machine has not reached yet.

The market prices the box score. An acquirer prices the player.

Learn to see the engine, and you learn to see the value the market cannot. That is the Jordan Premium. It is sitting in plain sight, priced at a dollar.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

JPMorgan’s sum-of-the-parts model for Arrowhead assigns $1 per share to the company’s brain program. Not 1 billion. $1.

That number is not an insult. It is an accounting convention. Analysts price what has been proven and hold a placeholder for what has not, because a model that pays in advance for unproven platforms has stopped being a model. The placeholder is honest.

The question, then, is not whether the Street has overlooked the central nervous system platform. It has not. It has explicitly chosen not to value it yet, and that choice is internally consistent: there is no human evidence to price, so a placeholder is the disciplined answer. The argument of this note is not that the choice is wrong today. It is that the choice is about to be overtaken by the exact evidence it has been waiting for.

It is also the most important number in the model, because the thing it is holding a place for is not one drug.

1. What the market is actually pricing

When the SHASTA readout landed, the market rerated Arrowhead in a hurry. The stock rose roughly 19 percent in a single session, its best day in nearly eight months, to a fresh 52-week high. Analysts moved with it: Morgan Stanley lifted its target to $120, Piper Sandler to $126, Chardan to $115, with others following. The cardiometabolic data was real, and the Street repriced it enthusiastically and fast.

That is exactly what makes the next observation so striking. Look at what those same, freshly raised targets still assign to Arrowhead’s brain program. In JPMorgan’s sum-of-the-parts model, it is $1. The analysts who had just moved their targets $15 to $40 higher on the cardiometabolic franchise did not move the platform, because there was nothing new to move it on.

That is the structure worth holding in mind. The market prices Arrowhead’s drugs readily, and repriced them the moment SHASTA gave it something to model. What it will not price is Arrowhead’s platform, and it declines for a defensible reason: the platform’s central claim has never been proven in a human brain. This September, the first data that could prove it arrive. The drugs already have their catalyst. The platform is still waiting for its.

2. A keystone, not a brick

An arch is not built like a wall. Every stone leans on the others, and none of them carries load until the last stone, the keystone, is set at the top. Before it goes in, the structure is scaffolding and intention. After it goes in, every stone locks into place and the arch carries weight it could not carry a moment earlier.

ARO-MAPT is the keystone of this thesis. It has been dosing subjects since December 2025, and management has now guided topline data from the healthy-volunteer cohort to September, so the readout is an imminent result from a trial already underway, not a distant event. Beyond that timing, it is not testing one proposition. It is testing four, at the same time, in the same patients.

The drug question. Does lowering tau in the human brain accomplish anything? Tau is the protein whose tangles track most closely with cognitive decline in Alzheimer’s disease. One tau-lowering drug, Biogen’s diranersen, has produced a suggestive clinical signal, but it missed its primary endpoint and did not reach statistical significance, so whether removing tau changes the course of the illness remains unproven.

The delivery question. Can an injection under the skin silence a gene inside the brain? This is the one that matters most, because nobody has done it. Every genetic medicine for the brain in the clinic today is delivered by lumbar puncture, a needle placed into the spinal canal.

The pipeline question. Arrowhead has guided a substantial expansion of its central nervous system pipeline at the end of 2026, contingent on encouraging data, and on the earnings call management tied that expansion directly to a successful MAPT readout, noting it would validate the platform for numerous additional CNS programs including partnered ones. Today that expansion is a promise. A good readout converts it into a plan.

The platform question. Does the engine that reached liver, lung, muscle, adipose tissue, and now the brain keep converting delivery capability into clinical programs at the pace it has managed so far?

Four propositions. One readout.

3. Why a good result would compound rather than add

Here is the part that models handle badly, and it is worth walking through slowly because it is the analytical core of this note.

When several uncertain propositions must all be true, their probabilities multiply rather than add. Give each of the four above an even chance and the joint probability is not one half. It is one sixteenth. That is roughly how a platform ends up valued at $1: not because anyone believes it is worth $1, but because a chain of individually reasonable discounts produces a number near zero at the end of the chain.

Now run it in the other direction. A readout that provides the first human validation of the delivery platform does not remove one term from that chain. It removes the condition every other term was hanging from. The drug question, the pipeline question, and the platform question were all discounted for the same underlying doubt, which is whether Arrowhead can put a silencing molecule where it needs to go. Answer that doubt once, and three other discounts collapse alongside it.

This is why the repricing would be nonlinear. The model does not move from $1 to $2. The model changes category, from a pipeline of separately discounted drugs to a validated platform, and platforms are valued on an entirely different basis. One clarification keeps this honest: a good readout would be the first human proof of concept for the delivery architecture, not a guarantee that every future central nervous system program built on it will succeed. What it validates is the route. Each program still has to earn its own approval. That is enough to move the platform off a placeholder, because the market is not pricing certainty on every program; it is pricing whether the architecture works at all.

4. The precedent nobody is citing

There is a temptation to treat all of this as theory. It is not. The most important part of the argument has already been tested in the market, in the same organ, against the same modality, delivered by the same route.

In 2016, Biogen launched Spinraza, an antisense oligonucleotide for spinal muscular atrophy delivered by lumbar puncture. It was the first treatment ever approved for the disease, and it became the standard of care.

In 2020, Roche launched Evrysdi. It works on the same underlying biology, the splicing of the SMN2 gene, toward the same therapeutic goal. The meaningful difference is that patients drink it.

By 2024, Evrysdi was the global market leader in spinal muscular atrophy, with more than 16,000 patients treated and revenue growing 18 percent. Spinraza’s revenue fell roughly 10 percent to $1.57 billion. Roche’s own explanation for the gain was that Evrysdi is the only noninvasive treatment for the disease. Trade coverage put it less delicately: the oral drug removes the need for painful lumbar injections.

Figure 1. Reported annual revenues. Evrysdi converted from Swiss francs; 2023 figures derived from reported year-over-year changes. The incumbent was first, effective, entrenched, and backed by a large company. It lost its lead in roughly four years, and it lost on route of administration.

Read that sequence carefully, because it is this entire thesis in miniature. Nothing about Spinraza stopped working. What changed is that patients were offered the same biology without the needle in the spine, and they took it. That is what a delivery shift looks like when it arrives. It is neither gradual nor polite.

5. What the precedent implies for the incumbents

Every genetic medicine for the brain in clinical development today is delivered into the spinal canal.

Ionis, the pioneer of the field, describes a neurology franchise that addresses all major brain regions, with 13 investigational medicines in clinical development. Spinraza for spinal muscular atrophy and Qalsody for SOD1-ALS are on the market. ION582 for Angelman syndrome is in Phase 3 with Breakthrough Therapy designation. ION717 targets prion disease, zilganersen has cleared its pivotal study in Alexander disease, and further programs address Huntington’s disease, multiple system atrophy, Parkinson’s, and Alzheimer’s. Diranersen, the tau program partnered with Biogen, belongs to the same family. Every one of them is administered by lumbar puncture.

Those are real medicines, and several of them are genuinely important advances for patients who had nothing. Spinraza alone still generates over $1.5 billion a year, and the broader intrathecal neurology franchise across these companies runs to billions more in current and projected revenue, all of it delivered by lumbar puncture. The argument here is not that they stop working. The argument is that their long-term value quietly assumes the route survives, and a validated subcutaneous alternative would not compete with them one drug at a time. It would date the route they all share.

Two honest limits belong on that claim. Antisense chemistry reaches targets and cell types that RNA interference may not, so the two approaches are not perfectly substitutable, and not every brain target will yield to a silencing molecule delivered under the skin. A first-in-human readout also proves biology rather than commercial displacement, which takes years to play out.

There is a further wrinkle that makes the route question sharper than mere convenience. Diranersen’s own trial produced an inverse dose response, in which the lowest dose performed best, alongside a confusional state that climbed from 5 percent on placebo to 28 percent at the highest dose. The chief executives of both Voyager and Denali publicly attributed that pattern to delivery rather than to tau biology. The same trial appears twice in this note, once as evidence that tau-lowering is not yet proven and here as evidence that the route may be the problem, and both readings can hold at once: the drug missed, and the delivery is a plausible reason it did. If that reading is right, the intrathecal route is not simply inconvenient. It may be the constraint on the dose.

6. Value does not appear, it moves

Markets reprice shifts of this kind abruptly, and the mechanism is worth understanding. In the clinic, a transition from one delivery route to another takes years. In a model it takes an afternoon, because an analyst does not gradually shade down an incumbent’s terminal growth rate. The analyst changes the assumption.

A validated subcutaneous route into the brain would therefore do two things simultaneously. It would create a platform premium where a placeholder used to sit, and it would begin subtracting terminal value from franchises built on the older route. The total value of treating brain disease would not change much on the day of the readout. The ownership of that value would start to.

That is the difference between a good clinical result and a repricing event.

7. How large a repricing, and why the number is conservative

The natural question is how large. This note will not answer it with a single price target, because a point estimate on an unproven readout is false precision. What it will do is build the number from the model already on the Street, state every assumption, and then show that the result is conservative against what buyers have actually paid. A skeptical analyst should be able to rebuild it and land in the same range.

Begin with the model itself, since the argument requires no new one. JPMorgan's sum-of-the-parts is a discounted-cash-flow build on roughly 134 million shares. In the breakdown published with its $95 target, the components were approximately $48 a share for Redemplo in severe hypertriglyceridemia, $5 for Redemplo in familial chylomicronemia, $5 for zodasiran, $10 for the obesity programs, $12 for partner milestones, and the balance in cash and tax assets. The brain platform, meaning ARO-MAPT plus the entire central nervous system pipeline plus the delivery technology, was carried at $1. JPMorgan raised the target to $100 the day after the third-quarter print. That raise followed a quarter dominated by cardiometabolic and commercial progress, the priority review voucher, the SHASTA strength, the accelerated sHTG path, rather than any human brain data, so there is no reason to think the extra value reflects a new credit for the platform. Absent a fresh readout, the platform remains the placeholder this section reprices. That single dollar is the line the argument turns on. Everything else is left as JPMorgan has it.

The four components of a repriced platform

A good readout does not lift the platform line by a few dollars. It forces an analyst to build a line item that does not currently exist, out of four distinct value pools. Each is estimated separately below, deliberately, so that a reader can dispute any one without collapsing the rest.

One: ARO-MAPT itself. Value the lead asset the way an analyst values any de-risked clinical program, with a risk-adjusted net present value. Assume a peak-sales estimate for a subcutaneous tau therapy in early Alzheimer’s that is deliberately modest by the standards of the indication, on the order of $4 to $6 billion, reflecting a large patient population against meaningful competition and pricing pressure. Assume an unadjusted program value of roughly 1.5 to 2 times peak, standard for a durable therapy with a decade of exclusivity. Then apply a probability of success that a positive biomarker readout would support but not inflate, in the range of 15 to 20 percent, which respects Alzheimer’s long history of late-stage failure. The product lands near $12 to $18 a share. Note the discipline in that figure: it already assumes most versions of this drug fail.

Two: the wholly-owned central nervous system pipeline. Arrowhead has guided a substantial expansion of its own central nervous system programs contingent on encouraging data, a linkage management restated on the earnings call. A positive readout converts that guidance into credible, separately valuable programs beyond tau. Ascribe only a few risk-adjusted dollars to each of a small number of them and the pool is worth roughly $10 to $15 a share. This is distinct from the value of ARO-MAPT and distinct from the platform’s licensing value below, and it is priced as option value, not as certainty.

Three: the delivery platform as a business asset. Separate from any drug Arrowhead develops itself is the value of a proven subcutaneous route to the brain that other companies will pay to use. This is not speculative. Novartis has already paid $200 million up front and committed up to $2 billion for one program and a few targets built on this platform, before any human brain data. That is the observed price of a single slice. Assigning the entire platform’s licensing potential $12 to $20 a share, roughly $1.5 to $2.5 billion, values the whole at less than what Novartis committed for a fraction. A conservative anchor by construction.

Four: validation of the existing partner licenses. JPMorgan already carries $12 a share for partner milestones. A positive readout raises the probability of the central nervous system portion of those milestones, the Novartis synuclein program and the Sarepta ataxia and Huntington’s programs, all of which ride the same architecture. Marking up only that portion adds roughly $5 to $10 a share. This is an increase to an existing line, not a new invention, which makes it the least disputable of the four.

Summed, the four pools rebuild the platform line from $1 to roughly $40 to $55 a share. Since that line entered JPMorgan’s target at $1, replacing it means adding roughly $39 to $54 of platform value on top of the rest of the model. Set against JPMorgan’s current $100 target, that points to a base case in the rough vicinity of $140 to $155. The precise figure depends on JPMorgan’s latest component split, which is not the point. The point is the shape of the move: a repricing of $40 to $55 a share, or something over 40 percent, off a target that still prices the platform at nothing.

Figure 2. Illustrative, not a forecast. The scenarios reprice only JPMorgan’s $1 platform line; every other component of JPMorgan’s target is held fixed. Figures illustrate magnitude and are not price targets.

Why this is the conservative case, not the bullish one

The test of any target is what informed buyers pay for comparable assets, and here the comparison is unusually direct. In October 2025 Novartis agreed to acquire Avidity Biosciences for approximately $12 billion, an $11 billion enterprise value, for a platform that delivers RNA to one tissue, muscle, with three late-stage assets. Novartis described the capability as one competitors had struggled to replicate and paid a 46 percent premium for it. The comparison is not exact, since Avidity also carried three late-stage clinical assets that Arrowhead’s early brain program does not yet match, but it remains informative on one point the debate turns on: what a proven single-tissue delivery platform commands in a real transaction. Alnylam, whose platform remains concentrated in the liver, carries a market capitalization in the tens of billions and is itself now pushing RNAi into Alzheimer’s, which tells you where the field believes the value is going.

Set the base case against those marks. It implies a platform worth roughly $45 a share, about $6 billion. Novartis paid twice that for a single-tissue platform. The base case therefore values Arrowhead’s entire multi-tissue platform, liver, lung, muscle, adipose, and a validated route to the brain, at half of what one tissue fetched in a real transaction months ago. Either the base case is too low, or Novartis materially overpaid for Avidity. Both cannot be true, and a buyer paying an $11 billion enterprise value in cash is the harder number to dismiss.

The right way to read the base case, then, is as a floor rather than a midpoint. It is built from deliberately conservative inputs at every step, a modest peak-sales figure, a low probability of success, a licensing value set below what a partner has already paid for a fraction of the platform, and it still lands beneath the price a real buyer paid for a narrower asset months ago. A base case that sits below the observable market-clearing price is doing its job as a floor. The honest implication is that the expected value most likely sits above the stated base range, not at its center, and the numbers are kept low on purpose so that the case does not depend on the optimistic end of any single assumption.

One source of upside sits entirely outside these figures and is worth naming precisely because it is not in them. The four pools value Arrowhead as a standalone platform. They contain no control premium. A positive readout would raise the market’s implied probability of an acquisition, and an acquirer would pay above the standalone value, that is what a control premium is. That premium is real and it skews the entire distribution to the upside, but it is left out of the modeled numbers on purpose, because quantifying it would mean stacking a guessed probability of a deal on top of a guessed premium, and a case that needs a takeover to work is a weaker case than one that does not. The repricing above stands on fundamentals alone. The acquisition premium is additional upside on top of it, directional rather than modeled, and it widens the right tail well beyond the bull case.

The magnitude is not an aggressive assumption laid on top of the model. It is what the model produces once the zero is filled in, and it still values a proven multi-tissue platform below what a single tissue sold for this year.

The bull case, and what it requires

The bull case, roughly $185 to $210, is not a larger version of the same arithmetic. It requires the category switch described earlier to actually occur: the market stops valuing Arrowhead as a pipeline of risk-adjusted drugs and starts valuing it as a platform company, on the higher multiple those command. That is where the pipeline expansion, the partnered licenses, and a live acquisition premium all begin to carry value at once, and it is the softest of the three scenarios because it depends on a change in how the market frames the company, not only on the data. It is included for completeness and flagged as the least certain.

The objections a careful reader will raise

Three are worth answering directly.

1. That Alzheimer’s always fails: conceded, which is why the probability of success above sits at 15 to 20 percent rather than higher, and why the platform’s value does not depend on ARO-MAPT’s clinical success alone, since the delivery proof validates the route regardless of the drug’s eventual outcome in dementia.

2. That a biomarker is not clinical benefit: also conceded, and it is why the readout is a repricing trigger rather than a settlement, with full value accruing over years as later data matures.

3. That the drug value and the platform value double-count: they do not, and the four pools above are defined to be mutually exclusive, one drug, other drugs, licensing to third parties, and an uplift to an existing milestone line. On share count, the analysis uses JPMorgan’s own 134 million throughout, so a larger diluted figure would lower every per-share number proportionally while leaving the percentage move, which is the quantity that matters, unchanged.

8. Why proof, not price, has been the obstacle to a deal

The most common objection to the acquisition thesis is that Arrowhead has become expensive. That has the logic backwards.

A large acquirer cannot justify paying platform multiples for a platform that has not been proven. That is a governance problem before it is a financial one, since the board that approves the premium has to defend the evidence behind it. The obstacle was never the price of the asset. It was the absence of the evidence that would make the price defensible in a boardroom.

Proof removes that obstacle, and it removes it in the direction of urgency. A de-risked delivery platform that reaches the brain would be the scarcest asset in an industry facing the largest patent expiration cycle in two decades, and there would be exactly one of them. It would also carry a defensive motive that does not exist today, because whoever owns the successor route owns an option on every franchise built on the route it replaces.

Novartis has already partially voted. In 2025 it paid $200 million up front, with up to $2 billion in milestones, for a preclinical Arrowhead brain program and access to the platform, before any human brain data existed at all. That is what a sophisticated buyer pays for an unproven platform. Novartis is not the only buyer paying, either: within the most recent quarter Madrigal licensed a clinical-stage Arrowhead liver program for $25 million up front and up to $975 million in milestones, one more sophisticated buyer paying to rent the engine rather than build one. The interesting question is what a buyer pays for a proven platform, and what a rival pays to keep it from happening.

Novartis is not the only one exposed to the readout. The same subcutaneous delivery platform ARO-MAPT is about to report on in humans is the one that carries a row of already-licensed brain programs. Novartis holds the rights to ARO-SNCA for Parkinson's disease, described in the deal itself as subcutaneous delivery to the central nervous system, plus options on further targets. Sarepta has licensed a set of central nervous system programs run on the same architecture, covering ataxias and Huntington's disease, with the right to add more.

Every one of those licenses was written on the belief that a subcutaneous injection can silence a gene in the brain. ARO-MAPT is the first clinical test of that belief, now dosing patients with topline data guided to September. A positive readout does not just validate Arrowhead's own programs; it validates every partner's license at once, and confirms that the companies which paid for early access were paying for something real.

None of this makes a transaction certain. It makes the specific thing that has been preventing one go away, which changes both the probability and the timeline.

9. The honest asymmetry

Everything above is conditional, and the condition may not be met.

If ARO-MAPT disappoints, the sequence runs in reverse. The platform premium does not appear. The pipeline expansion guided for the end of 2026 reverts to a hypothesis. The intrathecal incumbents receive a reprieve, because the route everyone criticizes remains the only route that works. The delivery question, the keystone, stays unanswered, and the discount stays applied.

What does not change is the floor. SHASTA-3 and SHASTA-4 have already read out, plozasiran is approved and launching in five geographies, the cardiometabolic franchise is real revenue rather than a projection, and the balance sheet holds roughly $1.57 billion in cash and investments even after the company committed $215 million to a priority review voucher to pull the sHTG approval forward. Management has put the peak sales of that broader approval in the $3 to $4 billion a year range. A disappointing brain readout does not touch any of that.

Underneath that floor, the company is compressing the approval timeline on two separate fronts, and the distinction between them is worth getting right. The priority review voucher shortens the review clock itself, taking the FDA standard review from ten months down to six once the clock starts. Per JPMorgan, management has already told the FDA of its intent to use the voucher, a step required ninety days before filing, and separately intends to request the agency’s Split Real-Time Application Review, or STAR. STAR does not obviously shorten the six-month clock further. It works on a different segment of the timeline, letting a sponsor split the submission into two parts filed roughly two months apart so the agency can begin reviewing the first part before the complete package arrives, with the formal clock starting on the second.

The benefit is front-loading rather than a shorter clock, so the honest way to hold it is as a second, smaller accelerator on the submission-to-clock-start window, not as further compression of the six months the voucher already buys. Two caveats keep it grounded: STAR is a limited pilot with a small number of slots, and it carries eligibility conditions, including a disqualifier tied to foreign manufacturing sites, so an intent to request is not the same as an acceptance. The signal that matters is directional. A company does not pursue two independent acceleration mechanisms at once for an approval it is unsure it wants to reach quickly.

It is worth naming the pattern in these moves, because it is the same quality the platform thesis depends on. Management treated time as a quantified asset and acted on it. It paid for the voucher in cash rather than issuing stock, it timed the regulatory communication to the ninety-day requirement rather than improvising, it layered a second acceleration request on top, and the chief financial officer put the company’s own arithmetic on the decision, describing the four-month pull-forward as worth more than three times the price of the voucher on present value alone, before any competitive benefit from reaching the market ahead of a rival. Read together, these are the actions of a team that knows precisely what its time is worth and spends to protect it. That disposition is not incidental to this note. The value in the sections above depends on execution, on a company that converts capability into approved, launched, partnered programs at a consistent pace, and the way management handled this approval is one more piece of evidence that the execution is real.

The asymmetry is the actual investment observation in this note, and it is more useful than any target price. The downside is bounded by a commercial franchise that already exists. The upside is not a higher number in the same model. It is a different model.

One caution belongs here on what would count as success. A first-in-human readout of this kind is a biomarker and safety event. It shows whether the drug reaches the brain, how much tau it removes, how long the effect persists, and whether patients tolerate it. It does not show that patients get better, which requires years and far larger trials. Reading a strong biomarker result as proof of clinical benefit would be the same error as pricing the platform at $1, made in the opposite direction.

10. What to watch when the data arrives

Five things will separate a good headline from a result that confirms the thesis.

Depth of knockdown. In primates, Arrowhead reported roughly 70 to 80 percent reduction of tau messenger RNA across brain regions, and 50 to 60 percent reduction of tau protein in cerebrospinal fluid sustained for months. The two figures measure different things, and the distinction matters for reading the human data. Messenger RNA knockdown cannot be measured directly in a living human brain, so the number a first-in-human study reports is the cerebrospinal fluid tau protein reduction.

Management has now named its target explicitly, guiding to a 50 to 60 percent knockdown and anchoring that level to the degree of tau lowering associated with clinical improvement in the reference literature. That is the benchmark to hold the September data against, and it lines up with the primate cerebrospinal fluid figure rather than the higher messenger RNA number. A reader who remembers the 70 to 80 percent primate mRNA figure and expects it in humans is measuring against the wrong yardstick, the gap between species is where optimism usually goes to die, and the honest comparison is the cerebrospinal fluid number the company has itself put forward.

Regional distribution. This is the most important item on the list and the least discussed. A drug delivered into spinal fluid diffuses inward from the surface, so it reaches superficial cortex more readily than the deep structures beneath, and those deep structures carry much of what patients and families actually care about. Cerebrospinal fluid tau cannot show this; only imaging can, which is why the exploratory tau-PET readout, if the company reports it, matters more than the headline knockdown number. Whether Arrowhead shows the drug reaching deep structures, rather than an aggregate figure alone, is the difference between reaching the brain and reaching the part of the brain that matters. A leading tau imaging researcher raised exactly this question about the Biogen data, and Biogen did not answer it.

Durability. Duration of effect per dose determines dosing frequency, and dosing frequency is where a subcutaneous route turns a scientific advantage into a commercial one.

Safety, specifically its absence. The signature that follows oligonucleotides in spinal fluid includes inflammation of the cerebrospinal fluid, rising neurofilament light as a marker of neuronal injury, and ventricular enlargement. A clean profile on those measures would not merely reassure. It would be the affirmative case that changing the route solves the problem rather than trading one problem for another.

What the company chooses to disclose. A company confident in its regional data shows regional data. The shape of the disclosure will say almost as much as the numbers inside it.

11. The position, and the move

Chess players recognize positions like this one. Every piece is developed, the center is prepared, and the entire game reduces to a single break in the middle of the board. Until that break is played, the position is only potential, and the stronger player is usually the one who understood several moves earlier that everything had already been arranged.

Arrowhead has spent more than a decade arranging this position: seven tissues, 19 clinical programs, its own manufacturing plant, an approved and launching medicine, partners who pay it for hitting deadlines, and a balance sheet that lets it refuse a low offer.

The readout in September does not create that position. It reveals whether the position was real.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. Forward-looking analysis of an unannounced readout. Nothing here is a prediction of clinical results. Revenue and franchise figures are drawn from company reports and public disclosures. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Let me save you some time. If you open the earnings release and see a big loss, do not panic, and do not celebrate the revenue jump either. This quarter ended June 30. That is before the huge SHASTA trial results, before the launch really got going, before everything that actually moved this stock. The numbers you are looking at are a photograph of a company that has already changed, so we are not going to spend much time on them.

Here is what I actually care about today, in plain terms.

1. They just paid to make their biggest approval come faster

This is the headline, and most people will walk right past it. Arrowhead bought something called a priority review voucher. Think of it as a fast-pass at the FDA. Normally the agency takes about 10 months to review a drug application. This voucher cuts that to 6.

They are going to use it on plozasiran, their triglyceride drug, to expand it to the much larger group of patients with severe hypertriglyceridemia. Here is why that matters to you as an owner: that bigger approval is by far the most valuable single thing in this company. On the call today management put a number on it, saying the broad indication could drive peak sales in the $3 to $4 billion a year range. The analysts who put a price on Arrowhead give that one approval far more weight than the small rare-disease version already on the market.

How much did they pay? The filings show $215 million for the voucher, in cash. That is a real number, not a rounding error, and they spent it to shave four months off the review of the one approval that matters most. On the call the finance chief said that moving the launch forward those four months is worth, by their own math, more than three times what they paid for the voucher, before you even count the edge of beating a competitor to market.

You do not spend $215 million to speed up an approval you are worried about. Companies hedge when they are nervous. Arrowhead just did the opposite of hedging. That tells you how they feel about their own data.

There is a quieter signal here too, for those who have followed the SHASTA story with me. People kept asking whether Arrowhead would have to wait for one more trial, SHASTA-5, before filing. Buying a fast-pass to file now is your answer. They are not waiting. On the call, asked directly whether they would shut SHASTA-5 down now, management said no, they are keeping it running to help shape the label, not because the filing needs it. That is the definition of a backup, not a gate.

2. The launch is not just starting, it is speeding up

Prescriptions for REDEMPLO roughly doubled in three months. More than 400 different doctors have now prescribed it, mostly heart-prevention and hormone specialists, and the big insurers are covering it. They also got approved to sell it in Europe and Australia during the quarter.

On the call they connected this to the bigger prize. The rare-disease launch is a dry run. The team said the broad triglyceride launch would roughly quadruple the doctors they need to reach, from about 5,000 to more than 20,000, and that they are onboarding the extra salespeople now, ahead of a possible broad launch in the second quarter of next year. In other words, they are staffing up for the big label before they even have it, which is another way of saying they expect to get it.

Why does a simple investor care about launch numbers for a small rare-disease drug? Because this is the floor under the whole stock. The exciting part of Arrowhead, the brain program, has not reported yet. While we wait for that, it matters enormously that there is a real, growing, actual business selling actual medicine in five countries underneath it. A launch that doubles in its first full quarter is that floor getting stronger.

3. Another partner is paying to use Arrowhead’s technology

This one is not today’s news, it was struck earlier in the quarter, but its revenue shows up in these numbers so it is worth a word. Arrowhead licensed one of its earlier-stage liver programs to Madrigal Pharmaceuticals. Madrigal paid $25 million up front and could pay up to $975 million more down the road, plus a cut of sales.

Forget the exact numbers. Here is the pattern that matters, and it is the same one Novartis and Sarepta showed before with much bigger checks. Other drug companies keep paying Arrowhead to use its technology, while Arrowhead keeps its best programs for itself. That is the single hardest thing to see on an earnings statement and the single hardest thing for a competitor to copy: a machine that other people will rent. One detail I enjoyed: Madrigal already licensed similar liver technology from a Chinese competitor, and it came to Arrowhead anyway.

4. The pipeline behind it kept moving

One genuinely fresh item beyond the headline. Their cholesterol drug zodasiran finished enrolling its big trial, and demand was strong enough that they raised the target from 60 to 70 patients, with results expected in mid-2027. It is a small thing on its own, but it is one more program moving forward on schedule while the main event waits in the wings.

5. The one thing I was waiting for: a date on the brain

Now the big one, and the call delivered it. Management gave a date for the first look at ARO-MAPT, the brain program: topline data in September. That is not the vague second-half-of-the-year language we had before. It is next month.

Be clear about what this readout is and is not. This first look is from the healthy-volunteer part of the study, so it is a proof-of-concept test, does the drug reach the brain, silence its target, and stay safe, rather than a result in Alzheimer’s patients showing they got better. The patient part of the study is enrolling separately. September is the moment we find out whether Arrowhead can do the thing no one has done: reach a brain target with a simple injection under the skin, instead of a needle in the spine. If that works, it does not just matter for this one drug. It validates the whole delivery platform behind a stack of other brain programs, including ones partners have already paid for.

That is the readout that could genuinely re-rate this company, and it is now weeks away, not quarters.

A quieter thing I noticed on the call

This one is a read on tone, not a fact, so take it as one investor’s ear rather than anything the company said outright. When you listen to how management talks now, they are not really asking you to value a triglyceride drug. The CEO closed by saying, in so many words, of course look at plozasiran, but also look at the engine we have built and the dozens of medicines it can produce. That is a company telling you, and telling anyone else listening, to price the factory, not the one product coming off the line.

The tell that stuck with me was on the brain program. Management noted that a good September readout would not just help this one drug, it would validate the delivery platform behind a set of other brain programs, including ones that partners have already licensed. Read that again with a big drugmaker’s deal team in mind. It says the moment this platform is proven, the partners who signed early look smart, and the window to get in before proof is closing. Companies do not usually spell that out unless they want the right people to hear it.

I want to be careful here, because it is easy to talk yourself into a takeover story, and I am not doing that. There is nothing in these remarks about a sale, a process, or a banker. What I hear is a company deliberately raising the value of its platform in the minds of both investors and potential partners, right before the event that could prove that platform is real, while keeping every option open, including going it alone. That is posture, and it is smart posture. It is not a deal. I would not want you reading it as one.

What I make of all this

Strip it down and the quarter did four good things: it made the biggest approval come faster, it showed the launch speeding up, it booked revenue from another partner paying for the technology, and it moved the pipeline forward. None of that is the brain readout, which still decides how big this story gets.

That is the setup I want heading into the fall, and I mean setup in the chess sense. A strong player does not win by grabbing a piece early. They spend the game quietly improving their position, and then, when the pieces are where they need to be, one move decides it. Arrowhead has spent this year building the position: an approved drug, a launch that works, a balance sheet that lets them wait, partners paying to use the platform. That built-up position is the base under the stock. What comes next is the move that resolves it.

September is when the pieces start to move. First data on ARO-DIMER-PA, their two-genes-in-one drug, and, more importantly to me, that first look at the brain. The brain readout is the move I am watching, because if it lands, it does not just win a piece. It changes what kind of game this is.

The quarter itself was never the point, and a recap of moves already made rarely is. The point is that the position is ready and the decisive move is finally on the board. It is next month, and I will be watching.

A Note on Supporting Independent Research

If this reaction note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This reaction note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of August 2026. Numbers from Arrowhead's Q3 FY2026 release, quarter ended June 30, 2026. Cash and investments about $1.57 billion.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Every argument for Arrowhead eventually rests on one claim: the platform works. That is an execution claim, and execution can be measured. This note measures it.

The headline, from Arrowhead’s own filings: 19 company-discovered drug candidates now in clinical trials, spanning Phase 1 through Phase 3, on a platform proven to deliver to 7 distinct cell types. The company spent $607 million on research and development in fiscal 2025 to run that engine. Alnylam spent roughly $1 billion. Ionis spent $916 million. Both are excellent companies, and by the estimates of their disclosed pipelines used here, neither reaches as many tissues.

In chess, development means bringing your pieces off the back rank into active play. The player who develops more pieces in fewer moves controls the board. It is the same word drug developers use, and it means very nearly the same thing.

1. Tissue breadth is the number that matters

Program counts flatter whoever runs the most trials. The harder measure is how many different tissues a company can actually deliver medicine to, because each new tissue is not one drug. It is permission to attempt every disease in that tissue.

Arrowhead’s disclosed clinical programs already span five tissues: liver, lung, muscle, adipose, and the central nervous system. The company has also disclosed that it is extending the platform into two more, ocular and cardiomyocyte, its sixth and seventh tissues, though it has not yet named targets in either. Most of the field, including the two larger peers, remains concentrated in the liver, which is the easiest destination in the body to reach and the one everyone solved first. Getting anywhere else is the hard part, and it is where Arrowhead has spent its moves. Cardiac tissue alone, once the cardiomyocyte work reaches patients, would open one of the largest untouched territories in medicine.

Figure 1. Tissue breadth against annual research spending. Bubble size is the number of clinical-stage programs. Arrowhead reaches more tissues, with a larger pipeline, on less money than either larger peer. Arrowhead is shown with 19 clinical-stage programs and seven tissues: the five in which it has disclosed clinical programs, plus ocular and cardiomyocyte, which it has disclosed it is entering. Targets in those two have not been named. Peer program and tissue counts are estimates drawn from company disclosures.

2. Tempo: the pace of getting to the clinic

Breadth is one half of the execution claim. Speed is the other, and it is the half the chess metaphor points at. In the opening, the player who develops pieces fastest dictates the game, forcing the opponent to react rather than build. Arrowhead develops quickly.

The company describes its discovery engine, in its own filings, as capable of generating multiple new clinical candidates every year, and the record bears that out: the clinical count has climbed from roughly 10 candidates a few years ago to 19 today. For context, the industry benchmark from hit identification to a nominated candidate averages 33 to 36 months, before the further stretch of studies required to reach human testing. An engine that adds multiple clinical candidates a year is running well inside the field’s typical cadence.

The most telling evidence is that a competitor pays Arrowhead for its speed. Under the Sarepta collaboration, Sarepta nominates targets and Arrowhead delivers investigational-ready constructs across six programs spanning muscle, cardiac, and central nervous system tissue. A sophisticated partner chose to outsource the distance from target to clinic to Arrowhead rather than cover it itself. That is the market pricing Arrowhead’s tempo directly, and it is the same tempo that produced ARO-033 in the registry before the market knew the program existed.

3. Why a tissue is worth more than a drug

The case for tissue expansion is usually made as a matter of ambition. It is better understood as a matter of structure. Four reasons make it the variable that decides this field.

The liver is commoditized. Every serious company in this modality cracked liver delivery years ago. That is precisely why the fight between plozasiran and olezarsen is being waged over percentage points on the same gene in the same organ: two good drugs, one destination, competing on margins. When everyone can reach a place, arriving there stops being an advantage. The only exit from that kind of competition is a tissue no one else has reached.

Most disease is outside the liver. A company that can only deliver to one organ has a ceiling on what it can ever treat, no matter how elegant its chemistry becomes. Each new tissue does not add a drug. It adds every lowerable disease in that tissue at once, which is why the list of targets Arrowhead could credibly pursue runs to hundreds rather than dozens.

Breadth is a hedge, and this is the reason most often missed. In a single-tissue company, every program shares one point of failure: if the delivery mechanism disappoints, the whole pipeline disappoints together. 7 validated tissues mean 7 substantially independent delivery problems already solved, so a setback in one does not travel to the others. That is a lower risk of ruin, not merely a wider set of chances, and it is why a broad platform deserves a different valuation framework than a deep one.

Each tissue makes the next one cheaper. Every conquest leaves behind reusable knowledge: ligand chemistry, molecules that tune how the drug moves through the body, safety experience with regulators, and a manufacturing plant whose cost is spread across everything that follows. Tissue expansion is not a series of equally expensive conquests. It gets easier as it goes. An engine that becomes more efficient the longer it runs does not converge with its competitors over time. It separates from them.

The honest objection is that focus has value too. Alnylam concentrated on the liver and has six approved products to Arrowhead’s one, which is a serious argument that depth converts to revenue sooner than breadth does. It is correct about the past decade. The question this paper raises is which approach owns the next one.

4. The cost picture, stated honestly

Divide research spending by clinical-stage programs and you get a rough cost per program: roughly $34 million at Arrowhead, and, using estimated peer program counts, on the order of $40 million at Alnylam and $46 million at Ionis. Arrowhead is leaner, though not dramatically so, and that distinction matters more than the direction of it.

The proxy is crude, and it deserves the caveats. Spending is lumpy. Programs sit at different stages, and a Phase 3 trial costs many times what a Phase 1 does. Partnered programs have some of their costs carried by Takeda, GSK, Sarepta, Amgen, Novartis, and Sanofi, which lowers Arrowhead's reported spending for reasons the counter-case takes up below. Smaller companies such as Silence and Wave spend far less in absolute terms, but they run a handful of programs across one to three tissues. Cheap alone is not the achievement.

What the numbers support is narrower and more durable than a claim of dramatic cost advantage. Arrowhead occupies the productive middle: more breadth and throughput than the small players, less spending than the large ones. It is the best combination of the two on the board.

5. Why it costs less, mechanically

Efficiency without an explanation is a coincidence. Arrowhead’s annual report supplies the mechanism. The design philosophy is to begin with a structurally simple molecule and add only the chemistry strictly necessary to achieve the required knockdown and duration. The company states plainly that its platform is built for simplified manufacturing and reduced costs. Simpler molecules take fewer synthesis steps, which makes each batch cheaper and faster to produce.

Two further structural advantages compound it. Arrowhead identifies potent RNA sequences rapidly using proprietary selection rules, which shortens the distance from target to candidate. It also manufactures in its own facility rather than queuing for slots at a contract manufacturer, which removes a bottleneck that routinely costs competitors months.

6. The proof that is audited rather than asserted

Any company can claim it executes well. Milestone payments are different, because the counterparty sets the bar, verifies the result, and pays in cash. In fiscal 2025, Arrowhead earned $300 million in milestones from Sarepta alone: $100 million when it hit the first enrollment target and won authorization to escalate dosing in the ARO-DM1 study, and $200 million when it cleared a safety committee review and reached the second enrollment target. Nobody pays $200 million for a good slide. They pay because the trial enrolled and the review cleared, on time.

Novartis then paid $200 million up front, with up to $2 billion in milestones, for a program that had not yet entered human trials. That is a sophisticated buyer pricing the engine rather than the asset.

There is a quieter piece of evidence as well. In June, a new Arrowhead candidate called ARO-033 appeared in the clinical trial registry, a placebo-controlled first-in-human study in roughly 42 healthy volunteers dosed subcutaneously. While Arrowhead has not yet officially disclosed the program’s target, research indicates it is an ocular program, most likely aimed at dry age-related macular degeneration. A candidate reached human testing before most of the market noticed it existed, which is what a running engine looks like from the outside.

On that basis the commercial logic is considerable. Dry age-related macular degeneration is a market generally sized at $3 to $5 billion, and it is underpenetrated because the approved therapies require an injection directly into the eye every one to two months. The mechanism is telling as well, since the complement proteins that drive the disease are made largely in the liver, which raises the possibility of treating an eye condition with a subcutaneous injection rather than a needle in the eye, and which fits the two complement programs Arrowhead already runs. The company has not formally confirmed the indication, so it should be held as a strong inference rather than a fact. What does not depend on it is the execution point: the engine put another candidate into humans before the market knew it existed.

7. The engine pays for itself

Here is the fact that separates Arrowhead from nearly every company running a pipeline this size. In fiscal 2025 it reported $829 million in revenue, $98 million in operating income, and $30 million in net income. It was profitable. Most companies running 19 clinical programs burn hundreds of millions and return to shareholders for more money. Arrowhead ran one of the broadest pipelines in the field, across more tissues than either larger peer, and finished the year in the black.

8. Quality, not just volume

Throughput proves the machine runs. It does not prove the output is good. For that, look at the cases where Arrowhead and a competitor pursued the identical target, which controls for the possibility that Arrowhead simply chose easier problems.

In alpha-1 antitrypsin deficiency, Arrowhead’s fazirsiran and Dicerna’s belcesiran went after the same gene. Fazirsiran published in the New England Journal of Medicine, showed a 94 percent reduction in the accumulated disease protein in the liver, produced fibrosis regression in a majority of biopsied patients, and advanced into Phase 3 with Takeda. It got further, faster. In severe hypertriglyceridemia, plozasiran and olezarsen target the same gene, and plozasiran has just delivered replicated 79 and 81 percent triglyceride reductions with a statistically significant reduction in acute pancreatitis, dosed four times a year against twelve.

One more marker of capability rather than volume: ARO-DIMER-PA is, by the company’s account, the first clinical candidate designed to silence two genes with a single molecule. The engine is not only fast. It does things the other engines have not done.

9. The honest counter-case

Four objections deserve a hearing, and one of them lands.

Alnylam has six approved products. Arrowhead has one. On cost per approval, which is the metric that ultimately matters, Arrowhead loses today and it is not close. The rebuttal is that approvals lag the engine that produces them, and Arrowhead only reached commercial stage in November of 2025. That is a real answer, but it is an answer about the future, and readers should weigh it as such.

The other three objections are weaker. Alnylam’s larger spending partly reflects a commercial organization supporting six marketed drugs, which is a different cost, not a worse one. Some of Arrowhead’s speed comes from RNAi biology in the liver rather than from management. Partnering also genuinely offloads late-stage costs, so the claim that Arrowhead would be cheaper standing alone remains unproven. That last point deserves a caveat of its own, though. Persuading Takeda, GSK, Sarepta, Amgen, and Novartis to fund your trials, pay you milestones for hitting them, and leave the wholly owned cardiometabolic, obesity, and brain programs untouched is not an accounting artifact. It is a deliberate strategy, and executing it is itself a form of efficiency.

10. What it means, and what to watch Tuesday

An acquirer buying Arrowhead is not buying 19 programs. Programs can be licensed one at a time. It is buying the machine that produced them, and machines of this kind have proven very hard to build from scratch. Novo Nordisk understood this in 2021 when it paid roughly $3.3 billion for Dicerna, acquiring an RNAi platform rather than any single approved drug, and notably paying that price for the platform even though the head-to-head program discussed above was lagging Arrowhead’s. Every large pharmaceutical company facing the patent expirations of the coming decade needs replacement revenue, and the fastest route is to buy an engine that is already running.

Arrowhead reports fiscal third quarter results on Tuesday, August 4. The quarter closed on June 30, before the SHASTA readout and before the first look at the brain program, so the financial statements are history. The engine is what to watch instead: the research spending line and what it bought, the pace of programs moving between phases, the launch of Redemplo, and above all the guidance on when the tau readout arrives. The numbers describe a quarter that has already ended. The commentary describes the machine that determines every quarter after it.

Arrowhead has developed more pieces, onto more squares, in fewer moves than anyone else on this board. Development is not the same thing as winning. It is what makes winning possible, and it is the part that cannot be improvised later.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. Financial figures are drawn from audited annual filings. Peer program and tissue counts are estimates from public disclosures and are approximate. Cost per program is an indicative proxy, not a precise measure of development cost. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Going back through Arrowhead’s recent public comments changed my read on one important point from my last note, enough that it deserves its own write-up. The company spoke directly about the pancreatitis question, the one everyone is watching in the coming SHASTA results, and what management said shifts how that result should be understood. Everything here comes from those public comments.

What management has said

In two public investor appearances, the RBC Capital Markets and Jefferies fireside chats, Arrowhead’s Chief Medical Officer, James Hamilton, addressed the acute pancreatitis endpoint directly, and the transcripts are on the record. He said the company is cautiously optimistic that SHASTA-3 and SHASTA-4 will actually prove a reduction in pancreatitis to the standard scientists treat as proof, and that the trials are large enough to do it based on the number of pancreatitis cases showing up so far. A quick word on what that means. To prove an effect on something, a trial needs enough of those events to occur during the study, otherwise there is too little to measure. Hamilton gave the number on those calls, the RBC Global Healthcare and Jefferies fireside chats in mid-2026: if roughly nine or more pancreatitis events occur, at rates like those seen in the company’s earlier CORE studies, that is enough to give a reliable answer. He noted, too, that the events seen so far have not fallen far outside what they expected. A word on how a company knows anything while blinded: treatment assignments stay hidden, but the company can still see the total number of adjudicated pancreatitis events piling up across the whole trial. That aggregate count, without revealing which arm the events landed in, is enough to gauge whether the trial is likely to have the statistical power it needs.

How that reframes the endpoint

This puts pancreatitis in a more precise light than the market conversation, mine included, has generally allowed. Here is the cleanest way to hold it. Triglyceride lowering is the main thing these trials were built and sized to prove, and it is widely expected to come through. Pancreatitis is a second thing they track, and whether they can prove it depends on one variable: how many pancreatitis events actually occur during the study. If enough occur, the trials can prove it. If too few occur, they cannot, no matter how well the drug works. Management is saying it believes enough will occur, and that proof on pancreatitis is genuinely within reach, not out of the question the way my first note implied.

Squaring this with the sell side

This is worth squaring with the sell side, because there is a real tension in how the pancreatitis endpoint is being described. Pancreatitis is not a vague hope hanging off these trials. It is a formally named secondary endpoint in both SHASTA-3 and SHASTA-4, an adjudicated count of pancreatitis events and related hospitalizations, assessed by an independent committee against pre-set criteria. It was built into the trials on purpose.

Against that, JPMorgan’s July 17 note, the same one that raised its price target to $95 while valuing the entire brain platform at a single dollar, carries a one-line caveat that the trials are not powered to show a pancreatitis reduction. Both things can be true, and the reconciliation is the whole point. The trials are powered first for triglyceride reduction, which is the primary endpoint. Pancreatitis is a secondary endpoint, and whether it reaches statistical significance depends on one thing: whether enough pancreatitis events happen during the study to measure a difference. The honest statement is not that the trials cannot show pancreatitis, it is that they will show it only if the event count cooperates. Management, watching the blinded event rate, is guiding that it expects it will.

There is a strong reason to take that guidance seriously, and it is the piece the sell-side framing tends to skip. Plozasiran has already hit statistical significance on pancreatitis once, in the Phase 3 FCS trial, where the reduction in adjudicated events came in at an odds ratio of 0.17 with a p-value of 0.03. The drug has demonstrably moved this endpoint in a pivotal setting before. The open question in SHASTA-3/4 is therefore not whether the drug can reduce pancreatitis, which is already on the record, it is whether the larger and somewhat less severe sHTG population will generate enough events for the effect to clear significance again. That is a question about event counts, not about whether the biology works.

Which is what makes JPMorgan’s own scenarios worth reading closely. Its best case, worth 15 to 30 percent upside, is built on proving a statistically significant pancreatitis reduction, and its middle case treats a result that falls short of significance as, in the bank’s words, perceived negatively at first, with buyers stepping in depending on the magnitude. The point is not to guess at what the analysts privately believe. It is simpler and entirely on the page: JPMorgan’s own valuation framework assigns real additional upside to a significant pancreatitis result. Whatever the caveat about powering, the endpoint plainly remains an important determinant of value in the model itself. That is consistent with what management is guiding.

Worth adding on that dollar: valuing the brain platform at a single dollar, up from the zero it carried before, concedes the platform is worth more than nothing while still pricing it at a rounding error, a tacit admission of the point I made in Zero.

Why it raises the stakes

There is a cost to management raising expectations this way, and it should not be glossed over. Guidance sets the bar, and by guiding to proof on pancreatitis, management has raised the standard the readout will be judged against. The comfortable reading from my first note, that a pancreatitis miss would just mean the trials were too small to prove it and could be shrugged off, does not survive the company itself saying it expects to prove it. The result now carries real weight in both directions: proof would be a genuine win the market is primed for, and falling short would sting more than an underpowered endpoint otherwise would, because it would miss a bar the company set for itself. Higher expectation, higher stakes.

What it clarifies about SHASTA-5

It also corrects a piece of the surrounding debate that has the logic backwards, and this part cuts in Arrowhead’s favor. SHASTA-5 is not a fallback that exists because SHASTA-3/4 cannot demonstrate pancreatitis. Per Hamilton, it is a separate, dedicated outcomes trial in high-risk patients, those with prior pancreatitis events, designed to provide even stronger, confirmatory evidence, particularly for payers. The framing that treats SHASTA-5 as the consolation study for an endpoint the main trials cannot reach is mistaken. The main trials may reach it, and SHASTA-5 is built to reinforce the case rather than to rescue it.

The real question into the readout

Strip it down and the question was never whether SHASTA-3/4 can show pancreatitis. Management has publicly guided that it believes they can. The question is whether enough pancreatitis events actually occurred during the study, which no one will know for certain until the final data is unblinded and analyzed. That is the single thing the result turns on, and it is the one to watch. Everything else, the triglyceride result almost certainly coming through, the underlying biology, the real-world case, sits on firmer ground. This is what makes the coming readout more than another triglyceride study. It is a direct test of whether Arrowhead’s confidence in the pancreatitis endpoint was warranted, a test the company chose to invite by telling the market it expects to pass.

The discipline of this work is separating what a trial can prove from what the market assumes. This update tightens exactly that line on the pancreatitis question, and it is on the record straight, ahead of the results rather than after them.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

A pivotal readout is coming for Redemplo in severe high triglycerides, the SHASTA-3 and SHASTA-4 topline, expected within days, with the full 12-month data set for a Hot Line presentation at the European Society of Cardiology Congress in Munich in late August, the slot the congress reserves for its most practice-changing trials. Before it lands, it is worth separating what the trial was designed to measure from what the market has decided to judge it on, because those are not the same thing, and the gap between them is where the stock is most likely to be mispriced in the first hour after the results.

What the trial is built to show

One piece of vocabulary makes the whole thing clear, so here it is in plain terms. When statisticians say a trial is powered to prove something, they mean it was built big enough, with enough patients and enough time, to give a reliable yes-or-no answer on that specific question. A trial can measure a hundred things, but it is only powered to prove the one or two it was sized around. Power depends largely on how often the event happens and on how many patients are enrolled: when an event is uncommon, even a drug with a substantial effect may require thousands of patients or years of follow-up before statistical significance can be demonstrated. Measuring something is not the same as being able to prove it, and that single distinction is the entire point of this note.

The primary job of this trial is triglyceride reduction, and on that measure the bar is not really in doubt. Investors look for something above roughly 60 to 70 percent. The earlier SHASTA-2 study already delivered about 74 percent, and the main competing drug has shown triglyceride reductions in a comparable neighborhood, roughly 55 to 72 percent across its trials. Triglyceride lowering is the mechanism, it is what the drug is designed to do, and it is what this trial is powered to demonstrate. On the thing the trial was built to prove, expectations are high and, by most reckoning, likely to be met.

What the market has decided to grade

The number investors are actually fixated on is different. It is the reduction in acute pancreatitis events, the dangerous real-world consequence of very high triglycerides. The benchmark in everyone’s mind is the competitor’s headline of an 85 percent reduction in those events. That figure, worth understanding, came from a trial run in a pancreatitis-prone population and built around pancreatitis events, not from a triglyceride-sized study like this one, which is precisely why it makes an unfair yardstick for SHASTA. The reflex on results day, then, will be to compare Redemplo’s pancreatitis number against that bar and grade the drug a winner or a loser on the spot.

Here is the problem with that reflex, and it is not a subtle one. Pancreatitis is not an afterthought in these trials. It is a formally tracked outcome, the studies count pancreatitis events, related hospitalizations, and emergency visits, and they were described from the start as designed to look at whether the drug lowers both triglycerides and the rate of pancreatitis. The events are measured, in other words, and measured carefully.

What the trial can prove is a different matter, and this is the crux. The trial was sized around triglycerides, roughly 750 patients over a single year, which is enough to give a clean answer on triglyceride lowering. Pancreatitis, though, is a rare event. In a group that size over one year, only a small number of pancreatitis cases will occur at all, and that is simply too few to produce a statistically reliable result, the kind that clears the bar scientists and regulators treat as proof. The drug can genuinely reduce pancreatitis and the trial can still be unable to prove it to that standard, purely because it was not built to. Measured, yes. Powered to prove, no. Much of the print-day risk lives in that gap.

There is a clean piece of evidence that this is deliberate, and it is the most convincing detail of all. Arrowhead built a separate trial, SHASTA-5, for the specific purpose of proving a reduction in pancreatitis, enrolling only high-risk patients who have already suffered multiple pancreatitis attacks, and running for up to three years rather than one. A company does not construct a dedicated, years-long trial to prove something its main trials could already prove. The existence of SHASTA-5 is the clearest possible confirmation that SHASTA-3 and SHASTA-4 were never meant to settle the pancreatitis question. That job was handed to a different study, on purpose.

Why the distinction matters on print day

Follow that through to print day. If the pancreatitis numbers do not reach that bar of statistical proof, the quick, headline-reading reaction will be that the drug missed. That reading would be wrong, or at least badly incomplete, because you cannot miss a bar the trial was never built to clear. A pancreatitis result that falls short of formal proof, in a trial sized for triglycerides, is a feature of how the study was designed, not a verdict on whether the medicine works. What actually matters in that case is the size of the pancreatitis reduction and which direction it points, not whether it crossed a proof threshold the trial was never meant to reach.

The medical reality and the market reaction are likely to split here, and even the Wall Street analysts have quietly admitted it, noting that doctors will lean on the established biology, lower triglycerides mean fewer pancreatitis attacks, even where one trial cannot prove the reduction to a statistical certainty. Doctors treat the mechanism. Headlines grade the statistics. Those are two different audiences drawing two different conclusions from the very same result.

Figure 1: Powered to prove one thing, graded on another

The trial is sized to demonstrate triglyceride reduction, where the bar is expected to be cleared. The market will grade it on acute pancreatitis reduction, an outcome the trial is not powered to prove statistically. A significance miss on the second is a design feature, not a drug failure. Illustrative framing of the powering distinction.

How to read the result without being whipsawed

Hold three cases in advance, so the headline does not set the interpretation for you. If triglycerides clear the bar and pancreatitis shows a large reduction that also reaches significance, that is an unambiguous win, and the market will treat it as one. If triglycerides clear the bar and pancreatitis reduction is large in magnitude but short of significance, the headline may read negative for an hour, and it should not, because that is the trial doing exactly what a triglyceride-powered study does with a rare event. The number to read in that case is the size and direction of the pancreatitis effect, not whether it earned a stamp of statistical proof. Only the third case, a triglyceride result that falls short of the expected range, would be a genuine disappointment on the terms the trial was actually built to test.

The tie to the larger thesis

This is the same distinction that runs through everything I have written on this company. Separate the question a study was designed to answer from the question the market wants answered, and the mispricing usually lives in the gap. On results day the gap will sit between a triglyceride result the trial can prove and a pancreatitis result it cannot, and the first reaction is likely to judge the second as if the trial had been built to settle it.

Chess has a precise word for this situation. A player can hold a winning position, material up, the outcome not in doubt to anyone who actually reads the board, while the scoreboard still shows the game as undecided, because checkmate has not yet been forced. The impatient spectator glances over, sees no mate, and assumes nothing has happened. The player knows the win is already on the board and simply has not been delivered yet. Lower the triglycerides and you have the winning position. The forced mate, statistical proof on pancreatitis, was assigned to a different game, SHASTA-5, on purpose.

When the results land, do not ask whether Redemplo delivered checkmate in a trial that was never set up to force one. Ask whether it is winning. On triglycerides, it almost certainly is, and a winning position converts. The market may spend a headline or two confusing an undelivered mate for a lost game. That confusion is not a verdict on the drug. It is the buying opportunity.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Every so often an argument arrives fully assembled, made by someone with no interest in making it. This is one of those. JPMorgan published a note last week reiterating an Overweight rating on Arrowhead with a price target of $88. Inside that note is a sentence that should stop any careful reader, and a table that contradicts it.

The sentence says the brain program is the first asset in Arrowhead’s pipeline aimed at crossing the blood-brain barrier to reach the clinic, and that management expects a substantial expansion of the entire central nervous system pipeline if its first readout is encouraging. The table says that program is worth nothing.

Where the $88 comes from

A price target is not a slogan. It is arithmetic, and the arithmetic is published. Here is how JPMorgan builds its $88.

Figure 1: What JPMorgan’s $88 is made of

The stated components of JPMorgan’s December 2026 price target for Arrowhead, per share. The brain platform, the company’s most differentiated asset, appears nowhere. Composition from JPMorgan’s published note, July 2026.

Roughly $43 a share for the approved triglyceride drug in its larger indication. About $4 for the same drug in the rare disease where it is already approved. Around $5 for a second cardiometabolic drug, about $10 for the obesity programs, and roughly $12 for potential milestone payments from partners. The rest is cash, tax assets, and an unspecified remainder labeled pipeline value.

Read that list again and note what is missing. The delivery platform that lets Arrowhead put gene-silencing drugs into tissues nobody else can reach carries no line. The brain program, ARO-MAPT, carries no line. The bench of central nervous system targets behind it carries no line. The platform is not modeled conservatively. It is not modeled at all.

The contradiction, stated plainly

Hold the two halves of that note side by side. In the text, JPMorgan tells clients that the brain readout is important derisking, that it is the first blood-brain-barrier asset the company has put into humans, and that a good result triggers a substantial pipeline expansion beginning at the end of 2026. In the model, the same firm assigns that asset, that platform, and that expansion a value of zero.

Both cannot be right. Either the platform matters, in which case the price target is missing its most important input, or it does not matter, in which case the note should not describe it as a major derisking event. What JPMorgan has actually published is a valuation of Arrowhead as a cardiometabolic company that happens to own a brain platform for free.

This is not a criticism of the analyst. It is how sell-side models work, and it is precisely the mechanism I have been describing for months. A discounted cash flow can only value what it can forecast, and it cannot forecast a platform whose first human data does not exist yet. Faced with an unproven asset, the model does the only thing it knows how to do. It assigns zero and waits. The result is a price target that captures the company Arrowhead is today and none of the company it is becoming.

Zero is not the conservative answer

The defense an analyst would offer is that a model cannot value what has not read out. Set that defense against the same analyst’s own arithmetic. Roughly $10 of the $88 sits on the obesity programs, which is the right call, since those programs have already produced human data, meaningful reductions in visceral, total, and liver fat, and doubled weight loss in combination with tirzepatide. About $12 sits on milestone payments that hinge on other companies’ trials. Both are estimates of things not yet certain, and the analyst is right to make them, because making them is the job. The model is entirely willing to price an early clinical asset on a probability, right up to the moment it reaches the brain platform, where it suddenly assigns nothing. That is not caution. It is selective, and the selection lands on the single most valuable asset in the company.

The point cuts deeper than one note, because risk-adjusting unproven assets is not something biotech analysts occasionally do. It is the job. In most industries an analyst forecasts revenue that already exists. In biotechnology almost nothing exists yet, so the entire discipline is built on putting numbers on things that have not happened. Probability of technical success, phase-by-phase attrition rates, risk-adjusted net present value, probability-weighted peak sales: these are not exotic instruments. They are the daily vocabulary of the profession, and analysts rightly take pride in wielding them. Assigning a defensible number to a deeply uncertain asset is the craft itself.

A zero, in any case, is not a number the model produced. It is the number that appears when nobody enters one. There is a difference between running the calculation and arriving at something small, which is rigorous, and never creating the line item at all, which is an absence wearing the costume of an estimate. A conservative analyst would take a low probability of success, apply a modest value, and publish a small figure. That is defensible and it is honest work. Zero is not conservatism. Zero is the only output that requires no analysis whatsoever.

There is a cost to that absence, and it is not merely academic. A price target is supposed to be a forecast, which means it should already carry the probability-weighted value of events that are foreseeable. The brain readout is about as foreseeable as an event in this business gets. It is scheduled, the company has said when to expect it, the bar for success is public, and the consequences of clearing that bar are estimable within a range. A model that carries no expectation for it is not forecasting the future. It is photographing the present and putting a future date on the frame.

Notice the date on that frame. The price target runs to December 2026. The readout arrives in the fall. The target is therefore dated after the single most important event of Arrowhead’s year, and priced as though that event will not occur.

To be clear about what is and is not being argued. A stock should move sharply when a great deal is learned, and a large repricing after a genuine binary readout is the correct outcome, not a failure. What should not happen is that the repricing comes as news to the model. The purpose of risk-adjusting an unproven asset is to hold, today, a considered view of what tomorrow might bring, so that when tomorrow comes the analyst is updating a number rather than inventing one, and is not blindsided by an event that was on the calendar all along.

The fair objection is that sell-side convention often does keep early-stage and preclinical assets out of a formal discounted cash flow, handling them qualitatively in the text instead. That convention is real, and in most cases it is harmless. It stops being harmless when the excluded asset is the most valuable thing the company owns, and when the same analyst, in the same document, calls it major derisking. At that point the convention is not prudence. It is the reason the mispricing exists.

Recognize what a zero actually asserts. It is not a shrug, and it is not caution. Written down, a zero is a specific and aggressive claim: probability of success multiplied by value equals nothing. Not small. Not uncertain. Nothing. To hold that view of Arrowhead’s brain platform, an analyst must believe either that ARO-MAPT has essentially no chance of working, or that a proven subcutaneous route into the human brain would be worth nothing once it did. No analyst would say either sentence out loud, and yet the model says both.

The minimum honest answer is not a zero. It is a range. Take a probability of success, take a value if it works, multiply, and publish the number. That is the ordinary machinery of sell-side valuation, applied everywhere else in the very same note. The anchors for that estimate are not hard to find. What informed buyers have actually paid for brain access, examined below, sets a floor, and discounting those prices aggressively still does not get you to zero.

The asset is not undifferentiated guesswork either. Arrowhead has spent years removing risk from this program in ways an analyst can actually see: primate data showing roughly 50 to 60 percent knockdown in the brain sustained for months, an approved trial enrolling patients today, a partner who paid real money for a piece of the platform, and a patent estate built around the delivery route itself. The target has now been derisked as well, by someone else’s capital. Biogen’s diranersen has shown that lowering tau in the human brain produces measurable clinical benefit, which removes the most fundamental question hanging over ARO-MAPT: whether the thing it is aimed at is worth aiming at. The platform is more derisked today than it was on the day the price target was published. The valuation assigned to it has not moved.

Why this is the strongest evidence yet

For months these white papers have argued that the market prices Arrowhead’s drugs and ignores its platform. That was an assertion. This is a receipt.

Consider the source. This is not a bearish analyst reaching for reasons to be negative. It is a bulge-bracket firm that rates the stock Overweight, that recommends buying it, and that in the same document praises the brain program in the warmest terms available. Even in the mouth of a bull, the platform is worth nothing. If the most enthusiastic sell-side model in the room carries a zero in that line, ask what is actually inside the roughly $72 a share the market is paying today.

The answer is: the triglyceride franchise, the obesity programs, some milestones, and the cash. That is the whole stock. Everything these white papers have called the crown jewel, the delivery technology, the brain pipeline, the strategic scarcity that makes three large pharmaceutical companies pay attention, is being handed to buyers at no charge.

What the platform is worth to someone who has to buy it

Set the models aside and look at what strategic buyers actually pay, because they cannot afford the luxury of a zero. Novartis committed $200 million upfront and as much as $2 billion for a narrow slice of Arrowhead’s neurology work, and it did so while already owning its own liver-targeted RNAi drug and while cheap liver-focused licensing deals were freely available. It was not buying the cardiometabolic pipeline that makes up the whole of JPMorgan’s price target. It was buying access to the brain.

BioArctic makes the point sharper still. With a blood-brain-barrier delivery technology but no approved drug of its own riding on it, it has signed four separate agreements in about two years, with Bristol Myers, Novartis, Lilly, and Eisai, each worth from hundreds of millions to well over a billion dollars, for nothing more than a way across the barrier. Four large pharmaceutical companies have paid, repeatedly and in public, simply for the right to try. Arrowhead has the only platform of its kind already in the clinic, a brain drug dosing humans today, and a partner that has committed as much as $2 billion to one corner of it. Whatever the right number is, the observed evidence says it begins in the billions. Zero is not a conservative estimate of it. Zero is a placeholder for a number the model cannot generate.

Sarepta is the third data point, and it tests a different claim than the other two. Novartis and BioArctic price the value of reaching the brain. Sarepta prices the value of the platform itself, its capacity to keep producing licensable programs across tissues. In late 2024 Sarepta licensed a suite of Arrowhead’s clinical and preclinical programs spanning muscle, lung, and the central nervous system, including central nervous system targets in Huntington’s disease and the spinocerebellar ataxias. It paid $825 million immediately, $500 million in cash plus a $325 million equity stake taken at a 35 percent premium, committed a further $250 million over five years, and put up to roughly $10 billion in milestones behind the collaboration, with the right to commission six more targets from the platform on demand.

Read what that structure actually says. A sophisticated partner did not buy one drug. It bought standing access to the factory, the right to keep pulling new programs off Arrowhead’s delivery platform for years. That is the precise asset JPMorgan labels pipeline value and scores at nothing. Sarepta named the reason itself, calling Arrowhead’s approach to crossing the blood-brain barrier with a subcutaneous shot a potential paradigm shift for the central nervous system programs it was licensing. The acquiring partner identified, by name, the capability the model refuses to value. Note the honest limits: several of these programs are early, the headline figure is milestone-heavy rather than banked, and Sarepta has had its own turbulence, so the realized total will depend on execution. None of that touches the point, because the point is not what Sarepta will eventually pay. It is what an informed party agreed the platform was worth paying for in the first place, and that number was not zero. It was among the largest platform-licensing commitments in the sector.

The event that removes the excuse

Here is why this matters now rather than in the abstract. A model can carry a zero only while the asset remains unproven. The moment human data exists, the zero becomes indefensible, and every analyst carrying one has to replace it with a real number.

Arrowhead’s first human brain readout is expected late in the third quarter or early in the fourth. The bar is public: diranersen, the competing intrathecal drug, lowered tau in the spinal fluid by roughly 50 to 60 percent, and Arrowhead management has said it is looking for a comparable reduction in its own study as the mark of success. Its primate data already sits in that range, and its modeling projects sustained knockdown of 50 to 70 percent on quarterly dosing.

Consider what a positive result would do to a model like JPMorgan’s. It would not adjust an assumption. It would force the creation of a line item that does not currently exist, in a valuation where the largest single component is a triglyceride drug. Analysts do not re-rate gently when they have to build a new section of the model from nothing. That is the mechanical path from $88 to something that starts with a different digit.

What would make this wrong

Honesty requires the obvious caveat. The zero is only wrong if the platform works. If the brain readout disappoints, if the knockdown comes in well below the 50 to 60 percent bar, then the models were right to assign nothing, and the stock is roughly worth what the cardiometabolic franchise is worth. That is the risk, stated without varnish.

Note the asymmetry, though. If the platform fails, the market was correct and the stock is priced about right. If the platform works, the market is carrying a zero on the most strategically scarce asset in the sector, and it has to fix that in a hurry. Losing is being right about the price you already paid. Winning is a repricing that no model in the room is currently prepared for.

The hanging piece

Chess has a word for this. A piece is hanging when it sits on the board undefended, fully available for capture, and the player who should be watching it simply has not noticed. The piece has lost none of its value. Nobody is counting it.

That is what a zero in a valuation model actually describes. It does not say the brain platform is worthless. It says nobody has been forced to put a number on it, so the line stays empty and the position looks quieter than it is. The asset sits there in plain sight, undefended, worth exactly what it was worth before anyone bothered to look.

The trouble with a hanging piece is that it does not stay hanging. Somebody eventually looks at the board and counts it. It might be an analyst, obliged to build a line item after a readout leaves no excuse for the zero. It might be a strategic buyer who has been counting all along, which is what Novartis was doing when it wrote a check for the brain while the models were writing nothing.

What it all means

The most valuable thing Arrowhead owns does not appear in the arithmetic of the bank that recommends buying it. That is the entire thesis in a sentence, and this time it is not a claim from a letter with a position. It is published, sourced, and reiterated with an Overweight rating.

The market is not wrong about the triglyceride drug. It is not wrong about obesity, or the milestones, or the cash. It is simply not counting the road into the brain, because nothing has yet compelled it to. A price target is a bet on the company you can already see. The whole argument for owning this one rests on the company nobody has priced yet.

In chess, a piece that nobody defends is not a piece without value. It is a piece about to change hands.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. Figures cited from JPMorgan’s published research note dated July 2026 and from company disclosures. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Biogen presented the full Phase 2 CELIA results for diranersen at AAIC today, and by tonight every summary will have converged on the same question: does lowering tau treat Alzheimer’s disease. That is a fair question. It is not the one that moves the most value, and the gap between those two questions is where this note lives.

Two things were tested in that trial, not one, and only one of them is being talked about.

Two questions were on trial, not one

Think of a drug as a package that has to reach an address. The first question is whether the package arrives and does its job once it gets there. The second is whether that job actually helps the patient.

Those questions are worth very different amounts. A delivery answer travels. Prove that you can get a gene-silencing drug into the human brain and switch off a gene there, and you have opened the door for every drug that follows down the same road, whatever it aims at. An efficacy answer does not travel. Prove that lowering tau helps in Alzheimer’s, and you have proved exactly that, and nothing about the next target or the next disease. One answer opens a portfolio. The other adds a drug.

The market will grade the second question and shrug at the first. It has that backwards, and the rest of this note explains why.

What the data actually showed

Start with what was already public. In May, Biogen reported that CELIA missed its primary endpoint. The trial was supposed to show that higher doses worked better than lower ones, and it did not. Everything else, though, worked. Tau came down in the spinal fluid and, more impressively, tau came down in brain scans, at every dose, and it stayed down. Patients declined more slowly at every dose. The oddity: the best result came at the lowest dose, 60 mg given every 24 weeks, while the most serious side effects showed up at the highest dose. Biogen is pushing ahead to final-stage trials anyway.

Today’s presentation filled in the numbers, and they are better than the May summary implied. Tau in the spinal fluid fell by 50 to 65 percent across the dose arms by week 72, and tau also came down on brain scans in every brain region they looked at. No tau drug had ever moved both of those measures at once in a study this size. On the patient side, the winning dose slowed the decline of the disease by 26 percent, a difference of 0.54 points, on the main scale doctors use to track cognition and daily function, and by 42 and 50 percent on two pure memory-and-thinking tests. For scale, Leqembi, the amyloid drug already approved and on the market, slowed decline by 27 percent on that same main scale. A tau drug just matched an approved Alzheimer’s drug, and beat it on the thinking tests.

Then comes the detail almost no one will write about. Diranersen is injected into the spinal canal, a lumbar puncture, the same procedure people call a spinal tap. The three most common side effects in the whole trial were pain from the procedure, post-puncture syndrome, and confusion in the days right after dosing. Two of those three are the needle rather than the medicine, and the cleanest evidence for that is the placebo group: 57.9 percent of the patients who received no drug at all still had an adverse event attributed to the injection procedure. Fifty-eight percent, from the needle alone.

The third one, confusion, is more interesting, and it is not procedural. Every arm in the trial received an intrathecal injection every 12 weeks, drug or placebo, so the number of punctures was identical no matter which group a patient landed in. Confusion nonetheless grew more common the more drug a patient received. A side effect that tracks the dose cannot be caused by a procedure that does not vary with the dose. It is not the puncture. It is what the puncture delivers, and the concentration spike a bolus into the spinal fluid creates. Biogen also confirmed that this class does not carry the brain swelling and small bleeds that come with the amyloid drugs, because that risk belongs to the amyloid approach, not the tau one.

The full safety table adds something the May topline concealed. Harm climbed with dose while benefit did not. Side effects that Biogen’s own investigators judged related to the treatment affected 24.6 percent of the placebo group, then 37.7 percent at the winning low dose, 40.9 percent at the middle dose, and 57.8 percent at the highest dose, rising at every step. Serious side effects judged related to treatment ran from zero on placebo to 10.3 percent at the top dose, though not in a straight line, since the middle dose came in slightly below the low one. Set the exception aside and the shape is unmistakable. The most harm was concentrated in the arm that received the most drug, and Biogen’s own words for what that arm delivered in return were a lower effect size at the higher dose levels.

Figure 1: Level on the global scale, ahead on cognition, absent on function

Slowing of decline versus placebo at 18 months, as compiled by Biogen. Diranersen figures are the 60 mg every-24-weeks arm from the Phase 2 CELIA study (nominal significance, 60 patients); lecanemab and donanemab figures are from their Phase 3 trials (roughly 900 patients each). NR indicates the endpoint was not reported for that trial. Cross-trial comparisons are illustrative, not head-to-head. Source: Biogen AAIC 2026 investor presentation, July 14, 2026.

How it stacks up against the amyloid drugs

The comparison everyone will want, and almost no one will run properly today, is diranersen against the approved amyloid antibodies. Run it carefully, because the honest version is more interesting than the cheerleading one.

Take the main scale first, the one regulators weigh most heavily, which measures cognition and daily function together. Diranersen slowed decline by 26 percent at its best dose. Leqembi slowed it by 27 percent. Kisunla, the other approved amyloid drug, managed 29 percent. The tau drug therefore landed level with both approved drugs on the measure that matters most. On the pure thinking-and-memory tests, the picture tilts. Diranersen slowed decline by 42 percent where Leqembi managed 26 percent and Kisunla managed 20 percent, and it produced a 50 percent effect on a standard memory test where Kisunla managed 16 percent. On the two composite scales that blend cognition and function, diranersen scored 23 percent on ADCOMS against Leqembi’s 24, and 30 percent on iADRS against Kisunla’s 22, the only scales on which each of those drugs reported. On cognition alone, the tau drug looks better than the drugs already on pharmacy shelves. Everywhere else, it looks like a peer.

There is one column where it does not look like a peer, and Biogen printed it without comment. On the standalone measure of daily functioning, the ability to manage money, drive, keep up hobbies, diranersen showed zero separation from placebo. Leqembi showed 36 percent on that instrument. Aducanumab, in the trial that worked, showed 42 percent. Zero is not a small number. Daily functioning is what families actually feel, and it is a large part of what regulators are buying when they approve an Alzheimer’s drug.

Biogen’s answer to that, and it is a real answer rather than a dodge, is that the functional subdomains inside the main scale did move. Community affairs slowed by 21 percent, home and hobbies by 24 percent, personal care by 29 percent. Two instruments measuring roughly the same thing disagreed, and the one Biogen highlighted is the one that agreed with the drug. That may be noise in a 60-patient arm. It may be a real gap between what a clinician observes and what a caregiver questionnaire captures. It cannot be waved away, and it is the single largest hole in the registrational case.

Four further caveats keep this from being a victory lap. This is a mid-stage result resting on 60 patients in the winning group, the smallest arm in a study that put nearly twice as many patients in each of the others, against late-stage trials with roughly 900 patients each, and effects of this kind shrink more often than they grow when the trial gets bigger. The brain-scan substudy at the winning dose rested on 19 patients at baseline and 16 at the end. The statistics behind diranersen’s numbers are softer, too, held to a looser standard than the approved drugs were. The winning arm also entered the trial carrying less amyloid and fewer double copies of the highest-risk Alzheimer’s gene than the arms it beat, which is the kind of imbalance that can flatter a result. In fairness, it cuts both ways: that same arm started with worse cognition and more advanced disease, which would ordinarily predict faster decline, not slower. Randomization did its job imperfectly in both directions, which is what happens when an arm has 60 people in it. No single trial settles a question like this.

The safety comparison runs firmly the other way, and it is the more durable advantage. The amyloid drugs can cause brain swelling and small brain bleeds. That risk brings the FDA’s strongest warning label, repeated brain scans to monitor for it, and a genetic test before treatment even starts. The tau approach does not carry that risk, and this trial confirmed it. Nothing in diranersen’s safety profile is a mechanism attacking the brain’s blood vessels. Its burden is the route and what the route delivers. Put those together and the strategic picture is clear. Tau is now a proven target rather than a theory, and the drugs competing to hit it will be separated by how they are delivered and how safe they are, not by whether the idea works. That is precisely the ground Arrowhead built ARO-MAPT to fight on.

The endgame is a combination, and that changes everything

Look at those two columns again. The amyloid drugs did better on daily functioning. The tau drug did better on thinking and memory. Those do not look like two drugs competing to do the same job. They look like two drugs doing different halves of one job.

The biology says the same thing. Alzheimer’s is a two-protein disease. Amyloid builds up first, tau follows, and tau is the one that tracks most closely with symptoms, the protein that tangles inside brain cells in the places where memory actually fails. Clearing amyloid alone treats the trigger and leaves the bullet in flight. Almost everyone in this field now expects the eventual answer to be both, an amyloid drug and a tau drug together, and Biogen happens to own one of each.

Here is what almost no one is saying about that. If combination therapy is the destination, then how a drug is delivered stops being a matter of convenience and becomes the thing that decides whether the destination is reachable at all. Build that combination out of the standard of care as it stood until this week and you get an intravenous infusion in a clinic every two weeks for eighteen months, then an infusion every four weeks after that, plus a lumbar puncture every six months, for the rest of a patient’s life. Burdens do not simply add when you combine therapies. They compound, because the patient has to accept all of it, the doctor has to schedule all of it, and the payer has to fund all of it. Two clinic-bound drugs is not twice as difficult as one. It is disqualifying.

The timing here is almost too neat. One day before this presentation, the FDA approved Leqembi Iqlik, a once-weekly subcutaneous autoinjector, as a starting dose for early Alzheimer’s, which makes lecanemab the first anti-amyloid therapy a patient can take at home from the first dose through maintenance. The Alzheimer’s Drug Discovery Foundation said out loud what the approval means: a step toward the scalable care model the disease will need as the field moves from single drugs toward combinations. The amyloid half of the future combination just left the infusion center. The tau half is still in it.

Now picture the combination built out of what exists after this week: an at-home autoinjector for the amyloid drug, alongside a tau drug given as a shot under the skin once a quarter. There is exactly one tau program in clinical development that fits that description, and it is Arrowhead’s ARO-MAPT. Diranersen cannot be that drug, because a spinal tap does not happen at home. Every anti-tau antibody that might have been that drug has already failed. The regimen an ordinary neurologist can prescribe and an ordinary patient can live with for years is amyloid by autoinjector plus tau by subcutaneous injection, and Arrowhead owns the only candidate for the second half of it.

Readers of my first paper, The Needle Wins, will recognize the argument, because this is that argument arriving in a new disease. The thesis there was that the auto-injector had already normalized self-administration for tens of millions of people, and that any therapy which could migrate into that format would capture a market that clinic-bound competitors could not reach. Alzheimer’s crossed that line yesterday. The needle wins in neurology too, and the drug positioned to benefit most from it is not the one that just won the tau argument.

Be honest about the caveats. No one has run the combination trial, so the benefit is a hypothesis rather than a result, the costs of stacking two branded biologics will meet real resistance from insurers, and the safety of combining them has to be established rather than assumed. ARO-MAPT has also not yet shown a single human data point. Grant all of that, and the strategic point still stands. The moment the field decides the future is combination therapy, the drug that can be given as a simple shot is not merely the more pleasant option. It is the only version of the future that actually works, and Arrowhead is the only company holding a tau asset built for it.

The finding nobody else will write about

The strangest result in the trial is the one most likely to be glossed over. The lowest dose worked best. Diranersen was tested at three dose levels, and the smallest one, given twice a year, beat both of the bigger ones on essentially every measure of patient benefit. That is why the study technically failed its main goal, which was to show that more drug produces more benefit. More drug did not.

The full data sharpens this into something stronger than the topline allowed. More drug did not merely fail to help. More drug did more of everything except help. The highest dose lowered tau the furthest in the spinal fluid, drove tau down the furthest on brain scans, produced the most treatment-related side effects, produced the most serious ones, and delivered the worst clinical result of the three. The lowest dose lowered tau the least of the three and helped the most. That is not a flat dose-response curve. That is an inverted one, running through both benefit and harm at the same time.

Figure 2: Harm scaled with dose. Benefit ran the other way.

Treatment-emergent adverse events assessed by the investigator as related to study treatment, by randomized arm, from Biogen’s CELIA safety table (data cut 11 March 2026). Treatment-related adverse events rose at every step of the dose ladder. Serious treatment-related events rose from zero on placebo to 10.3 percent at the top dose, with a small non-monotonic dip at the middle dose. Clinical benefit ran the other way: the 60 mg every-24-weeks arm produced the largest slowing of decline on CDR-SB, and Biogen reports a lower effect size at the higher dose levels. Source: Biogen AAIC 2026 investor presentation, July 14, 2026.

There are two ways to read that, and the whole tau field turns on which one is true.

The first reading is biological. Tau is not purely a villain. Healthy brain cells use it for ordinary jobs, so stripping out too much of it may carry a cost of its own, and the curve turns down because the target itself has a floor. If that is right, the ceiling belongs to tau, and it applies to every drug that lowers tau, including Arrowhead’s.

The second reading is the needle. Harm rose monotonically with intrathecal exposure in Biogen’s own safety table, from zero treatment-related serious events on placebo to 10.3 percent at the top dose, with confusion specifically growing more common at higher doses. A drug that is helping a patient and injuring him at the same time will show exactly this curve, and the injury here is concentrated in events that trace to the route and to the peak concentrations a bolus into the spinal canal creates. If that is right, the ceiling belongs to the delivery, not to the target, and a route that reaches the brain gently and evenly does not inherit it.

Today’s data cannot separate those two readings, and any analyst who tells you otherwise is selling something. What it does establish is that the ceiling is real, that it arrived well below the doses Biogen tested, and that at least part of it is attributable to the way the drug gets in. Both readings converge on the same commercial conclusion. The winning technology in tau is not the one that hits hardest. It is the one that can hold a steady, moderate, precisely controlled reduction without paying an escalating toxicity toll to get there, which happens to be a description of what a quarterly injection under the skin is built to do.

The read-through to ARO-MAPT

The data landed on the most favorable branch available, and it landed on two of them at once. The mechanism worked and the route hurt.

Start with the mechanism. Deep tau knockdown produced a real cognitive signal, which validates tau as a target and, with it, the premise beneath Arrowhead’s ARO-MAPT. Someone else spent the capital to de-risk the target. Arrowhead inherits the benefit. The competitive question now narrows to delivery burden, and that is precisely where a subcutaneous injection has an obvious advantage over a repeat spinal tap.

Then the route. The winning regimen, 60 mg every six months, means two lumbar punctures a year, for life. Two of the three most common adverse events in the trial are the puncture itself, and the third is the concentration spike the puncture delivers. Every one of them is an argument for changing the route rather than changing the drug. The subcutaneous case no longer needs to be argued in the abstract. It is written into Biogen’s own safety table.

Steelman the other side, because there is a real counterargument and it appeared in this deck. Ninety-four percent of the patients who finished the study chose to continue into the extension, which means they signed up for years of further spinal taps. Patients tolerate the needle better than the delivery thesis assumes. Two honest responses. Clinical trial volunteers are the most motivated patients in the disease and are not the population that decides whether a drug reaches millions of people. Twice-yearly dosing is also genuinely less frequent than a quarterly subcutaneous injection, so the argument for a shot under the skin cannot rest on how often, only on what kind and where. The case is invasiveness and setting, not arithmetic, and it should be argued on those terms.

Where the route stops being a preference and becomes the whole game

Alzheimer’s is the largest tau market. It is not the market where delivery decides the winner, because in Alzheimer’s the two routes cover roughly the same ground. Tau pathology in Alzheimer’s begins in the entorhinal cortex and hippocampus and spreads through the association cortices, and those structures sit reasonably close to the fluid spaces that a spinal injection can reach. Diranersen’s 50 to 65 percent reduction in spinal fluid tau is evidence that intrathecal delivery gets to the places Alzheimer’s lives.

Now consider what today’s result opens up. CELIA validated tau lowering as a mechanism, not as an Alzheimer’s drug. The same mechanism points at a set of rarer diseases where tau is not one of two proteins but the only one: progressive supranuclear palsy, corticobasal degeneration, and the inherited frontotemporal dementias caused by mutations in the tau gene itself. None of them has an approved disease-modifying therapy. All of them are now more investable than they were yesterday, because the target has been reached and lowered in a human brain with a cognitive signal attached.

These are also the diseases that live in exactly the wrong part of the brain for a needle in the spine. Progressive supranuclear palsy is a disease of the subthalamic nucleus, the substantia nigra, the red nucleus, and the brainstem nuclei, including the structure whose degeneration produces the vertical gaze palsy that defines the illness. A drug injected into the lumbar spine travels up the fluid column and diffuses inward from the brain’s outer surfaces, so the structures nearest the fluid see the most drug and the structures buried deepest see the least. That gradient is a property of the route, not of the molecule, and no amount of chemistry improvement repeals it.

Look at what Biogen has published from its own animal work, and then at what it has not. Its intrathecal tau drug produced 77 percent knockdown in the frontal cortex and 74 percent in the hippocampus, which are precisely the structures the spinal fluid bathes most easily, and those are strong numbers. There is no published figure for the substantia nigra, and none for the brainstem. A program this far advanced, in a field this competitive, does not leave favorable data unpublished. The silence is the gradient. Arrowhead’s drug travels through the bloodstream instead, using a receptor expressed on the lining of brain blood vessels everywhere. Across 14 brain regions in primates, drug accumulation ran from 0.47 micrograms per gram in the substantia nigra to 1.55 in the motor cortex, a spread of roughly threefold, with the lowest region still above the threshold that produces knockdown. Arrowhead’s own slide put it plainly: the distribution overcomes the intrathecal limitation in deep brain delivery.

Hold the caveat firmly. That is a monkey, not a person, and the human distribution data does not exist yet in any program. Grant the caveat and the strategic shape is still unmistakable. In Alzheimer’s, the route is a commercial advantage. In the rare tauopathies, the route is the difference between a drug that reaches the disease and one that does not, and those are the indications with no competition, orphan pricing, and an accelerated regulatory path.

One more thing the route argument gains today. Arrowhead is not the only company that concluded the failures in tau were about getting there rather than about tau. Denali’s DNL628 uses the same class of receptor-mediated brain transport, delivered intravenously, with its first patient data expected in the first half of 2027. A third serious player betting on brain-crossing tau knockdown is corroboration of the thesis rather than a threat to it, and on the current timelines Arrowhead reads out first and is alone in the subcutaneous lane.

The number to grade the autumn on

The most useful thing to take from today is a bar, and it is now a precise one. Diranersen lowered total tau in the spinal fluid by 50 to 65 percent across the dose arms, and the arm that produced the clinical benefit sat at the shallow end of that range. Arrowhead’s management has said it is looking for a comparable reduction in its own healthy-volunteer study as the mark of success. The autumn readout now has a number rather than a mood, and the number is roughly half.

Arrowhead’s animal data already sits there. In primates, ARO-MAPT produced roughly 50 to 60 percent reductions in tau in the spinal fluid, holding for up to four months after the last dose, and its modeling projects sustained knockdown of 50 to 70 percent on quarterly dosing. My own translation framework, published before today, was more conservative than the company’s: 40 to 55 percent in humans at an optimal loading dose, with anything above 55 percent exceptional and anything below 30 percent a translation failure. That conservatism used to be a concession. Today it is a fit. Since the arm that produced the benefit sat at the shallow end of the band, a 40 to 55 percent human result for ARO-MAPT is not a disappointing near-miss of the benchmark. It lands in the range that worked.

Be clear-eyed about the flip side, because this is the real risk and it is quantitative rather than binary. The advantage of a shot under the skin only counts if the knockdown lands in the right range. Convenience does not rescue a weaker drug. If ARO-MAPT reaches the brain but silences only a fraction of what a spinal injection achieves, the delivery win is real and the commercial case is not. What today changed is the shape of the target. Arrowhead no longer has to beat diranersen on depth of knockdown, because depth of knockdown is not what won this trial. It has to land in the band, hold it steadily, and then win on everything else.

Set expectations correctly on what the autumn actually delivers. The readout coming in late September or October is the healthy-volunteer portion of the Phase 1/2a study. It answers whether a subcutaneous injection crosses into the human brain and lowers tau, and how much. It does not answer whether patients decline more slowly, because it does not enroll patients. Alzheimer’s patient data comes later, in 2027. Anyone expecting a cognitive result this autumn is going to be disappointed by a study that was never designed to produce one, and anyone who understands what is actually being tested will recognize it as the only question that has ever mattered for this program.

One practical note on timing

Expect the readthrough to be a slow burn rather than a same-day move. Arrowhead has its own topline coming in severe hypertriglyceridemia, the SHASTA readout, and that is the nearer and louder catalyst. JPMorgan made the point plainly: full credit for the tau work may only be realized on the back of that cardiometabolic topline. A tape focused on one readout does not price a second one that belongs to a competitor. The derisking today is real, and it will still be real in the autumn, when Arrowhead’s own brain data arrives and the market finally has to price it directly.

The gambit

Chess has a word for what Biogen just did. A gambit is a deliberate sacrifice, material given up on purpose to gain position. The player who offers it accepts a visible, immediate loss in exchange for something harder to see on the board: open lines, freer pieces, a position that pays out later.

Biogen sacrificed the endpoint. It gave up the clean win, a met primary and an unambiguous headline, and what it purchased with that loss was position for the entire field. Tau is now a target that has been reached, engaged, and lowered in the human brain, with a cognitive signal attached that matches the approved amyloid antibody. That knowledge did not exist in a randomized trial before today, and Biogen paid for it with a missed primary, an invasive route, and a dose curve that turned out to argue against its own higher doses.

Look closely at what Biogen is now proposing to do with the position. Its final slide says the data supports moving diranersen into registrational studies. Its next-steps slide commits to nothing firmer than continued engagement with regulators on Phase 3 planning, with no start date and, tellingly, no declared dose. The company intends to take the lowest dose, from the smallest arm, in a trial that failed the prespecified test of whether dose matters at all, into a program that will cost it hundreds of millions of dollars. That is the second half of the gambit, and it is the half that has not been paid for yet.

Here is the thing about a gambit, though. The player who sacrifices is not always the player who collects. A gambit opens a line, and whoever has a piece already trained on that line is the one who benefits from it. Biogen opened the tau file with a drug that has to go into the spine. Arrowhead is aiming down the same line with a shot under the skin, and it did not pay a dollar for the position it just inherited.

What it means

Today was a delivery win dressed up as an argument about tau. A drug reached the human brain, found its target, and cleared out tau, which is what this field has been chasing for a decade. Whether tau is the right thing to chase is a separate question, still open, and it will be settled in years of late-stage trials, not in a conference room in London.

The lesson for a platform investor is the one I keep returning to. Bet on the road, not on the destination. Targets fail, and they fail often. A validated way into the brain does not, and it can be pointed at the next target, and the one after that. Arrowhead’s own first human brain readout arrives later this year, and it should be judged on exactly the terms this note has laid out: can it get there, how much drug it takes, and how precisely the knockdown can be controlled. Whether it cures anything is a question for a different year.

Biogen made the sacrifice. The position is open. Watch who plays into it.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The hottest worry in biotech right now is China. Chinese drug companies are rising fast, copying proven Western medicines cheaper and quicker, and selling them to big pharma. A reader asked me a fair question: does this hurt Arrowhead? The honest answer is not a simple no. China is real, it has reached Arrowhead’s field, and it does threaten part of the business. What it cannot touch is the part that actually matters, and this note explains where that line is, in plain terms.

First, take the threat seriously

Any answer that just brushes China off is worthless, so let me give the threat its due. Chinese drug companies signed a record $137.7 billion of licensing deals in 2025, and 2026 is on pace to beat it. Chinese medicines now make up about half of all the big licensing deals in the world. The reason is simple: Western drug giants have huge products losing patent protection, and they can fill the gap by buying Chinese drugs for a fraction of what it costs to buy a Western company. This has already reached Arrowhead’s corner of medicine. Earlier this year, a U.S. company, Madrigal, signed a deal worth up to $4.4 billion with a Chinese firm called Ribo for liver-disease drugs of the same type Arrowhead makes.

These Chinese companies are not amateurs, either. Ribo has raised about $250 million and even runs a lab in Sweden. Another, Sirnaomics, has been at this since 2007. A third, Argo, was started by a scientist who used to work at Arrowhead. The skill is real, then, and some of it has walked right out of Arrowhead’s own door. Any honest look starts by admitting that.

What China can copy, and what it can’t

Here is the key idea, and it is simpler than it sounds. Think of one of these drugs as a package that has to be delivered to a specific address in the body. The medicine itself is the package. The organ it needs to reach, the liver, the muscle, the lung, the brain, is the address. The hard part was never making the package. It was always the delivery.

Delivering to the liver is like dropping a package at a house on a busy main road. Everybody knows how to get there, the route is published, and it is no longer a secret. That is why the liver drugs, the ones for cholesterol and triglycerides, are the copyable part. China is strong at exactly this kind of copying, so over time cheaper Chinese look-alikes can chip away at prices in that area, and that touches a slice of Arrowhead’s income. That much is fair to admit, and admitting it is what makes the rest believable.

The real edge is delivery, and it grows the farther from the liver you go

Beyond the liver, everything changes. Getting a drug into muscle, lung, or brain is not a matter of copying a known route. It is a hard problem that takes years of trial and error to solve, and this is where Arrowhead is ahead. By its own count, and it is a fair one, Arrowhead has spent more than a decade learning to make these drugs potent, long-lasting, and safe, and it now has drugs in human testing across seven different parts of the body. Reaching one hard organ is impressive. Reaching seven is a different league.

Figure 1: The farther from the liver, the fewer competitors

How crowded each part of the body is with companies testing this kind of drug. The liver is crowded and easy to copy, and it empties out as you move away from it. No one has followed Arrowhead into the brain yet. Numbers are a rough illustration; Arrowhead reports drugs in testing across seven parts of the body.

Be fair about what this edge is, though. It is a head start, not a locked door. The leading Chinese companies already have their own delivery methods and are working on organs beyond the liver, and talent moves around, as the ex-Arrowhead scientist at Argo shows. The honest claim, then, is not that no one can ever follow. It is that Arrowhead is years ahead, and the further you get from the liver, the wider that lead becomes.

The brain is where the lead is widest

At the far end sits the brain, and here Arrowhead’s lead is not just wide, no one has reached it the easy way at all. Every RNAi drug ever approved works only in the liver, Arrowhead’s own approved drug included. Getting this kind of medicine past the brain’s natural wall, with a simple shot rather than surgery or a spinal tap, has never been done in people by anyone, Western or Chinese. The Chinese brain work that exists is early lab research in animals, not a real human program. Arrowhead’s brain drug, ARO-MAPT, is on track to be the first to show it can switch off a target gene in the human brain, with early results expected in 2026. Say that plainly: it has not happened yet. That readout is the hinge the whole brain case turns on. If it confirms Arrowhead can reach the brain, being first is not a slogan, it is the whole advantage, because a proven way in works for every drug that follows. If it disappoints, the brain lead is a promise, not a fact. Whether this one drug then goes on to beat the disease is a further question, harder and years away.

Why being first in the brain matters so much

Suppose the readout lands. Being first is often overrated, but in the brain it is unusually powerful, and it snowballs. Here is why it is different from being first with a liver drug.

Figure 2: The head start that keeps growing

Why a rival lands years behind. It has to crack brain delivery first, the very thing that has stalled the field for years, before it can even begin the long testing process. The timeline is a rough illustration; the order is not.

The delivery problem comes before the clock even starts. A competitor cannot begin the long years of brain-disease trials until it has first figured out how to get the drug into the brain, which is the very thing that has stalled the whole field for a decade. A rival is therefore not one step behind Arrowhead. It is a whole delivery breakthrough plus a full round of trials behind, and brain trials are among the longest in medicine. The head start is measured in years before anyone else even reaches the starting line.

The lead also feeds on itself. By going first, Arrowhead grabs the best targets: it already has drugs aimed at the proteins behind Alzheimer’s, Parkinson’s, and Huntington’s. Being first attracts the big partners who pay to fund the next round, Novartis has already committed up to $2 billion for the brain platform, and that money buys the next drugs, which produce the data that lands the next partner. The first approved brain drug also becomes the standard everyone else is measured against. Each of these advantages makes the next one bigger. That is why a company that reaches the brain first is far harder to catch than one that is merely first in a crowded liver market.

Then comes the part that outlasts all of it. Once a brain drug is actually being prescribed, it digs in. Brain specialists are a small, careful world, and doctors who have learned one treatment, watched it work, and grown comfortable with its quirks do not switch on a whim. Treatment guidelines get written around the drug that got there first. Insurers put it in the preferred slot and make every latecomer fight for coverage. Patients doing well on a long-term medicine are rarely moved off it. A rival showing up years later with a slightly better drug still has to pry all of that loose, one doctor and one insurer at a time. Being first also makes the next drug easier: every brain program teaches Arrowhead something about delivery it can reuse, so its tenth brain drug costs less and moves faster than its first, while a competitor is still struggling through its first.

The patents are hard to get around

There is a legal layer on top of all this, and being first shapes it too. A patent can only protect something new, something no one has done before. In a crowded field, where a lot of similar work already exists, a company can patent only narrow slivers, because everything else is already taken. In a brand-new field, where almost nothing came before, the first company in can patent broadly. Arrowhead is first into the brain, so there is very little earlier work to box in its claims, which means its patents can cover wide ground. It also runs its own in-house patent team, building that protection from the start.

This matters most where the money is. A rival that wanted to sell a copycat brain drug in the United States, the market that counts, would not just have to match the science. It would have to invent a completely different route around a wide wall of Arrowhead patents. Patents are not a magic shield, and a determined competitor can sometimes design around them. Doing so is slow and expensive, though, and it often leaves the copycat a step behind with a weaker drug, while Arrowhead keeps pulling further ahead.

Why China’s rise actually helps Arrowhead

Put the two halves together and something surprising happens. If the brain bet pays off, China’s rise raises Arrowhead’s value instead of lowering it. When everything that can be copied gets copied and turns cheap, the one thing that cannot be copied becomes rarer, and rare is exactly what makes something valuable. This also sharpens the buyout case rather than weakening it. A big drug company can now buy a cheap liver drug from China, which means the reason to buy Arrowhead was never its liver drugs in the first place. It is the delivery skill and the head start in the brain, and those are the two things no amount of money can buy from China. The proof is already on the table, and it is stronger than it first looks. Novartis already owns a liver drug of exactly this kind, called Leqvio, so it had no need of Arrowhead for the liver at all. It still paid Arrowhead $200 million up front and promised up to $2 billion, every dollar of it for the brain platform. Buyers have already shown which part they will pay up for.

What could go wrong

It is only fair to say how this could be wrong. The largest risk is the most basic one: the brain lead is not proven yet. Everything in the brain half of this note rests on the 2026 readout showing that Arrowhead can actually reach the brain. If that result disappoints, there is no first-mover position to defend and the brain advantage does not exist. Even if the delivery works, whether lowering the target treats the disease is a separate and harder question that will take years. The other risks are about how long the lead lasts rather than whether it starts: China is pouring money into reaching organs beyond the liver and learning fast, helped by talent that keeps moving, so the years-ahead lead could shrink quicker than expected, and the copycat pressure on the liver drugs could prove bigger than the modest hit described here. None of these turns the easy-to-copy drugs into the crown jewel. The honest posture is simple: the liver headwind is real and here now, and the brain prize is real but still unproven.

The move no one can copy

Chess has a useful idea here. Every serious player memorizes the openings, the published moves that begin a game. They are free for anyone to study and copy, move for move, which is exactly what the copycats do best. The real edge shows up later, in positions the book has never seen, where the memorized moves run out and only the player who arrived first knows what to do. The liver is the opening. Everyone has it by heart. The brain is a position with no book at all, and Arrowhead is about to make the first move into it.

Here, then, is the whole paper in a breath. China can copy the drug. It cannot copy the move no one has played yet, and the first move into the brain is the one that wins the game. The more the world fills with cheap copies of the openings, the more valuable the one player becomes who is writing a book everyone else will have to study. That player is Arrowhead, and it is the one thing a cornered buyer cannot buy from China at any price.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

This note translates the game theory trilogy into plain numbers. The Forced Move series argues that three large drugmakers, Novartis, Lilly, and Roche, may each be pushed toward acquiring Arrowhead, not because they want to, but because the cost of letting a rival buy it first can be worse than the cost of buying it themselves. That is what a forced move means in chess: a move you make because every alternative is worse. This note shows how that idea looks once you attach real numbers to it, and how those numbers are built.

A quick word on the patent cliff

Every large drugmaker lives in fear of the patent cliff. A drug is protected by patents for a set number of years. When that protection ends, cheaper copies, generics for ordinary pills and biosimilars for the more complex biologic drugs, flood in, and the original medicine can lose most of its sales within a year or two. A company with a big drug going off patent has a revenue hole to fill, and filling it is urgent.

The three companies in this story face that cliff on very different clocks. Figure 1 shows the cumulative sales each one is set to lose to expiring patents over the next ten years.

Figure 1: The patent cliff arrives on three different clocks

Cumulative branded revenue each company is projected to lose to patent expiry, 2026 through 2035. Modeled from public sales and known expiry dates.

Novartis is bleeding now. Its heart-failure blockbuster Entresto, which sold roughly $7.7 billion in 2024, began losing United States protection in 2025, and the company has called 2026 its largest patent-expiry year ever. Roche faces a slower wave that builds mid-decade, led by its multiple-sclerosis drug Ocrevus losing protection around 2028 and 2029. Lilly barely bends, because its giant obesity and diabetes franchise, Mounjaro and Zepbound, is protected into the late 2030s, so its near-term hole is small.

The shape of those three lines is the first half of the story. Novartis needs a replacement engine today. Roche needs one soon. Lilly can afford to wait.

The one idea that changes everything

Arrowhead is attractive to all three because its platform works like a factory for new medicines, which is exactly what a company with a revenue hole needs. That much is ordinary. The idea that turns this into a forced move is less obvious, and it is the heart of the argument.

Most people weigh an acquisition as buy versus do not buy, where not buying simply saves the purchase price. That framing is wrong here. The real choice is buy it yourself versus let a rival buy it. Letting a rival win is not free. You still face your own patent cliff with no new engine to fill it, and now a competitor owns a platform it can turn against your business. Inaction carries a price tag, and once you see that, the math tips.

The payoff grid

Figure 2 puts that logic onto a single grid.

Figure 2: The three-way payoff grid

Net present value to each company (columns) under each possible winner (rows), in billions of dollars, at an assumed $120 billion acquisition price. Green is a gain from winning; red is a loss when a rival wins. Modeled base case.

Each row is one possible outcome, the company that wins Arrowhead. Each column is the result for one company. Every square then answers a single question: if the company on the left wins, what happens to the company named at the top?

The green squares run down the diagonal, where a company wins the auction itself, and those are gains. Every red square is an outcome where a rival wins instead, and those are losses. Here is the punchline. Pick any single column and read down it. You will find one green square and two red ones. No company has a comfortable do-nothing option, because if it stays out, one of the other two wins and it takes a loss. The only good outcome is the one you have to pay for. That is the forced move.

A few specifics are worth seeing. Novartis has the most to gain by winning, because its cliff is the most urgent. Roche faces the steepest single loss on the board, the $45 billion it would suffer if Novartis wins, because Arrowhead’s brain-delivery work sits right next to Roche’s own brain franchise, so a Novartis-owned Arrowhead would be a direct threat. Lilly’s squares are the smallest in both directions, because it is the least cornered.

Where the numbers come from

None of these figures are facts pulled from a filing. They are estimates, built from a few simple rules, and it is worth knowing exactly how, so you can judge them for yourself.

Start with the price. The base grid assumes a sale clears at about $120 billion, which sits in the middle of a realistic range for an asset like this.

Next comes the value of owning Arrowhead, which differs by buyer. It starts from a common baseline, the standalone worth of the platform and pipeline, built from the parts in the next section at about $90 billion, then adds an amount unique to each buyer for the synergies and cliff-filling it gains. Subtract the price from that total, and the result is the green diagonal number, the net gain of winning.

Then come the losses, and here a tempting mistake was avoided. It is natural to think a company that loses Arrowhead loses two things: the cliff-filling it misses and the competitive damage of a rival holding the platform. Counting both is wrong. Your patent cliff is unfilled whether Arrowhead stays independent or a rival buys it, so you never actually had that cliff-filling to lose; it belongs entirely to the gain from winning. The only genuine loss from a rival winning is the extra competitive damage that rival does with the platform, over and above the competition an independent Arrowhead already poses, so that is the single thing the red squares count. This keeps the same pipeline from being counted twice, once as a gain and once again as a loss.

What the platform is worth on its own

That $90 billion baseline is not a number borrowed from thin air, and it is worth building from the parts. Figure 3 does that.

Figure 3: Building the $90 billion standalone value

A modeled sum of the parts. The tangible floor rests on named programs and signed contracts; the platform option value is the contested estimate. Risk-adjusted and illustrative.

The tangible floor comes first. Arrowhead’s wholly-owned pipeline, led by the approved triglyceride-lowering drug plozasiran and its much larger late-stage program, alongside the obesity, tau, and complement candidates, carries the most identifiable value, on the order of $43 billion on a risk-adjusted basis. Its partnership streams, the milestones and royalties owed by Sarepta, Amgen, GSK, Novartis, and others, together with net cash, add roughly $12 billion. Those pieces give a tangible floor near $55 billion, the part grounded in named assets and signed contracts.

The platform option value is the rest, about $35 billion, and it is the real bet. This is the worth of the delivery engine itself, its proven ability to reach the liver, lung, muscle, fat, kidney, and now the brain, and to keep generating new programs not yet named. It is the hardest piece to pin down and the easiest to argue over, which is why Figure 3 shows it separately. Value the engine conservatively and the standalone value sits near $90 billion; value it the way a true believer in the platform would, and it climbs well past that.

Two things follow. The $90 billion baseline used throughout this note is a deliberately conservative reading, a solid tangible floor plus a restrained platform value, sitting at the low end of the wider sale range. The single largest source of disagreement about what Arrowhead is worth is therefore not the pipeline, which is fairly concrete, but how much credit to give the engine that keeps building it.

What the precedents say

Modeled numbers feel less abstract when set against real deals, and three precedents are worth knowing. In 2019, Novartis bought The Medicines Company for $9.7 billion, a premium of about 41 percent over the prior month’s average price, to acquire a single siRNA drug, inclisiran, which became its cholesterol medicine Leqvio. That deal put nearly $10 billion behind one asset, from the very company at the center of this analysis. Arrowhead is not one asset; it is a platform with roughly a dozen programs across the body, including the brain.

Two larger deals fill in the picture. In 2021, Novo Nordisk paid $3.3 billion for Dicerna, another RNAi company. In 2023, Pfizer paid $43 billion for Seagen to own an antibody-drug-conjugate platform, financing most of it with about $31 billion of new debt. Large platform deals happen, they clear regulators, and acquirers take on serious debt to do them.

Two lessons carry over. Biotech takeovers routinely price at premiums of 40 percent to 100 percent or more over the trading price, so a wide gap between Arrowhead’s roughly $12 billion market value and a strategic price is the norm, not a stretch. A buyer with an urgent need also pays up, as Novartis did with a double-digit premium for one cardiovascular siRNA when it wanted to anchor that franchise. The platform logic that justified $9.7 billion for inclisiran applies with far more force to an entire delivery engine.

How high would each company bid?

There is a clean way to put a floor and a ceiling on what each company should rationally pay, with the real bid landing somewhere between the two.

The floor is the denial value, the competitive damage a company avoids purely by keeping the most threatening rival from winning. A company should be willing to commit at least this much for defense alone, before counting a single dollar of owning the asset, because preventing that particular rival is worth exactly that avoided loss. For Novartis, letting Roche win would cost about $30 billion, so $30 billion is its floor. For Roche, letting Novartis win would cost about $45 billion, the steepest figure on the board, because a Novartis-owned Arrowhead would aim the brain-delivery platform straight at Roche. For Lilly, letting Novartis win would cost about $20 billion.

The ceiling sits far higher. The most a company should pay is that same denial value plus the full value of owning Arrowhead in its own hands. That works out to roughly $200 billion for Novartis, $205 billion for Roche, and $160 billion for Lilly. Every one of those ceilings towers over any realistic clearing price, which is precisely why a contested auction would run hot.

Put plainly: the floor is the loss avoided, the ceiling is that loss avoided plus the gain from owning, and the rational bid lives in the band between them, pushed upward by how hard the other two press. Folding the gain into the floor would be a mistake, because it would collapse the floor and the ceiling into one number and erase the band entirely.

One subtlety is worth getting right: the ceiling has two layers. The bottom layer is the plain value of owning Arrowhead, and it holds whether or not anyone else bids, because even an independent Arrowhead competes with these three in lipids, in metabolic disease, and in complement, and could partner with any of their rivals at any time. Owning it neutralizes that competitor either way, so part of the ceiling has nothing to do with a bidding war.

The top layer is the rival-control premium, the $30 billion for Novartis or the $45 billion for Roche, the extra harm of a specific, deep-pocketed rival seizing the platform and aiming it at you. That premium exists only while a live rival is actually bidding, and it falls away the moment the rival steps back. The forced move is sharpest in that top layer, yet the layer beneath still gives each company a standing reason to want Arrowhead off the board.

Notice that Roche carries both the highest floor and the highest ceiling, even though its patent cliff is less urgent than Novartis’s. What drives Roche is not its own revenue hole but the prospect of a rival seizing the brain platform, which makes its case a matter of defense rather than need.

Arrowhead’s walk-away: the $90 billion floor

Every walk-away price so far has belonged to a buyer. Arrowhead has one of its own, and it anchors the entire deal. A seller’s walk-away is the value of its best alternative to selling, which for Arrowhead is simply continuing to operate independently. That value is the standalone worth built in Figure 3, about $90 billion. It is the price below which Arrowhead should refuse any offer and stay independent, because below it shareholders are better off keeping the company than selling it. That single number is the floor under everything.

This floor is not a negotiating pose; it has real force. A public-company board owes its shareholders a duty, and accepting a bid beneath the company’s own standalone value would hand shareholders less than they already hold by doing nothing. No board can defend that, and few would survive trying. That makes $90 billion a line with teeth, not a wish.

What makes the floor robust is what sits inside it. The $90 billion is not a snapshot of today’s revenue; it already includes roughly $35 billion of platform option value, the future programs the delivery engine will keep producing. Staying independent means keeping all of that upside for existing shareholders. A buyer must therefore pay at least $90 billion simply to match what Arrowhead’s owners already possess by doing nothing at all. Anything less asks them to sell the future at a discount, and they should not.

Arrowhead also feels none of the pressure its suitors feel, and that is the heart of the matter. It is not a distressed seller. It has an approved drug generating revenue, a deep partnered pipeline throwing off milestones, and the runway to keep building. The whole thesis of this series is that the buyers are cornered by their patent cliffs; the seller is cornered by nothing. A party under a clock negotiating against a party with no clock does not set the price low. That asymmetry is precisely what lets Arrowhead hold its floor and push the final number up toward the buyers’ ceilings rather than down toward its own.

The floor is not even static. A successful first readout from the brain program would lift the platform’s standalone value, and with it the price below which Arrowhead refuses to sell. Time and data work for the seller. The same event that tightens the screws on the buyers raises Arrowhead’s walk-away, which is itself a reason a confident board would wait rather than take an early offer.

Put both sides on the table and the deal space is clear. Arrowhead should not sell below roughly $90 billion, while every buyer ceiling, the $160 to $205 billion figures from the bidding section, sits far above that floor. The zone of a possible deal is therefore wide, and with three motivated buyers competing inside it, the clearing price is pushed up through that zone rather than down to its floor. The realistic $90 to $150 billion sale range is simply where a rising seller floor and a contested set of buyer ceilings are most likely to meet. The $90 billion anchors the bottom of that range for one reason: it is the least Arrowhead should ever accept to give up its independence.

What changes if the price changes?

A fair question is how sensitive all of this is to the price. Figure 4 redraws the grid across the realistic sale range, at $150 billion, $120 billion, and $90 billion. Watch what moves and what holds still.

Figure 4: The grid across the realistic sale range

The payoff grid recalculated at $150 billion, $120 billion, and $90 billion. The red losses are identical across all three; only the green gains change as the price moves.

The red squares never change. The damage a rival does by owning the platform has nothing to do with what was paid for it, so the cost of losing is identical across all three panels. Only the green gains move, and watching them move across the range is instructive.

At $90 billion, the low end, every buyer wins handsomely: Novartis nets $80 billion, Roche $70 billion, even Lilly $50 billion. At $120 billion the gains shrink but stay clearly positive for all three. At $150 billion, the top of the range, something telling happens. Lilly’s own square turns red, because $150 billion now exceeds what Arrowhead is worth in Lilly’s hands. The instinct is to say Lilly should walk away, and the instinct is wrong. An overpriced win at $150 billion costs Lilly about $10 billion, while letting Novartis take the asset instead costs it $20 billion, so Lilly keeps bidding rather than accept the worse outcome. That red square is the winner’s curse made visible: a forced move can push a buyer past the point where winning makes sense on its own, purely because losing is worse.

That dynamic decides how an auction would actually end. As the price climbs past the top of the realistic range, the weakest-fit buyer drops out first, Lilly at its $160 billion ceiling, leaving the two most motivated, Novartis and Roche, to set the final price. The grid shows the outcome at each fixed price; how high each would actually go is the separate question answered by the floors and ceilings above.

Why not build, license, or buy someone else?

A fair challenge runs through all of this: if these companies need RNAi and brain delivery, why must they buy Arrowhead? They could build the capability themselves, license a single program, or buy a different company. The honest answer is that each alternative is weaker, and seeing why strengthens the case.

Building takes time the cornered companies do not have. Delivering RNA into tissues beyond the liver, and especially into the brain, has taken Arrowhead more than a decade of chemistry. A Novartis staring at its cliff in 2026 cannot wait out a ten-year internal program.

Licensing one program solves one problem, not the strategic one. A license gives a buyer a single drug on someone else’s terms; it does not hand over the platform, the delivery toolkit, the dozens of future programs, or the people who built them, the scientists who have solved one hard delivery problem after another, pushed RNAi into tissue after tissue beyond the liver, and engineered trigger chemistry at the leading edge of the field. A license leaves all of that, and the asset itself, on the table for a rival. The Sarepta and GSK deals with Arrowhead show that licensing happens, yet none of them removed Arrowhead as a target.

Buying a different RNAi company is the strongest objection, and the obvious candidate is Alnylam. Here the distinction matters. Alnylam is a finished franchise: profitable, with 2026 product revenue guided to roughly $4.9 to $5.3 billion, anchored by its heart drug, and valued near $42 billion before any premium. It is the better company to own outright, a mature and cash-generative business. It is the worse fit for this particular need, because its delivery is concentrated in the liver, it carries less of the brain and extrahepatic optionality a cliff-facing buyer is reaching for, and it is already entangled with two of the three buyers, since Novartis commercializes its Leqvio and Roche partners on another of its drugs. Arrowhead is the engine: broader tissue reach, a real path into the brain, a deep cardiometabolic pipeline, and far more future revenue still ahead of it. That does not make Arrowhead cheaper. Its market value is a fraction of Alnylam’s today, near $12 billion against $42 billion, yet the strategic price it would command, the $90 to $150 billion in this note, sits above what Alnylam would cost to acquire. A buyer pays more for Arrowhead precisely because it is buying the future and the breadth rather than a single mature franchise. Alnylam is the better company to own, Arrowhead the better company to acquire.

Can they actually pay, and clear the regulators?

A ceiling no one can fund or clear past regulators is not a real ceiling, so two practical checks matter. On the money, all three can write the check. Lilly, valued at over $1.1 trillion, has by far the most room. Roche is large and cash-generative across drugs and diagnostics. Novartis carries more debt, with net debt around $22 billion after recent moves, yet it has shown it will borrow for the right asset, and the Pfizer purchase of Seagen showed a buyer raising roughly $31 billion in fresh debt for a platform it wanted. A price in the range discussed here is large, yet within reach for each, especially with a mix of debt and stock.

On the regulators, the path looks clearer than for a typical mega-merger. Arrowhead’s only marketed product today is plozasiran, a therapy for a rare triglyceride disorder, and none of the three buyers sells a competing product in that small market, so a deal eliminates almost no existing competition, which is the usual antitrust trigger. The closest concern is overlap inside a single disease area, for instance Novartis already holding an RNAi cholesterol drug, and the standard remedy there is a narrow divestiture rather than a block. Pfizer cleared its Seagen deal by giving up one product’s United States royalties to satisfy the regulator. The lesson is that these deals get done, sometimes with a minor concession, rather than stopped.

How firm are these numbers

Honesty matters here. The patent-cliff figures behind Figure 1 are the most solid, drawn from public sales and known expiry dates, though they remain projections of how fast sales erode. The gains rest on two assumptions you can change: the $90 billion baseline value, whose softest piece is the platform option value broken out in Figure 3, and the price, which Figure 4 flexes across the realistic range. Both move the green numbers dollar for dollar. The competitive-damage figures in the red squares are the softest of all. Their relative size is well reasoned, with Roche losing most to a Novartis win, yet the exact dollars are estimates and should be read as approximate rather than precise. To make that concrete, the competitive-damage cells are best read with a band of roughly 30 percent either way, so Roche’s $45 billion loss to a Novartis win is better understood as a range from about $30 billion to $60 billion. One thing the model now gets right by construction: it counts each piece of value only once, never as both a gain and a loss.

What would break this thesis

Honest analysis names what would prove it wrong, and several things would. The clearest is the science. Arrowhead’s brain program, ARO-MAPT, has not yet shown that it works in people, and a clear failure at its first human readout would knock out the most valuable part of the platform and deflate the urgency for the brain-focused buyer, Roche above all.

A rival platform could leap ahead. If another company demonstrated cheaper or better delivery into the brain or other hard tissues, Arrowhead’s scarcity, the very thing that makes it worth fighting over, would erode.

The buyers could simply decline. A forced move is a claim about incentives, not a guarantee of behavior. Boards delay, balk at premiums, and sometimes choose to build despite the logic, so the thesis predicts pressure, not certainty.

Arrowhead could take itself off the table. A large financing, a transformational partnership, or a clear statement of intent to stay independent would signal that management does not mean to sell, which would defer the whole question. Watching for those signals is part of testing the thesis rather than merely asserting it.

The clock: when the move gets forced

A forced move needs a trigger, and the triggers are dated. Figure 5 lines them up.

Figure 5: Two clocks running at once

The cliff clock below the line and Arrowhead’s proof points above it. The shaded window is where a revenue hole and a platform proof point overlap.

Two clocks run at the same time. The cliff clock is already ticking for Novartis, whose largest expiries land in 2026, and it builds toward Roche as Ocrevus rolls off around 2028 and 2029. Arrowhead’s side runs hot in the very same window: the sHTG Phase 3 data land in 2026 and a plozasiran sHTG approval could follow in 2027, while the first human readout from the brain program, the event most likely to convert the platform from promise into proof, is also expected in late 2026. That readout is a gate, not a footnote: it opens a substantial CNS pipeline expansion that Arrowhead has slated to begin at the end of 2026 and run through 2027, so it does not add a single proof point; it opens a portfolio. When a cluster of proof points on Arrowhead’s side meets a revenue hole on a buyer’s side, the pressure stops being theoretical. That overlap, more than any single number in this note, is what would set a forced move in motion.

What it all means

One contrast ties it all together. Arrowhead trades near $12 billion today, yet each of the three buyers could rationally justify paying somewhere between $160 and $205 billion, well over ten times that, once the cost of letting a rival win is counted. That gap, between a market price set by today’s results and a strategic price set by tomorrow’s threat, is the entire point of the Forced Move thesis. When all three would pay far more than the asset is likely to clear for, the result is not a quiet negotiation. It is a bidding war.

The grid does not promise that any deal will happen. Real acquisitions turn on personalities, regulators, balance sheets, and timing that no model captures. What it shows is why the pressure exists, why no company can comfortably sit out, and how the squeeze falls differently on each: Novartis cornered first by the timing of its cliff, Roche most threatened by a specific rival, Lilly the most able to wait. Chess players have a name for the moment when every comfortable option has quietly vanished and only one move keeps you in the game. They call it the forced move. The board is nearly set, and the clocks are running. No one at this table wants to pay $100 billion for a company the market prices at $12 billion. That, precisely, is why one of them will.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only, and is not investment advice. The figures shown are modeled estimates meant to illustrate a strategic argument, not forecasts of any specific transaction or price. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

About This Series

This is the third and final paper in a series imagining how three large pharmaceutical companies, Novartis, then Lilly, then Roche, would approach acquiring Arrowhead Pharmaceuticals, and how Arrowhead would respond. As with the first two, this paper is a strategic thought experiment built entirely on the public record: each company’s actual acquisition history, its publicly stated strategy, the way it has behaved in past deals under its current leadership, and the public facts about Arrowhead. It is not a prediction, and not a claim that any deal is under discussion. I have no knowledge of any such discussions. Part One introduced Novartis, the partner that knows the value, and sounded the warning the old chess players called “en garde”. Part Two introduced Lilly, the giant that can simply pay, whose entry was the “check” that forced the whole board to respond. This paper introduces the last and most reluctant suitor, and with it the position the entire series has been building toward, the one in which a player is compelled to move and every move is bad.

Executive Summary

Roche is the suitor with the deepest claim of all to the science Arrowhead is built on, and the strongest temperamental reluctance to do anything dramatic about it. That combination is what makes it the right subject for the finale. The depth of the claim is almost literal: the platform Arrowhead built its company on came from Roche, which sold its RNA interference business, the technology, the Wisconsin site, and the scientists, to Arrowhead in 2011. Roche also pioneered the delivery of medicines across the blood-brain barrier using the transferrin receptor, the same fundamental strategy Arrowhead now uses to carry its tau therapy into the brain. No potential acquirer has more of its own history embedded in the company it would be buying.

Roche is nonetheless the most disciplined and most price-sensitive of the three. It does fewer deals than its peers, it puts science at the center of every decision, it has publicly chosen to sit out the recent industry acquisition spree rather than overpay, and it relies on partnerships and licensing more heavily than any of its rivals. It has even told its investors, in plain language, that it faces no patent cliff and needs no rescue from dealmaking. Everything about how Roche prefers to operate argues against being drawn into a large, contested acquisition.

This is the setup for the position the series has been building toward, the one chess calls “zugzwang”, in which a player would prefer to do nothing but is compelled to move, and every available move worsens his position. Roche’s preferred move, to license rather than buy, no longer protects it once a rival might buy the whole platform. Walking away means watching a competitor capture the very science Roche pioneered. Bidding means abandoning the disciplined, no-cliff identity it has spent years projecting. This paper lays out why Arrowhead fits Roche more deeply than it fits anyone, how Roche actually does deals, and why, in this one case, the most disciplined player on the board is the one with no good move left.

I. The Position the Series Has Been Building Toward

Two warnings have already sounded on this board. In the first paper, Novartis heard “en garde”, the old courtesy that announced an attack on the queen, and recognized that the company best positioned to understand Arrowhead’s value was not the company that could most easily afford it. In the second, Lilly’s entry delivered a “check”, the forcing move that stripped every other suitor of the freedom to wait. Each paper tightened the position. This one closes it.

Chess has a word for the position in which a player would most like to pass, to do nothing and keep his advantages intact, but is not allowed to, because the rules require him to move, and every move he can make damages his own position. The word is “zugzwang”. It is one of the strangest and most instructive ideas in the game, because it describes a situation in which the obligation to act is itself the disadvantage. A player in “zugzwang” is not losing because his pieces are weak. He is losing because it is his turn, and every legal move makes things worse. The player who could simply sit still would be fine; the player who must do something is undone by the doing.

This is the position Roche faces in the contest for Arrowhead, and it is why Roche belongs at the end of the series rather than the beginning. Roche is, by temperament and by stated strategy, the player who would most prefer to pass. It is disciplined, it is science-first, it is the most price-sensitive of the three and the most reliant on partnership rather than acquisition, and in neuroscience it has consistently chosen the patient path of licensing over the dramatic path of buying. It has gone out of its way, publicly, to stand apart from the industry’s recent rush of dealmaking. The drama of this final paper is the spectacle of the one suitor who most wants to stand still being compelled, by the presence of the other two, to move, and discovering that every move available to it costs something it did not want to pay. The most disciplined player makes the most painful forced move, because he has the most to give up by abandoning his discipline, and the most to lose by clinging to it.

II. Why Arrowhead Fits Roche

The depth of the fit between Arrowhead and Roche is greater than for either other suitor, and it carries an irony so complete that it almost defies invention. Roche is not merely interested in the science Arrowhead practices. Roche built the foundation of it, owned it, and sold it to Arrowhead.

The history is a matter of public record. In 2011, Roche decided that RNA interference, the gene-silencing technology that is the entire basis of Arrowhead’s platform, was not a business worth keeping. It sold that business to Arrowhead: the research site in Madison, Wisconsin, the foundational delivery technology, the intellectual property, and a team of more than forty RNAi scientists who became the nucleus of Arrowhead’s research engine. Arrowhead was then worth less than $50 million. It took what Roche discarded and made it the seed of everything that followed. The science Roche would now have to pay an enormous price to acquire is the science it once owned outright and let go for a pittance, to the very company it would now be trying to buy. No rival can claim a connection to Arrowhead’s platform anything like this one, because no rival gave it away.

The brain is where the fit turns from history into live competition. Crossing the blood-brain barrier, the biological wall that keeps most drugs out of the brain, is the central obstacle in treating Alzheimer’s and most other neurological diseases, and for fifteen years Roche has been one of the world’s leaders in solving it. Its proprietary brain-delivery technology, the foundation of its flagship Alzheimer’s antibody trontinemab, works by attaching the drug to a fragment that latches onto a specific docking point on the cell surface, the transferrin receptor, and uses it as a shuttle to ferry the drug across the barrier. That is, at the level of fundamental strategy, the same approach Arrowhead uses to deliver its tau therapy: a fragment that binds the same receptor and carries a payload into the brain. The difference is the point of complementarity. Roche’s shuttle carries an antibody that clears amyloid, one of the two toxic proteins that accumulate in the Alzheimer’s brain; Arrowhead’s carries a genetic medicine that lowers tau, the other principal driver of the disease. Two companies, the same delivery strategy, aimed at the two halves of the same illness. No potential acquirer is better equipped to understand exactly what Arrowhead’s brain platform is worth, because Roche has spent fifteen years building the closest thing to it that anyone else owns.

The RNA platform tells the same story in reverse. Having sold its RNA interference business in 2011, Roche has spent recent years trying to buy and partner its way back into the field it walked away from, reaching for a capability Arrowhead has spent those same years compounding into a mature platform. To acquire Arrowhead’s RNA engine now would be to pay a vast premium to stand where Roche could have stood all along.

Obesity completes the picture, and here the fit is not a contrast but a direct synergy with a program Roche already owns. Roche has declared an ambition to become a top-three player in obesity, anchored by CT-388, a weight-loss drug from the same mechanistic family as the market-leading injections, acquired in its Carmot purchase, that produced weight loss in mid-stage testing comparable to the market leaders and is advancing into Phase 3. The difficulty Roche faces is the one its own executives and outside analysts have named: CT-388 enters a crowded field years behind the leaders, so its differentiation will have to come from combinations and from novel mechanisms layered onto the GLP-1 backbone, including approaches that preserve lean muscle and improve the quality of weight lost rather than simply the quantity. That is precisely the gap Arrowhead’s obesity programs are built to fill. They work through mechanisms entirely different from the GLP-1 drugs, aimed at exactly the next-generation questions, muscle preservation, fat quality, durability, on which the obesity market’s next phase will be decided. For Roche, Arrowhead is not a competing obesity bet to be weighed against CT-388; it is the differentiating layer that could make Roche’s own franchise the one that wins the second act of the weight-loss era. A company racing to catch the leaders has the strongest possible reason to want the mechanisms that leapfrog them. Across all three areas, the brain, the RNA platform beneath them, and obesity, Roche is not entering a new field but returning to one it once occupied, pioneered, or is now racing to lead.

One feature of the platform sits less comfortably with Roche than with the others, and it foreshadows the bind to come. The platform does not confine its output to areas Roche already knows; it will keep generating programs across many tissues, some far from Roche’s focus. For a company that prides itself on selectivity, on developing only what clears its bar and walking away from the rest, that open-ended generativity is a genuine complication, because it asks Roche either to broaden beyond its chosen lanes or to license away what it will not pursue. The very thing that makes Arrowhead most valuable, its endless capacity to generate new programs, is the thing that fits least comfortably with how the most disciplined suitor prefers to operate.

III. The Cliff Roche Says It Does Not Have

Each paper in this series has treated the patent cliff differently, because each company stands in a different relation to it. Novartis faces a real and arriving cliff and acquires openly to fill it. Lilly faces no present cliff and buys from strength to front-run a distant one. Roche presents the most interesting case of the three, because Roche has told the world, in plain terms, that it has no patent cliff at all.

This is not an inference; it is Roche’s own stated position. In its investor presentations the company has declared, in so many words, that there is no patent cliff ahead, that its on-market portfolio will deliver growth through the latter part of the decade, and that its margins will hold. It is a confident, even proud posture, and it is central to how Roche presents itself: a science-driven company strong enough that it does not need to chase rescue deals the way its more exposed peers do. The message to investors is that Roche can afford to be disciplined precisely because it is not desperate.

The fuller picture is more nuanced, and the nuance matters for what follows. Beneath the no-cliff confidence, Roche does face real erosion of some older products as biosimilar competition arrives, the lower-cost copies that rivals can sell once a biologic drug loses its patent protection. Several long-standing biologics are exposed over the second half of the decade, among them the breast-cancer drugs Perjeta and Kadcyla, and, most significantly, Ocrevus, the multiple-sclerosis blockbuster that generates on the order of $8 to $10 billion a year and begins losing exclusivity toward the end of the decade. Roche’s position is not that nothing is eroding; it is that its growth drivers and deep pipeline more than offset the erosion, so that the net effect is continued growth rather than a cliff. That is a defensible claim, and quite possibly an accurate one. The important point for this paper is what it does to Roche’s room to maneuver. A company that has publicly staked its identity on having no cliff, and on not needing transformational acquisitions, has boxed itself in. It has told the market it does not need to do a big, dramatic deal, which makes doing one a reversal of its own narrative. Roche’s confidence is real, but it is also a constraint, because it raises the cost of being seen to act out of necessity. This is what sets up the cruelty of the final position. Roche is the one suitor for whom a large acquisition is not just expensive in money but expensive in identity.

IV. How Roche Actually Does Deals

Roche’s dealmaking style is the most disciplined and the most distinctive of the three suitors, and understanding it is essential to understanding why the forced move costs Roche more than it would cost anyone else. Where Lilly has become the industry’s most aggressive acquirer and Novartis signs deals by the dozen, Roche moves rarely and deliberately. It completes only a couple of acquisitions in a typical year, it places science at the center of every decision, and its leadership speaks consistently of discipline, of refusing to overpay, of maintaining a high bar. In 2026, as its peers pursued an acquisition spree, Roche’s chief executive publicly explained why the company was sitting it out, with not overpaying high among his reasons. Roche is proud, with cause, of being the disciplined one.

This does not mean Roche never does a large deal; it means it does them rarely and on strict terms. It has shown it will act decisively when the science and the price both clear its bar, paying around $7 billion for one late-stage asset in 2023 and acquiring its way into obesity the same year. The point is not that Roche cannot write a big check, it plainly can, and it keeps roughly $10 billion of dealmaking capacity available each year. The point is that it does so reluctantly, selectively, and on its own terms, and that it has deliberately chosen to stand apart from the kind of competitive bidding its rivals embrace.

On the question of how large a check it could write for Arrowhead specifically, Roche has more room than its restraint suggests. Working from its own filings, with net debt near $19 billion, earnings before depreciation and amortization on the order of $28 billion, and the highest credit ratings of the three suitors, Roche carries the largest borrowing capacity of the group, enough to fund perhaps $60 to $85 billion of an acquisition before straining its balance sheet. Combined with its own stock, that capacity reaches to something on the order of $120 billion without undue strain, and can stretch to roughly $155 to $160 billion, very roughly $1,000 to $1,030 a share, through a cash-and-stock structure with a contingent value right to bridge the clinical uncertainty. These are estimates from public filings rather than precise limits, but the implication is the one that makes Roche the finale: its capacity is ample, and its need, the Ocrevus revenue gap opening in 2028 and 2029, points at the same asset on the same timeline. Roche has both the reason to bid near the top of that range and the room to do it. It is the bidder forced in the strongest sense of the word, because the usual excuses, cannot afford it, do not need it, are both unavailable to it.

In one area that discipline takes a specific and telling form, and it is the most important fact for what follows. Roche relies on partnerships and licensing to an unusual degree; its own leadership has noted that a partnership underlies roughly sixty percent of its research pipeline and drug sales. In neuroscience especially, the field where Arrowhead’s lead program sits, Roche has favored licensing specific programs and technologies over buying companies outright, partnering for what it needs while keeping its commitments measured. This is a rational approach to a high-risk field: licensing lets Roche gain access to a promising asset without betting the company on it, preserving the discipline and optionality it prizes. For years it has been exactly the right way for a science-first, price-sensitive company to engage with the hardest area in drug development.

This preference for partnership is the key to the whole finale, because it is Roche’s natural move, and the position about to be described is precisely the one in which Roche’s natural move stops working. Everything in Roche’s history says that, confronted with an asset like Arrowhead’s tau program, it would reach first for a license: take the program it wants, structure a partnership, avoid the cost and the contested-auction dynamics it has spent years avoiding. That is what Roche does. The trap, as the next section shows, is that the one thing a license cannot do is keep the platform out of a rival’s hands, and in a contested situation that is the only thing that matters.

V. The Roche Playbook, and Why It Breaks

Put Roche’s deep fit, its no-cliff confidence, and its licensing preference together, and its preferred approach to Arrowhead is easy to predict. Roche would license. It would identify the program it most wants, most likely the tau therapy that complements its own brain-delivery work, and it would seek a partnership: rights to that program, perhaps to a few others, structured to give Roche access without forcing it into a transformational acquisition that violates its discipline and contradicts its no-cliff narrative. For a company that prizes selectivity and has spent years telling investors it does not need big deals, a targeted license is the obvious, comfortable, in-character move.

In a quiet world, that move works beautifully. A license gives Roche the one program it most wants, at a fraction of the cost and risk of buying the whole company, while leaving Roche free to remain the disciplined, science-first house it presents itself as. If Roche were the only suitor, licensing would be not just adequate but optimal, the textbook way for a risk-aware company to engage a promising platform without overcommitting.

The world of this series, though, is not quiet, and that is what breaks the playbook. The first two papers put two other suitors on the board, and at least one of them, Lilly, can buy the entire company without strain. This is the fact that turns Roche’s natural move into a trap. A license secures one program; it does not secure the platform. If Roche licenses the tau program and a rival then buys Arrowhead outright, Roche is left holding rights to a single asset while its competitor owns the engine that generates all the others, including the future brain programs that would compete directly with Roche’s own. Worse, an acquirer of Arrowhead might be able to disrupt or renegotiate the very license Roche was relying on. The licensing strategy, which is safe and smart when Roche is the only player, becomes the opposite of safe the moment the whole platform is in play, because it leaves the thing Roche most needs to prevent, a rival owning the science Roche pioneered, entirely unprevented. Roche’s preferred move does not lose gracefully. It fails at the one job that matters in a contest: keeping the asset away from the competition.

VI. “Zugzwang”

Now the position is complete, and it is worth stating with precision, because it is the destination of the entire series. Roche, the most disciplined and most reluctant of the three suitors, faces a board on which it would prefer above all to do nothing dramatic, to license quietly or to wait, and on which every move actually available to it worsens its position. This is “zugzwang”, and Roche is in it.

Consider the moves and what each one costs. Roche can license, its preferred move, but as the previous section showed, a license secures one program while leaving the platform for a rival to buy whole, so the move that feels safe is the one that fails at the only task that matters in a contest. Worse for Roche, the option may not even be on the table. A company fielding acquisition interest from two or three of the largest players in the industry has little reason to carve off a piece of its platform when a sale of the whole captures far more, so Arrowhead may simply decline to license its core science into the middle of a bidding process. Roche's safest move could be foreclosed not by its own hesitation but by the target's refusal to offer it. Roche can walk away, staying disciplined and preserving its no-cliff narrative, but walking away means standing aside while a competitor captures the transferrin-receptor brain-delivery science that Roche itself pioneered, watching its own frontier pass into a rival's hands. Roche can instead bid to win Arrowhead outright, which secures the asset but requires the one thing Roche most avoids: paying a contested premium in exactly the kind of bidding war it has publicly refused to join, against rivals with deeper pockets and fewer scruples about overpaying. Three moves, three different costs, and not one of them leaves Roche as well off as it would be if it could simply pass. That is the definition of the position. The obligation to respond is itself the trap.

The cruelty is sharpest for Roche precisely because Roche is the most disciplined player. For Lilly, winning Arrowhead is no reversal; aggressive acquisition is its stated strategy, so a winning bid is simply Lilly being Lilly. For Novartis, a stretch acquisition is unusual but not identity-breaking; it has stretched before. For Roche, every path violates something it values. Licensing violates its security, walking away violates its strategic interest, and winning a contested auction violates the disciplined, no-overpay identity it has spent years cultivating and has just publicly reaffirmed by sitting out the industry’s deal spree. The player with the most rigid discipline has the most to lose from being forced off it, which is why the forced move falls hardest on the suitor that most prizes its discipline. A less disciplined company would feel this position as a hard choice. Roche feels it as a genuine bind, because there is no move consistent with everything Roche wants to be.

There is a further twist hidden inside Roche’s own discipline. Years of restraint have left Roche with the means to act: a conservative balance sheet, ample deal capacity held in reserve, and a chief executive who has said plainly that the company retains the strategic flexibility for large acquisitions when the science and the price justify them. Discipline did not leave Roche unable to bid; it left Roche eminently able to. That removes the one excuse a forced player most wants, the comfort of incapacity. A company that genuinely could not afford the asset could walk away with its head high, pleading necessity. Roche cannot. It has the capital, it has the strategic rationale, and it has the deepest claim of anyone to the asset. Its discipline bought it the very capacity that now denies it the easy exit, because no one will believe Roche walked away because it could not act. They will know it chose not to. The disciplined player saved its strength for a moment exactly like this one, which is why the moment is so unforgiving.

VII. The Far Side of the Forced Move

Everything to this point has described the discomfort of the move itself, and that discomfort is real. A forced move, though, is defined only by the compulsion to make it, not by where it leads, and this is the place to say plainly what the language of traps can obscure: for Roche, of all three suitors, the move it is forced toward leads somewhere genuinely glorious. Lilly and Novartis are pushed toward Arrowhead largely by what they stand to lose. Roche is pushed toward the one asset on the board whose acquisition could become the proudest chapter in its modern history. It is at once the suitor with the most to lose by being forced and the most to gain by winning, and the second half of that sentence has gone understated for too long.

The redemption is the heart of it, and it is unique to Roche. The 2011 sale is the source of the bind, but it is equally the source of a story almost no acquisition can offer. To buy Arrowhead would be for Roche to reclaim the platform it invented and let go, to walk back into the field it abandoned and lead it, to convert what looks in hindsight like one of the costliest divestitures in its history into the foundation of its next era. Most corporate acquisitions are spreadsheets and synergies and integration plans, and no one writes songs about them. This one would be different. It would be the pioneer returning for the science it created, and finishing the work it once decided was not worth keeping. There are few stories in this industry a company could be prouder to tell, and fewer still that would fit so completely with how Roche likes to see itself, as the patient, science-first house that backs the hardest problems and stays for the long arc. Winning Arrowhead would not contradict that identity. It would vindicate it.

The strategic prize matches the symbolic one. An acquisition of Arrowhead would not, by itself, make Roche the largest company in the industry; the lead Lilly built on the obesity wave is not closed by a single deal, and it would be a mistake to claim otherwise. What it would do is arguably more durable than a change in the rankings. It would hand Roche the one validated genetic-medicine engine no competitor can match, secure its growth deep into the next decade with a pipeline that renews itself across tissue after tissue, and re-establish it as the leader of a field it helped create and then watched others build. There is a particular sting, and a particular prize, in the data beneath that engine. As a separate analysis in this body of work argues, the deepest moat Arrowhead holds is the proprietary, compounding record of fifteen years of experiments, a dataset no rival can buy or rebuild, that, fed into AI-driven design, makes its discovery faster and surer with every program. The moat is the data, not the software that reads it: AI models are available to everyone, but the proprietary record that makes them useful is available to no one else. Roche began that dataset. The experiments it ran before 2011, and the platform it sold, were the first entries in the very record that now cannot be reconstructed at any price. To acquire Arrowhead would be to buy back, vastly enlarged, the compounding advantage Roche itself started and then let another company spend fifteen years widening. Scale can be bought by anyone with enough cash, and the obesity wave lifting Roche’s rivals will eventually crest. A self-renewing, data-compounding platform that generates new medicines across the body for years is the rarer and more lasting advantage. Roche would be acquiring not a higher rung on a list, but the thing most likely to keep it near the top of the list for a generation, which is the prize a science-first company should want above almost any other.

None of this makes the act of bidding comfortable. A disciplined company does not relish paying a contested premium in a public auction, and Roche would feel that cost as sharply as the zugzwang describes. The discomfort, though, is the entry price, and Roche is the one player on the board for whom the destination so plainly justifies it. The forced move remains forced. It may also be the luckiest compulsion in Roche’s history, the push that carries the most disciplined company in the industry toward the best decade it could have written for itself. A player does not always choose the moment it is made to move. Sometimes the position that leaves it no comfortable choice is the very one that leads, against its own caution, to its finest hour.

VIII. How Arrowhead Plays It, and the Auction Resolves

From Arrowhead’s side of the table, the resolution of the series is not really about any single suitor’s tactics anymore. It is about the structure that the three suitors together have created, and Arrowhead’s role within it is the one developed across the whole BioBoyScout series: the company that does not need to sell, holding the position that lets it wait while others are forced to act.

By the final paper, the leverage analysis assembles itself. Arrowhead owns its manufacturing, has an approved product and revenue, and runs a platform deep enough to fund its own future, which means it is never forced to accept a disappointing offer; it can always choose to continue alone. Around that unforced center, three suitors now circle, each unable to let the others win. Novartis cannot lowball, because it knows the value too well. Lilly can pay the most and is the hardest to outbid. Roche cannot afford to let either rival capture the science it pioneered. That configuration, three players who cannot all win and at least one of whom cannot bear to lose, is the precise condition that turns a buyer’s market into a seller’s auction. Arrowhead does not need to manufacture the contest. It needs only to hold its position and let the suitors’ awareness of one another do the work, because the moment any one of them moves seriously, the others are compelled to respond, and the bidding rises not to the level any single buyer would have offered in isolation but to the level required to win a contested prize.

Roche’s role in that dynamic deserves a closer look, because its incentive does not disappear even in the case where it loses. Roche would, of course, prefer to win, to reclaim the science it once owned and to secure its own next decade. If it cannot, though, it is not reduced to a passive bystander. As the most informed party at the table, the one with the deepest claim and the clearest view of what the platform is worth, Roche is well placed to bid aggressively for a rational reason that has nothing to do with spite: to force a rival to pay the full, foreclosure-inclusive price rather than acquire the asset cheaply. A disciplined company does not bid past its own estimate of value to inflict pain. It can, however, bid up to that estimate without flinching, and its estimate is higher and better founded than almost anyone’s, which means Roche can push a competitor close to the true ceiling before stepping aside. There is a measure of cold consolation in that outcome. If Roche cannot keep the science it invented, it can at least ensure that the rival who takes it pays dearly, and that the technology Roche developed and once owned is carried off not at a bargain but at the hard-won price of a genuinely contested auction. Losing the asset is a defeat. Letting a competitor steal it cheaply would be a larger one, and that, at least, Roche has the standing and the knowledge to prevent.

This is the deepest expression of the foreclosure logic that runs through the series. The value of Arrowhead to each acquirer is not just what the platform is worth to that buyer; it is that amount plus the cost of letting a rival have it instead. In a quiet sale, only the first number is paid. In a contested auction, the second number, the value of denial, is dragged into the price, and it is captured by Arrowhead’s shareholders. The three-suitor structure is, in effect, a machine for converting the strategic value of foreclosure into realized acquisition value, and Roche’s predicament is what proves the machine is running, because the most disciplined player being forced to participate is the clearest possible sign that standing aside has become more expensive than bidding.

There is an affirmative side to this that the language of traps and forced moves can obscure, and it is the consideration most likely to make a winner of any of the three. Foreclosure explains why none of them can let a rival win; it does not capture how much the winner actually gains. The eventual owner of Arrowhead does not simply acquire a pipeline of programs to be tallied against the price. It acquires the only validated, multi-tissue genetic-medicine platform of its kind, with its own manufacturing, an approved product, and a roadmap of programs stretching across the liver, muscle, lung, fat, and the brain in the clinic, with the eye and the heart already emerging behind them and more tissues to follow, for years to come. Whichever company wins, if the platform performs as the series assumes, is likely to look back on the purchase not as the deal that strained its discipline but as the best acquisition it ever made, possibly the best any large drugmaker has made in a generation. The premium that looks shocking on the day of the announcement is measured against the wrong baseline; measured against a decade of compounding output and the franchises it will seed, even a record price can prove modest. The cruelest part of the position, then, is not merely that each suitor is forced to act. It is that each is forced to compete, at a punishing price, for what may turn out to be the prize of the era, which means the pain of bidding and the scale of the reward are the same fact seen from opposite sides. A player does not fight hardest to avoid a loss; a player fights hardest when the thing on the table is the best it will ever have the chance to buy.

IX. The Honest Counterweight

Honesty requires a clear statement of the ways this entire series could be wrong, and the caution belongs here, at the end, because it applies to all three papers at once. The scenario rests on a structure of rational actors competing for an asset, and there are several ways that structure might not form.

The first and most important caveat is that all three suitors might simply exercise discipline at the same time. Each of these companies prides itself, to varying degrees, on walking away from deals that do not meet its bar, and it is entirely possible that the price Arrowhead would accept exceeds what any of them judges rational, in which case no auction forms, no foreclosure premium is paid, and the contest this series imagines never materializes. A thought experiment about how suitors would behave in a contest is not a promise that a contest occurs. The second caveat is that an auction, even if it begins, can resolve quietly: a single suitor might move early and decisively, preempting the others with a friendly offer that Arrowhead’s board accepts before any bidding war develops, which would mean a sale but not the dramatic escalation the structure permits. The third and deepest caveat is the one this series has returned to throughout: all of it depends on the platform performing. Every suitor’s interest, every foreclosure calculation, every forced move, assumes that Arrowhead’s science continues to deliver, above all that its central nervous system program reads out well. No one competes for a platform whose lead program has just failed. The entire edifice of suitor interest rests on a clinical foundation that has not yet been fully proven, and if that foundation cracks, the contest dissolves with it.

There is also the open question, taken up earlier, of whether Roche would experience a forced acquisition as a defeat or a triumph, and honesty requires admitting that no outside analyst can settle it. The same facts support both readings. The bind is real: Roche would be pulled past its stated discipline, in public, at a contested price it has spent years refusing to pay. The vindication is equally real: it would be reclaiming the science it pioneered and securing its next decade in the process. Which feeling would dominate is a matter of how Roche chooses to see the moment, not something a spreadsheet decides, and the series has tried to give both their due rather than flatten the most interesting suitor into a single note.

These cautions and alternatives do not undo the analysis; they bound it. The series describes the conditions under which a contest forms and the dynamics that would govern it if it did, and it argues that those dynamics favor Arrowhead more than a simple sum-of-programs valuation would suggest. It does not claim the contest is inevitable, or that any deal is coming, or that the author knows anything about the private intentions of any company. Whether Roche’s forced move ends in defeat or vindication, the structural point holds either way: if Arrowhead’s platform delivers, the strategic logic facing these three suitors is the logic this series has described, and that logic favors the company being courted.

X. Conclusion: The Whole Board

Three suitors have now crossed the board, each for its own reasons and in its own style. Novartis is the partner who knows the value too well to lowball and too well to ignore. Lilly is the giant whose resources let it pay what others cannot, and whose mere entry forces everyone else to hurry. Roche is the disciplined pioneer, drawn against its own nature toward the science it helped invent, caught in a position where every move costs it something, and yet pulled toward the one prize that, once won, could become the proudest acquisition any of them ever makes. The styles differ, the motivations differ, the patent-cliff pressures differ, but the conclusion each reaches is the same: Arrowhead is a prize none of them can comfortably let another have.

That shared conclusion is the engine of the whole story. A single buyer, however motivated, negotiates against a seller. Three buyers, each unable to tolerate the others winning, negotiate against each other, and the seller who holds a strong enough position to wait becomes the one who sets the terms. This is why the series has insisted, across all three papers, that the number of suitors matters more than the identity of any one of them. One suitor is a negotiation. Three suitors who cannot all win is an auction, and an auction over an asset that cannot be allowed to fall to a rival is the most favorable situation a seller can occupy. The price such an auction produces will look enormous, and the commentary will call it an overpayment. The likelier truth, if the platform delivers, is the opposite: the winner will have bought one of the defining strategic assets of the decade, and in time the only regret on the board will belong to the two who let it go.

The series began with a warning and ends with a bind. “En garde” announced that the queen was under attack. The “check” forced the board to respond. “Zugzwang” is where it arrives: the position in which the most disciplined player of all, the one who most wished to stand still, is compelled to move and finds every move costly. That is the truest measure of how valuable the queen has become. You can learn more about a piece from how the players around it behave than from any tally of its worth, and when even the most patient, most disciplined player on the board cannot afford to wait, the piece at the center is worth more than any of them would have admitted while the game was still quiet.

Roche supplies the final irony, and it is the one that lingers. Fifteen years ago, Roche held the seed of this entire platform in its hands, the RNA business, the Madison scientists, the delivery technology, and judged it not worth keeping. It sold that seed to a company worth less than $50 million. The seed is now a forest, and Roche may have to pay tens of billions to walk back into woods it once owned and gave away. No fact in this series says more plainly what Arrowhead has become, or why the players who once let it go can no longer afford to let it pass to anyone else. The market is still counting the trees. Arrowhead is the queen who became a player, and the player who cannot be forced is the one who decides how the game ends.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It is a strategic thought experiment based entirely on publicly available information, including company acquisition histories, public strategic statements, earnings disclosures, and trade press reporting, as of the date of publication. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. It is not a prediction of any transaction, and the author has no knowledge of any actual deal discussions among any of the companies described. Scenarios involving how companies would behave are analytical interpretations grounded in documented past behavior, not statements of fact about any company’s intentions or any individual’s thinking. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now